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The overall aim of the research is to develop a computational platform based on HINT 
paradigm for manipulating, predicting and analyzing biomacromolecular-ligand structure. 
A second synergistic goal is to apply the above methodology to design novel and potent 
anti-cancer agents. 
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The crucial role of the microtubule in cell division has identified tubulin as an interesting 
target for the development of therapeutics for cancer. Pyrrole-containing molecules derived 
from nature have proven to be particularly useful as lead compounds for drug 
development. We have designed and developed a series of substituted pyrroles that inhibit 
growth and promote death of breast tumor cells at nM and μM concentrations in human 
breast tumor cell lines.  In another project, stilbene analogs were designed and developed 
as microtubule depolymerizing agents that showed anti-leukemic activity. A molecular 
modeling study was carried out to accurately represent the complex structure and the 
binding mode of a new class of tubulin inhibitors that bind at the αβ-tubulin colchicine site. 
These studies coupled with HINT interaction analyses were able to describe the complex 
structure and the binding modes of inhibitors. Qualitative analyses of the results showed 
general agreement with the experimental in vitro biological activity for these derivatives. 
Consequently, we have been designing new analogs that can be synthesized and tested; we 
believe that these molecules will be highly selective against cancer cells with minimal 
toxicity to the host tissue.  
 
Another goal of our research is to develop computational tools for drug design. The 
development and implementation of a novel cavity detection algorithm is also reported and 
discussed. The algorithm named VICE (Vectorial Identification of Cavity Extents) utilizes 
HINT toolkit functions to identify and delineate a binding pocket in a protein. The program 
is based on geometric criteria and applies simple integer grid maps to delineate binding 
   
 xix
sites. The algorithm was extensively tested on a diverse set of proteins and detects binding 
pockets of different shapes and sizes.   
 
The study also implemented the computational titration algorithm to understand the 
complexity of ligand binding and protonation state in the active site of HIV-1 protease.   
The Computational titration algorithm is a powerful tool for understanding ligand binding 
in a complex biochemical environment and allows generating hypothesis on the best model 
for binding.  
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CHAPTER 1 
 
 
Computer-Aided Drug Design: Introduction and Applications in 
Anti-Cancer Drug Design 
 
1.1 Introduction  
1.1.1 Cancer Therapy 
 
Cancer is a group of diseases in which there is an uncontrolled multiplication and spread 
of the body’s own cells within body in abnormal forms. Cancer may affect almost any 
tissue of the body and may metastasize to other tissues within the body. If the spread is 
not controlled, it can result in death. According to the American Cancer Society’s ‘Global 
Cancer Facts & Figures 2007’ and ‘Cancer Facts & Figures 2008’ cancer is the second 
leading cause of deaths after heart disease in developed countries and third leading cause 
of death in developing countries1,2. According to a report released by WHO, it is 
estimated that there will be 16 million new cases every year by 2020 and by 2050, the 
global burden is expected to grow to 27 million new cancer cases3,4.  Despite 
considerable progress in its diagnosis and treatment cancer continues to be one of the 
major health and socio-economic problems.   
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Over the last couple of decades, research has revealed considerable information about the 
molecular biology, pathobiochemistry and the intricate pathways involved in cancer5,6. 
Multiple factors are involved in the initiation, promotion and progression of cancer which 
lead to changes in the host genome and aberrant expression of oncogenes or tumor 
suppressor genes7-9. The abnormal cell multiplication and spread can be attributed to both 
external and internal factors. External factors like tobacco, chemicals, some viruses and 
radiations can cause mutations. These mutations cause altered gene expression which 
may activate protooncogenes to oncogenes like erbB, ras, myc etc.8,10,11. This, in turn, 
may result in uncontrolled cell proliferation and dedifferentiation. In-addition, inherited 
mutations in metabolism and certain immune conditions can cause expression of 
oncogenes11,12. These inadvertent factors may act together or in sequence to initiate or 
promote carcinogenesis and develop primary tumor, which, subsequently develops into a 
full fledged malignant tumor.   
 
Over the past decade, a number of chemotherapeutic drugs with different mechanism of 
actions and targeting various stages of metastatic cell growth have flooded the 
pharmaceutical market13,14. Based on their mechanism of action, these drugs can be 
classified into different classes as alkylating agents, antimetabolites, antibiotics, 
nucleoside analogues, antimitotic agents, etc15. However, most of these drugs are 
associated with severe toxicities and are not effective against all types of cancer. Thus, 
the search for new anticancer drugs and the development of more effective treatment 
strategies continues to be imperative16.  
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Until recently, anti-cancer drug discovery had extensively focused on the critical cell 
growth stage, mitosis, and any alteration or miscontrol of which can lead to development 
of human tumors. After the clinical success of taxol, microtubules have received 
considerable attention as the potential targets in the drug discovery process17-19. 
Microtubules form the cytoskeleton of a cell and are critical in mitosis and cell division. 
Tubulin, a heterodimeric protein forms the fundamental structural unit of a microtubule 
and joins in a head-to-tail fashion to form a long, filamentous protofilament. These 
protofilaments join laterally to form a hollow tube shaped protein polymer, the 
microtubule, which forms a mesh like network in eukaryotic cells. Besides playing an 
important role in mitosis, microtubules are involved in diverse cellular processes such as 
locomotion and intracellular transport. In addition, they play an important role in the 
development and maintenance of cell shape, signaling and transport of cellular 
components such as vesicles, mitochondria, etc. Thus, microtubules become an important 
target for anticancer drugs18. Since chemically diverse groups of anti-mitotic drugs that 
target microtubules and induce mitotic arrest have been used with great success against 
cancer, microtubules are considered as one of the best identified cancer targets17,18. 
However, research in this area is held back due to lack of a high resolution crystal 
structure that will aid in efficient structure-based drug design. Although there are several 
drugs which bind to tubulin protein and disrupt microtubule dynamics19, their clinical 
usefulness is limited by their unfavorable pharmacokinetic profiles and side effects. 
Furthermore, the limited availability and complexity in synthesis of pharmacologically 
active lead compounds and their chemical modification presents a major obstacle in 
improving the overall profile of a drug candidate. The complexity in development of anti-
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cancer chemotherapeutics makes it difficult to treat the disease and as a result it is 
necessary to come up with a rational program to identify potent leads that will stimulate 
the development of more effective anti-cancer chemotherapeutics. 
  
1.1.2 Drug Discovery 
Traditionally the strategy for discovering new drugs consisted of random screening of 
thousands of compounds derived from natural products to identify a lead20. Taking this 
lead structure, a program is developed for finding analogs exhibiting the desired 
biological properties. However, this entire process is highly laborious, expensive and 
conceptually inelegant. During last couple of decades pharmaceutical industry has 
experienced a paradigm shift in its approach to discover drugs. The traditional methods of 
drug discovery are now being supplemented by some more direct approaches which are 
derived from the understanding of the molecular processes involved in the underlying 
disease. Pure samples of protein targets are now being isolated and the three dimensional 
structure of both ligand and target site may be determined by X-ray crystallography or 
computational methods. It is now possible to learn how precisely topography of 
structures control the regulation of life processes. In order to further such progress, a 
rational approach to drug discovery has emerged in the pharmaceutical industry and has 
contributed to the rapid development of active candidates. New molecules are conceived 
either on the basis of the similarities they share with the known lead compound or their 
complementarities with 3D structures of known active sites21-23.  
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Understanding the three-dimensional aspects of drug-receptor interactions and their 
specificity at the molecular level has become a focal point in the modern drug discovery. 
Recent advances in genomics, bioinformatics, high-throughput screening and 
combinatorial synthesis are providing valuable inputs for the small molecular leads. 
However, optimizing the chemical and biochemical properties of a lead warrants 
substantial resources, which, in turn, will assist in the rational selection of “druggable” 
chemical entities, i.e., the selection of drug candidates/chemical entities that are more 
likely to have favorable characteristics for the treatment of human disease, thus 
improving the efficiency of the drug discovery/development process24.  
 
The drug discovery process is an interplay between computational and experimental 
approaches. Computer-aided drug design contributes to the understanding of 
biomolecular processes in a qualitative and quantitative way. It not only presents means 
for analyzing the details of the molecular machinery involved in a system and 
understanding the way the biological system functions, but also, provides the tools for 
predicting potential possibilities of the prototype candidate molecules. The techniques 
currently available provide extensive insights into the precise molecular features that are 
responsible for the regulation of the biological processes. These structural and 
physicochemical characteristics are of primary importance in understanding the structure 
–activity relationships and hence, the rational design of drug. Computer-aided drug 
design has opened the way to the discovery of lead molecules by a rational approach, and 
its central role in rational drug design has become fully apparent25.  
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1.1.3 Computer-Aided Molecular Design  
Computer-aided molecular design is expected to contribute to the discovery of novel 
molecules conceived on the basis of precise three dimensional stereochemical and 
physicochemical considerations. Systematic investigation of 3D stereochemical and 
physicochemical features of a protein and its binding site are crucial for designing small 
molecules that modulate protein functions. The ability to accurately predict binding mode 
from computer simulations is an invaluable resource in understanding biochemical 
process and drug action. Several aspects of molecular recognition can be discerned from 
the computational modeling of protein-ligand complex. Predicting the affinity of a new 
putative inhibitor for a macromolecular receptor is therefore imperative for designing of 
more potent analogs.  Though structural data available from x-ray crystallography and 
NMR has undeniably encouraged the efforts towards understanding the biological 
complexity of molecular recognition, fundamental uncertainties in binding site 
interactions and insufficient knowledge of well defined binding pockets are a major 
bottleneck in designing effective drugs with optimal activity.  
 
One important aspect in modeling bio-molecular systems or molecular recognition events 
is to accurately model the energetics of the binding. Although computational tools have 
been used to corroborate experimental data, the interaction energies calculated without 
the pH, ionization and entropic contributions are not always expected to correlate well 
with the experimentally measured free energies of binding. Subtle variations in 
microenvironment of a protein due to changes in experimental conditions such as pH, 
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buffer, ionic strength and temperature can influence the bio-molecular interactions and 
complex formation26. The primary goal of modeling studies is to accurately simulate the 
microenvironment of an active site. Calculation of binding free energy involves 
evaluation of both enthalpic and entropic contributions and forms an integral part of 
structure-based drug design protocol27,28. A meaningful description of the system can be 
obtained from thermodynamic analysis of protein-ligand interaction. To date, several 
structure-based modeling methods have been developed that give vital insight into the 
free energy changes of the system. Some of these methods viz. Free Energy Perturbation 
(FEP), Linear Interaction Energy (LIE), and Molecular Mechanics Poisson-Boltzmann 
Surface area (MM-PBSA) calculations involve extensive sampling of conformational 
states. However, the computational cost and human interaction necessary to perform 
these calculations make them less applicable for screening of a very large number of 
compounds and more viable in a later phase of drug design. These models can contribute 
significantly to the understanding of structural and energetic basis of protein-ligand 
interactions and hence, the structure-based design of novel compounds. Virtual screening 
methods involving database searching and docking tools along with de novo drug design 
tools facilitate identification and optimization of lead candidate. This research proposes 
the development and application of such tools to identify new anti-cancer drugs. In the 
subsequent subsections, the role of different computational approaches and the research 
plan to design and develop novel anti-cancer agents will be discussed. In section 1.2 we 
start with a brief review of approaches and technologies used in structure-based drug 
design. In the subsequent section 1.3 we highlight the HINT model and describe the 
Toolkit design. In the next section 1.4 we present a research plan for the design and 
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development of computational tools and their application in designing novel anti-cancer 
agents. 
 
1.2 Structure-Based Drug Design   
The purpose of structure-based drug design is to identify or construct molecules that bind 
with high affinity to a structurally defined binding site of a target protein. It is the process 
of using the three-dimensional structural information from a macromolecular target 
or/and ligand-target complexes to design novel drugs that may modulate target protein for 
desired activity. Recent computational approaches facilitate extraction of all the relevant 
information from available structures to understand specific molecular recognition events 
and to elucidate the function of the target macromolecule29.  
 
Structure-based drug design uses an efficient and intelligent approach to design improved 
ligands for the target24. The first step in structure-based drug design is the elucidation of 
three-dimensional structure of the target macromolecule (protein or nucleic acid) by X-
ray crystallography or NMR. In some cases, where direct structural information is 
unavailable, a homology model can be used as the starting point. However, there are 
instances where the function of a protein is unknown or the domain responsible for the 
activity is unidentified. Several methods are available for identification and 
characterization of the active site30,31. These programs can be sorted into different 
categories according to the approach they take to identify and delineate the active site (i) 
Evolutionary methods (structure/sequence alignments) (ii) probe/energy-based methods 
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(iii) geometric approaches. All these methods are likely to evolve with the availability of 
more structural and sequence data from structural genomics projects.  
 
 Recent advances in combinatorial chemistry, high throughput chemical synthesis and 
screening are providing valuable inputs for the identification of small molecular 
leads21,22,32. Once a lead compound has been identified, an iterative process of lead 
optimization begins that involves solving the three-dimensional structure of the lead 
compound bound to the target. Development of new computational drug design tools 
facilitates examination and characterization of the complex structure and the types of 
interactions that the bound ligand makes with the protein. The binding site specifies 
structural and physicochemical constraints that must be met by any putative ligand. 
Hence, it is imperative to analyze the binding site by mapping the characteristics that are 
essential for ligand recognition. Besides shape complementarity, which plays an 
important role in protein–ligand interactions, physicochemical complementarity is 
essential for the specificity of binding33.  
 
Many promising approaches towards the goal of automated ligand design and 
optimization have been reported34-37. In particular, there has been a surge in new methods 
in the past few years, greatly extending the approaches to ligand design. Lead 
optimization methods may involve improvements to existing lead compounds by 
introducing new functionality to the lead scaffold. A combinatorial library, thus 
generated, is screened against the target protein. Although, the approach is rational and 
has been successfully applied, the analogs generated are very similar to the lead 
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compound and this limits the discovery of diverse library of compounds. In another 
widely used and more successful approach, large databases of compounds are virtually 
screened23. It is a two pronged approach, in which, while maintaining pharmacophoric 
constraints on one hand, new lead compounds with different scaffolds can be identified, 
thereby, introducing diversity to the compound library. These virtual screening methods 
take each proposed ligand and attempt to position it in the active site of the receptor, or 
match it to a pharmacophore model38.  The compounds are scored and ranked based on 
their steric and physicochemical complementarity with the target site and the best 
compounds are tested with biochemical assays39. Another promising approach to generate 
entire novel series of compounds is de novo lead generation programs36. In contrast to the 
whole molecule docking approach, in de novo methods, fragments of molecules, usually 
small functional groups are docked into the site, scored, and linked together using 
different scaffolds. The methodology allows the diverse set of fragments to exhaustively 
explore the binding site. The final in silico library of compounds can be scored, ranked 
and synthesized in the laboratory. However, the main drawback with this approach is the 
stability and synthetic feasibility of the compound suggested. There are many excellent 
drug design software methods available capable of either virtual screening or de novo 
generation36,40. However, the main advantage of virtual screening from a database is that 
the hit compounds can normally be purchased and tested easily. The success of all these 
approaches depends on how well the protein-ligand complex is characterized and scored. 
Various techniques have proven to be efficient tools for generating near-native 
conformations of complexes41. However, there are still some inherent limitations that 
need to be addressed. The robustness of any computational approach depends on how 
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accurately the experimental information is derived and parameterized to simulate a 
biological system. Due to the multiplicity of factors controlling the binding in any 
biological system, the phenomenon is particularly difficult to model computationally. 
Thus the most demanding and rewarding answer to this problem is hoped to lie in rational 
drug design.  
 
1.2.1 Microenvironment & Active Site 
Molecular interactions are regulated by subtle recognition and discrimination patterns 
where three dimensional features and microenvironment of the active site plays a vital 
role. The first step in any rational drug design protocol is to identify and elucidate the 
active site in a protein molecule. These active sites themselves might not be observed 
from an initial inspection. Protein surfaces are formed by numerous cavities and 
protrusions that are interlinked through small narrow channels and more than often 
interspersed with numerous holes/voids. The size and shape of protein cavities dictates 
the three-dimensional geometry of ligands and guides the important intermolecular 
interactions that mediate binding. The study of cavities may give an insight into the 
mechanism of such interactions and might help in the design of novel ligands, substrates 
or inhibitors. The determination of binding pockets is, therefore, an important step 
towards the rational design of novel ligands. An in-depth analysis and classification of 
pockets on the surface of protein structures might also improve our understanding of the 
processes involved in structure-based drug design.  
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A number of successful methods have been developed for predicting ligand binding 
sites30. These methods basically take different approaches depending on the kind of 
information available. Evolutionary methods apply a heuristic approach by finding 
characteristic sequence patterns based on structure/sequence alignments.  The presence 
and evolutionary conservation of certain residue pairs, cofactors, metal ions and binding 
motifs can, therefore, give useful clues for deducing the biochemical function of an 
uncharacterized protein and location of the binding sites. These computational methods 
are useful for predicting the location of binding sites when direct experimental 
information is unavailable.  
 
Methods that use structural information, when available, are particularly promising since 
they can potentially identify and characterize an active site based on the properties of the 
pocket. These methods apply energy/probe to generate functional maps of the binding 
site indicating the most favorable regions for placing ligand groups with similar 
properties to the probes. The atomic details can be further evaluated by mapping the 
physicochemical properties of the binding surface such as hydrophobicity or electrostatic 
potentials.  
 
The properties/microenvironment of the cavity are responsible for the substrate 
specificity. Theoretical calculations simulating the microenvironment of binding site are 
plagued by very drastic approximations. The phenomena of solvation/desolvation and the 
effects of varying pH and electrostatics are difficult to model computationally. Under 
physiological conditions a protein (enzyme/receptor) is present in a milieu of solvents, 
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even after crystallization a protein crystal may contain upto 70% of solvent42, which 
includes the buffer solution as well. Exposure of protein crystal structure to these solvents 
and buffers during crystallization may affect the microenvironment of active site as these 
solvent molecules may distribute themselves within the different pH zones or solvent 
channels according to the nature of the residues lining these solvent pockets. The altered 
microenvironment may influence the ligand binding43 due to change in the protonation 
states of the active site residues. The binding of ligand/small molecule to biological 
macromolecules is further complicated by peculiarities in the metal ion binding, preferred 
coordination numbers, relative affinity for specific ions, and preferred binding orientation 
and the lowest energy ionization state. It is, thus, not always possible to accurately 
resolve the biological microenvironment experimentally or to model it computationally. 
Thus calculation of optimum ionization/protonation state of complex formation is crucial 
for understanding binding process and step towards desigining more selective ligands.  
 
1.2.2   Mapping the Binding Site 
Structural and physicochemical characterization of an active site has become a major goal 
in drug discovery44. Understanding the chemistry behind molecular recognition is a 
central issue in drug design. With the advances in experimental techniques of X-ray 
crystallography and NMR, the elucidation of binding features on a protein structure has 
become more convenient. The computational mapping of a binding site to generate a 
pharmacophore model directly from a protein crystal structure can reveal key elements in 
protein-ligand binding45. Such knowledge is indispensable for rational drug design, since 
in majority of cases, receptor–drug interactions are specific in nature. Correctly mapping 
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the binding site is an important step in structure-based drug design and can be used as the 
starting point for finding new lead compounds or drug candidates46.  
 
The structure-based mapping of binding site or receptor-based pharmacophore generation 
provides an ensemble of steric and electronic features that ensures optimal interactions 
with a specific biological target structure, although a pharmacophore can be calculated 
from both ligands or/and protein structure47. A receptor-based pharmacophore defines 
essential features for molecular recognition and receptor-ligand interaction48. Structure-
based mapping uses features complementary to a protein site to define the shape and 
physiochemical constraint of the target site49. The mapping of crucial features is 
challenging since the number of ‘Hot Spots’ and their strength is critical for hypothesis 
generation. This facilitates the docking process by defining a set of constraints that can be 
quantified in terms of how many and which pharmacophoric points can be matched by a 
ligand or a library of compounds. 
 
A Receptor-based pharmacophore can be defined as an arrangement in three-dimensional 
space of several (typically three to six) features considered to be relevant for specific 
binding50. These features can be specific such as hydrogen bond donor or acceptor, or 
aromatic moiety. These physicochemical attributes can be mapped on a cavity surface 
using different approaches based on surface conservation or energetic contouring with 
interacting molecular probes51. However, the challenge is to pinpoint the specific 
electrostatic or hydrophobic interactions complementary to the residues lining the active 
site. To some extent, probe-based methods have found success in defining the polar and 
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hydrophobic regions within the cavity52. The knowledge-based approach of assigning 
interaction sites have also been implemented (LUDI) where statistical analysis of 
hydrogen bond patterns and geometries in crystal packing is taken into account by 
generating an ensemble of interaction sites distributed over the region of acceptable 
geometries53. Similarly diffused/non-directional interactions such as hydrophobic 
interactions due to aliphatic or aromatic moiety can be assigned after study of its 
distribution pattern. This approach has the advantage that it is purely geometrical and 
therefore avoids costly calculations of potential energy functions53. 
  
While geometric matching and pinpointing of specific interactions between ligand and 
receptor atoms provides a very intuitive picture, it is clear from basic physical principles 
and from measurements that the energetics involved in the thermodynamic association 
and dissociation processes determines the binding affinity of the ligand, which, after all, 
is one of the key properties of a molecule in the drug discovery process. Pharmacophores 
do not encode these energetic aspects, but do provide a rough sketch of the binding 
pocket. The potential binding pockets are considered as binding sites if a small molecule 
can bind in pocket such that it can form sufficient energetically favorable interactions 
with the protein. Numerous other techniques and approaches have been developed to 
calculate binding energies28,54. This has important implications in understanding of the 
nature of protein interactions, identifying the suitability of sites as drug targets and for 
identifying critical regions for docking and structure-based drug design.  
 
 
   
 16
1.2.3 Docking 
Docking calculations are needed to predict how new hypothetical or existing compounds 
will bind to the protein. Given the three dimensional structure of a receptor, known 
ligands can be docked to examine how they fit so that a protein ligand complex can be 
characterized in detail and modifications that improve binding can be suggested. The 
docking methodology has found widespread applications in drug discovery since large 
number of small molecules can be virtually screened by docking compounds from a 
database into a receptor structure in an attempt to find novel compounds39,55.  
 
The docking approach can be thought of as a three step process. The first step involves 
characterization of binding site. This step identifies and delineates the binding site for 
docking. It is a critical step as it defines and sets the constraints to position the ligand in 
the defined binding region.  The second step is to correctly position a set of ligands in the 
binding site based on the defined constraints. This step involves exploration of the 
configurational and conformational space for the interaction between target and the 
ligand. This step tries to correctly predict and identify the most favorable binding mode 
of the ligand into the target active site. The third step is an elaborate process of 
energetically assessing the docked position of ligand and scoring and ranking the 
proposed protein-ligand complex.  
 
Although the first step of site characterization is crucial for docking, it is generally not 
considered to be a part of docking methodology as it has grown and developed as a 
separate field of study.  This broadly leaves the docking approach as a two component 
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approach of ‘search’ and ‘scoring’. Several different approaches have been developed for 
investigating the accessible conformational space of a ligand56,57. One of the earlier 
approaches involved was systematic search58. However, the search becomes more and 
more complex with the ligand flexibility as the number of degree of freedom of the 
ligand molecule increases. Such an approach was implemented in methods where ligand 
and binding pocket were considered to be rigid and ligand was fitted using shape 
complementarity via point complementarity or distance geometry approaches59,60. In such 
docking methods, the shape of both the receptor site and the ligand is investigated based 
on shape and pharmacophoric points. Orientations are generated through various 
alignment procedures in order to maximize the pharmacophoric constraints and shape 
complementarity. However, it is not feasible to exhaustively explore the available 
conformational space and a right balance between speed and accuracy has to be made so 
that as many binding modes as possible are explored. Fragment-based approaches that 
work by either incremental construction of ligand in the binding pocket or just by placing 
and joining the fragment circumvent the problem of combinatorial explosion of generated 
conformers in the previous approaches61-63.  
 
Stochastic methods involving random sampling of conformational space of ligand in the 
binding pocket have also been widely applied in many docking algorithms55. Algorithms 
using Monte Carlo sampling coupled with Metropolis criterion are applied to 
exhaustively search the conformational space64. Simulated annealing protocol combined 
with grid-based energy evaluation can be coupled with this approach to overcome high 
conformational energy barrier in conformational sampling65. Another such stochastic 
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approach that has been successfully implemented in docking algorithm is the genetic 
algorithm based sampling of conformational space66-68. In this approach, multi-
conformers referred as chromosomes are evaluated, crossed and mutated and the best 
possible solution is kept based on the fitness function. The solution is represented by the 
best scored conformation of the total conformers after a set number of generations. 
GOLD (Genetic Optimization for Ligand Docking) is the most applied and well known 
for flexible molecular docking69.  
 
In contrast to these systematic and stochastic approaches, molecular dynamics-based and 
heuristic tabu searches have been implemented to explore the sample space56,70,71. 
However, molecular dynamics is computationally expensive which has restricted its use 
in docking. To circumvent this exhaustive sampling, tabu search approaches were 
adopted where a list of already explored conformations were maintained and only 
unexplored spaces were sampled72. This avoids reinvestigating the space already sampled 
by associating the sampled conformations with a degree of penalty. Apart from these 
deterministic approaches hybrid consensus approaches have also been implemented that 
combine features from other two approaches73,74. Although these approaches can 
exhaustively and successfully sample and generate all the possible conformations within 
the active site, the success of any docking program depends on how well it can reproduce 
the experimental binding mode of ligand within the cavity. The idea is to successfully 
predict the most energetically favorable pose out of thousands of sampled conformers. 
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1.2.4 Scoring 
The success of whole molecule docking, de novo construction of molecules into a target 
site, or screening large virtual combinatorial libraries is ultimately dependent on the 
accuracy of the scoring function that ranks the compounds. Ligand orientations can be 
evaluated on the fly as the ligand or fragment is positioned within the cavity or all the 
generated poses can be scored in the end. The scoring methods that are used in high-
throughput settings dealing with thousands of diverse compounds can be evaluated by 
how well the corresponding relative binding affinities can be predicted. This need has led 
to the development of a wide variety of methods, which can be subdivided in four major 
approaches: force field-based methods, semi-empirical approaches, empirical scoring 
methods, knowledge-based potentials and lastly consensus scoring functions that are 
combination of multiple scoring functions55,75.  
 
Force field-based scoring methods generally use a molecular mechanics force field, 
which contains terms for intramolecular forces like bond, angle and dihedral terms 
between the atoms that are bonded to each other plus energy terms for intermolecular 
forces that describes the forces between non-bonded atoms such as van der Waals and 
Coulombic terms. There are a number of widely applied and successful molecular 
mechanics-based scoring functions76-79. Due to their simplicity, they are widely applied 
and suitable for use in virtual screening. Though faster and simpler, they are ideally not 
meant for simulating biomolecular interactions as these methods were developed for 
calculating gas phase enthalpy of binding. However, this class of scoring approach is 
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associated with many drawbacks and does not account for hydrophobic interactions, 
solvation and entropic effects. 
 
Empirical scoring methods offer an alternative approach to pure molecular mechanics-
based force field methods for scoring80. The underlying idea is that the binding free 
energy of a non-covalent protein-ligand complex can be factorized into a sum of 
localized and chemically intuitive interactions. The terms accounting for different 
contributions such as hydrogen bonds, hydrophobic interactions, entropic effects are 
normalized by weighting factors derived from regression analysis of the data from 
training sets comprised of well characterized protein-ligand complexes. Based on the 
assumption of additivity, the binding affinity is estimated as a sum of interactions 
multiplied by weighting factors and solved by equation of the type (1). 
 
ΔGbinding ≈ ∑ ΔGifi (rl, rp)                                                       (1) 
 
Where fi is a simple geometrical function of the ligand (rl) and receptor (rp) coordinates55. 
However, accuracy of these methods depends upon the quality of the experimental 
binding data and crystallographic structural data of the training set. 
 
Semi-empirical scoring functions, however, combine the above two approaches and 
incorporates empirical or empirically calibrated energetic terms for interactions that 
cannot be computed by pure molecular mechanics-based methods.  Thus, implicit binding 
energy terms such as hydrogen bonding, solvent effects, hydrophobicity and entropic 
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terms can be included in the scoring functions.  In contrast to force field-based scoring 
functions, semi-empirical scoring terms can more accurately estimate the binding energy 
by including entropic and solvation effects that are known to significantly affect 
biological interactions in aqueous medium81-84. 
 
Knowledge-based scoring functions85 are rule-based scoring functions where rules are 
derived from the analysis of structural data of known and well characterized receptor-
ligand interactions. Exponential growth and availability of structural data on protein-
ligand complexes has allowed deriving and formulating set of rules based on the 
frequency of interactions.  Scoring functions of this type try to capture the knowledge 
about protein-ligand binding that is implicitly stored in the protein data bank by means of 
statistical analysis of structural data. The potentials are obtained by statistical analysis of 
atom-pairing frequencies observed in crystal structures of protein-ligand complexes86. 
However, the accuracy of knowledge-based scoring function depends on the quality of 
experimental data, as it incorporates structural knowledge without referring to 
inconsistency in experimental and structural data. 
 
Though several approaches have been implemented in deriving a robust scoring function, 
none of the scoring functions are ideal, as a variety of approximations are made to make a 
compromise between speed and accuracy. Taking into consideration the limitations of a 
single scoring function, the concept of consensus scoring evolved based on the premise 
that combination of different scoring functions would probably lead to a better 
performance by overcoming inherent weaknesses in individual functions87. A consensus 
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between a set of scoring functions can be reached either by averaging the rank assigned 
by each scoring function or averaging the score value calculated by different functions. 
Although a number of scoring functions as well as their combinations have been 
implemented, ideally, the best scoring function should be able to discriminate between 
native and non-native binding modes and be able to calculate the actual free energy of 
binding.  
 
1.2.5 Free Energy Prediction 
Predicting the structure and binding affinity of ligand-receptor complex is a challenging 
process and forms an integral part of structure-based drug design protocol. Ligand 
binding is governed by kinetic and thermodynamic principles. The quantity of interest in 
determining binding constants is the free energy difference between the complexed and 
uncomplexed state.  
 
ΔGbinding  = ΔGcomplex – ΔGfree                                             (2) 
 
The free energy is measured with the Gibbs free energy (G) of the system. The standard 
free energy change of the ligand-receptor binding process can be expressed as ΔGº. The 
most common measurement for ΔG is through the equilibrium constant for the complex.  
 
ΔGbinding = -RT ln Keq = RT ln Kd                                        (3) 
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Where R is the gas constant, T is the absolute temperature in Kelvin. Since the 
equilibrium constant (Keq) or dissociation constant (Kd) is a direct measure of ligand 
affinity; calculation of ΔG, the free energy of binding is of great interest in drug design. 
Computationally, the goal is to estimate binding free energy, ΔGbinding, which can be 
directly related to the experimentally measured association constant (Ka). A useful way to 
consider the binding free energy is in terms of the changes in enthalpy and entropy on 
formation of complex, as expressed by the following equation: 
 
             ΔGbinding = ΔH- TΔS                                                   (4) 
 
 Enthalpic (ΔH) and entropic (ΔS) factors that contribute to ligand binding include the 
hydrophobic effect, van der Waal and dispersion interactions, hydrogen bonding, other 
electrostatic interactions and solvation effects.  
 
During the complex formation, both receptor binding site and the ligand become partially 
desolvated and there is structural reorganization of solvent molecules between the 
receptor and ligand. In a majority of cases the solvent molecules are displaced between 
receptor and ligand thereby replacing existing hydrogen bonds between solvent and 
receptor or ligand. Also there is a change in entropy on binding as it is accompanied by 
change in translational and rotational degrees of freedom for the ligand, receptor and 
solvent molecules. In order to calculate the binding energy accurately, the scoring 
function should include all the enthalpic and entropic terms. So far, there are a wide 
   
 24
variety of different techniques available for predicting the free energy of protein-ligand 
binding, but most scoring functions do not include all of these terms27,28,54,88.  
 
Most of the functions are based on the assumption that different contributions to free 
energy of binding are additive and can be calculated separately.  The free energy of 
binding can be partitioned and calculated as an additive contribution from different parts. 
The “master equation” can be written as: 
 
   ΔGbinding = ΔGsolvent + ΔGconf  + ΔGint + ΔGmotion                                      (5) 
 
Where, ΔGsolvent is the free energy contributions from the solvation or hydration free 
energy, ΔGconf is due to conformational changes in the protein and ligand, ΔGint is free 
energy due to specific protein-ligand complex as a result of their proximity and ΔGmotion 
is free energy as a function of motion of receptor and ligand89.   
 
Ideally, all the energy contributions should be ensemble averages as the complex, the free 
protein, and the ligand are dynamic entities and these free energies can be calculated by 
integrating over all possible configurations of the protein, ligand and solvent system. Free 
energy perturbation methods allow direct calculations of certain differences in free 
energies90. The basic idea of free energy perturbation is derived from statistical 
mechanics as it relates the free energy of a system and ensemble average of an energy 
function that describes the system. However, free energy perturbation still requires 
relatively large amounts of computer time, provides very limited conformational 
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searching and remains technically difficult. Consequently, most approaches use 
approximate methods54,89. 
 
The force-fields used for calculations of free energy and intermolecular interactions 
assume that steric and electrostatic forces are sufficient to account for the observed 
biological interactions. However, these alone are never sufficient in accurate prediction 
of biomolecular interactions as they do not always include solvation/desolvation effects. 
The entropic contributions to binding are much less well-defined and often poorly 
quantitated or even ignored in most of the cases. Most approaches sum up these 
interactions separately as distinct enthalpic and entropic contributions, whereas, in 
reality, the ligand-protein recognition is a concerted event and thermodynamic quantities 
cannot be just simply summed.  
 
1.3 HINT Model 
This work focuses on an alternative force field-based on the experimental information 
from log Po/w (partitioning coefficient for water/1-octanol). Since log Po/w is an 
experimentally derived thermodynamic quantity, it directly correlates with the free 
energy of interaction and encodes all non-covalent interactions in the biological 
environment as well as solvent effects and entropy91,92. The HINT model describes 
specific atom–atom interactions between two molecules, using the equation:  
 
HTOT = ∑∑ bij = ∑∑ (aiSi ajSjRijTij + rij)                  (6) 
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where a is the hydrophobic atom constant (derived from log Po/w), S is the solvent 
accessible surface area, T is a function that differentiates polar – polar interactions (acid – 
acid, acid – base or base – base), and R and r are functions of the distance between atoms 
i and j . The interaction score bij describes the specific atom–atom interaction between 
atoms i and j, and HTOT represents the total HINT interaction score. The HINT model is 
based on the assumption that each bij approximates a partial δg value for a specific atom–
atom interaction, thus the total HINT score, which is the cumulative sum of all the atom–
atom interactions, correlates with ΔGinteraction, i.e., ΔG = ∑(δG). The HINT paradigm has 
been extensively applied for predicting the free energy of binding for protein –ligand and 
other systems91,93-95.  
 
1.3.1 HINT Hypothesis  
Hydropathic interactions comprising of polar and hydrophobic interactions form the very 
foundation of intra and intermolecular interactions. Although polar interactions can be 
accurately quantified using quantum chemistry methods, hydrophobic interactions are 
hard to quantify. The thermodynamic factors which give rise to the hydrophobic effect 
are complex and still incompletely understood. The hydrophobic effect is considered to 
be the major driving force in protein folding resulting in the burial of the hydrophobic 
residues in the core of the protein. It is exemplified by the fact that oil and water do not 
mix and oil droplets coalesce together to form a separate layer. The Hydrophobic effect, 
which is considered to be mainly entropy driven, is also responsible for protein-ligand 
interaction and bio-macromolecular association. However, commonly used molecular 
mechanics-based forcefields do not include terms for quantifying entropic energy. There 
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are, however, computationally intensive free energy perturbation methods that are able to 
accurately calculate free energy of binding90,96.  
 
The HINT forcefield is based on empirically-derived Log Po/w values that intuitively 
estimate free energy of binding, ΔG96. Log Po/w is a thermodynamic quantity that encodes 
both enthalpic and entropic term. These include hydrogen-bonding, acid-base 
interactions, coulombic attractions as well as hydrophobic interactions. All of these are 
related to solvent partitioning phenomena and the free energy of transfer of a compound 
from one reference state, such as an organic solution, into water, involves free energy 
change comprised of enthalpic and entropic contributions. The two phases, i.e., octanol 
and water, correspond to hydrophobic and polar residues and also are analogous to the 
hydrophobic microenvironment inside the binding cavity and solvent system. Since the 
dissolution of any compound in a mixed solvent system involves the same fundamental 
processes as biomolecular interactions within or between proteins and ligands, HINT 
derives the information from bulk molecular solvent partitioning to discrete interactions 
between the atoms. The program calculates empirical atom-based hydropathic parameters 
(hydropathic atom constant) that encode all significant intermolecular and intramolecular 
non-covalent interactions implicated in drug binding or protein folding. The hydropathic 
atom constant forms the core of HINT paradigm. 
 
The hydrophobic atom constant, a, is the key parameter in the HINT model. The atom 
constant, a, is calculated using an adaptation of the hydrophobic fragment constant 
approach of Hansch and Leo97. However, contrary to the Hansch and Leo approach, that 
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calculates the total solvent partition constant for a molecule by summing up the fragment 
constants, HINT backtracks from this point and distributes and assign atom constant to 
each atom of a fragment or molecule. Facilitating this are two databases for small 
molecules and bio-macromolecules, with re-parameterized force-field atom types, 
modified factors for bond, ring, and branched chain fragment data. The molecular 
database is used for structure/connection based calculation of Log P. The database 
contains a data tree of partition information and a bare hydrophobic atom constant for 
each atom type.  These bare hydrophobic atom constant values can be modified by a 
variety of factors specific to the molecular environment. A series of simple rules based on 
atom connectivity and proximity to other atoms identify and apply these modification 
factors to atom constants. In case of bio-macromolecules, dictionary-based calculations 
are carried out for log P depending upon the acidic, basic or neutral solvent condition 
where the modification rules are implicitly applied. Hydrogen atoms can be treated 
explicitly to model interactions more accurately. These modification factors characterize 
actual biophysical phenomena related to the molecular structure and properties. These 
hydrophobic atom constants along with modification factors encode the thermodynamic 
information and reveal the potential type and strength of interaction that the atom may 
encounter. Coulombic, hydrogen bonding, dispersion as well as hydrophobic effects may 
be extracted from the hydrophobic atom constant by examination of the sign and 
magnitude of the constant.  
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1.3.2 HINT Calculation 
The basic principle and application of HINT methodology is calculation of experimental, 
information-rich hydropathic atom constants and calculation of atom-atom interactions in 
a bio-molecular system. The partition constant LogP is a thermodynamic parameter, 
which due to its unprocessed and unbiased experimental nature, contains interaction 
information specific to the biological environment as well as solvent effects and 
entropy98,99. HINT was created specifically to calculate all non-covalent interactions. In 
practice, the conceptually simple HINT model scores each atom–atom interaction within 
or between biological molecules according to equation (6). As mentioned bij is the 
interaction score between atoms i and j, a is the hydrophobic atom constant, S is the 
solvent accessible surface area (H2O probe), Tij is a logic function describing acid-acid, 
acid-base and base-base interaction, and Rij and rij are functions of the distance between 
atoms i and j (i.e. r). Generally the hydropathic-dependent function, Rij, is the simple 
exponential e–r and rij is an implementation of the Lennard- Jones potential function. The 
rij term is mostly a penalty function to prevent van der Waals violations. The double sum, 
∑∑bij, is the total interaction score for the system. The HINT convention is that favorable 
interactions are scored with bij > 0 and unfavorable interactions are scored with bij < 0. 
The logic function Tij returns a value of 1 or –1 depending on the character of the 
interacting polar atoms (i.e. a < 0): there are three possibilities: acid–acid, acid–base, or 
base–base; only acid–base is scored favourably. Since polar moieties are markedly 
differentiated from hydrophobic moieties, the explicit interactions between a ligand and 
its receptor can be predicted. Besides this, the general microenvironment of the binding 
site can also be characterized. Likewise, and more exciting, complementary binding 
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points within the binding pocket can also be derived, giving a deep insight as to what an 
ideal ligand would look like. The HINT forcefield and its free energy scoring functions 
have been extensively applied and validated and have shown to be useful in a wide 
variety of biomolecular simulations93,100-102. To further extend the capability and 
applicability of HINT program, all the algorithms have been incorporated in a toolkit103.     
 
1.4   Amalgamation of Experimental and Theoretical 
Approaches: Scope and Limitations 
The field of molecular modeling lies at the interface of experimental and theoretical 
approaches. Computational modeling techniques attempt to simulate an abstract model of 
a particular system and are often plagued by very drastic approximations. The problem is 
further compounded by inherent experimental errors and artifacts. While, structural data 
available from x-ray crystallography and NMR has undeniably encouraged the efforts 
towards understanding the structure and functions of protein, only partial agreement 
between experimental and theoretical data has been observed based on these crystal 
structures. Often the issue raised is how representative is a single crystal structure in a 
structure-based drug design project? In addition to the obvious correlation between 
crystal structure resolution and accuracy, there are other considerations such as the 
reliability of place water molecules and thermal motion of unconstrained residues. By 
and large it has been difficult to correlate solution binding data, crystallographic 
structural data with theoretical calculations. The main reason for this inconsistency could 
be attributed to inherent experimental constraints. The binding data is generally not of a 
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quality to enable accurate quantitative comparisons. Some spectroscopic experiments can 
give direct measurement of free energy while calorimetric experiments just yields the 
enthalpic or heat energy changes of system. In addition to this, ∆G computed via 
sophisticated simulations often do not correlate well with the experimental binding 
measurements as quite often computational chemists involved in pharmaceutical research 
interchangeably use Ki and IC50 with Kd data in calculation of free energy relationships. It 
is commonly becoming a practice in drug discovery community to have assays that 
generate IC50 values rather than equilibrium constants. These approximations severely 
undermine the accuracy of models and should be used with discretion.  
 
One of the main aims in structure based drug design is explaining the binding interactions 
between a drug and its target. This is often achieved by virtual screening, more 
specifically, identifying a lead molecule out of thousands of molecules by docking and 
predicting affinity against a target protein. There are number of issues that currently are 
not adequately addressed. For example, in such calculations enthalpic contributions are 
often estimated by theoretical methods, knowledge-based potential functions, or 
parameters derived from experimental data. The force-fields used for calculations of free 
energy and intermolecular interactions assume that steric and electrostatic forces are 
sufficient to account for the observed biological interactions. However, these alone are 
never sufficient in accurate prediction of biomolecular interactions as they do not always 
include solvation/desolvation effects. The phenomenon of solvation/desolvation within 
the protein active site resulting in hydrophobic interactions has been particularly difficult 
to model computationally. Besides this, appropriate consideration of ionization and 
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tautomerization state of ligand and protein is also very important. Assumption of 
structural rigidity as an approximation may have severe entropic repercussions. In 
addition, binding may lead to protein adaptability and additional conformational changes 
that are not normally considered. These entropic contributions to binding are much less 
well-defined and often poorly quantitated or even ignored in many cases. Most 
approaches sum up these interactions separately as distinct enthalpic and entropic 
contributions, whereas, in reality, the ligand-protein recognition is a concerted event and 
thermodynamic quantities cannot be just simply summed. The interaction energies 
calculated without entropic contributions are not always expected to correlate well with 
the measured free energies of binding. Virtual screening has limited accuracy in 
exchange for a list of few promising candidates for further evaluation.  
 
Pioneering studies in free energy calculation over the past few years have made 
significant progress towards this goal. Among the several methods available to calculate 
free energy, complex and time consuming molecular dynamics simulations with explicit 
water have been shown to correlate with free energy. Free energy perturbation (FEP) 
calculations based on statistical mechanics relates the free energy of a system calculating 
the ensemble averages and treating solvent molecules and ions explicitly. However, 
calculation of free energy using molecular dynamics simulation is plagued by errors from 
a variety of sources. Statistical errors arise from the limited sampling of configurations 
accompanied by errors arising from the imperfect equilibration of the system. Multiple 
levels of time and uncertainty are compounded for complex biomolecular systems with 
inclusion of solvents and counter ions.  However, the size of the system makes 
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approaches of this sort computationally expensive and so simplified models are generally 
applied.  
 
Though computational modeling techniques hold a great promise for future progress in 
drug discovery and development it is still an evolving technology and has number of 
limitations. However the tools and techniques should be used with great cautions. Any 
theoretical model generated should be validated with experimental methods. 
  
1.5 Research Plan  
A new methodology based on HINT paradigm94 is applied to design novel inhibitors of 
tubulin protein and predict the binding mode of the protein-ligand complexes. The 
research utilizes the biological data, correlated with structure, to optimize the current (and 
succeeding) drug leads to design more effective candidate compounds with improved 
efficacy and minimal toxicity.   The study also aims towards developing novel molecular 
modeling tools to design clinically viable molecules. 
 
Given the utility of microtubule targeting as a strategy in the treatment of malignancy, the 
design and development of a new and clinically active class of microtubule-targeting 
compounds is highly desired. Pyrrole containing molecules derived from nature have 
proven to be particularly useful as lead compounds for drug development104,105. Highly 
functionalized pyrroles have previously been demonstrated to have potent cytotoxicity 
against a variety of human tumors with activity expressed at nM and µM concentrations 
in human breast tumor cell lines106,107. Collaborators in this research have recently 
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developed a series of brominated pyrroles, whose structure suggests that they might 
interfere with tubulin function (Figure 1a, b). Both cellular studies with one of the 
compounds, JG-03-14 (3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic 
acid ethyl ester) and molecular modeling analysis tend to support the contention that 
these compounds function as microtubule poisons108. As described later, the development 
of additional synthetic or semi-synthetic pyrrole derivatives is greatly facilitated due to 
their relative ease of synthesis, which, in turn, facilitates manipulation of the molecular 
properties in adding and removing a broad range of functional groups109. Consequently, 
this research proposes to refine and develop pyrrole-containing alkaloids as new 
chemotherapeutic agents for the treatment of breast cancer. 
 
1.5.1 Preliminary Research/Data 
 
In the initial studies carried out by our collaborators, several substituted pyrroles (Figure 
1b) were evaluated for their inhibitory activity on the growth of MCF-7 breast tumor 
cells108.  The studies demonstrated that the highest degree of anti-proliferative activity 
was expressed by JG-03-14, while a lesser degree of activity was evident for compound 
JG-05-2. The other analogs examined failed to demonstrate significant anti-proliferative 
activity at concentrations up to 500 nM.   
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Figure 1: a) Highly functionalized pyrrole scaffold. b) Structure of substituted pyrroles. 
a) 
 
 
 
 
 
b) 
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These observations provided insight into the structural requirements for the growth 
inhibitory activity/cytotoxicity of this class of agents and offer significant opportunity for 
structural alterations, which could lead to an improved drug candidate. All the subsequent 
experimental studies conducted by our collaborators suggested that JG-03-14 promoted 
extensive cell death during the initial period of exposure. These observations indicated 
that JG-03-14 abrogates breast tumor cell growth and survival through both the 
promotion of autophagic cell death and induction of a permanent growth arrested state.  
COMPARE analysis across NCI cancer cell line panel evaluated similar activity profile 
of colchicine and JG-03-14 and further corroborated mechanism of action of JG-03-14 to 
be similar to that of colchicine. Thus, there is strong evidence that this class of 
compounds interferes with the microtubule function. The effects of JG-03-14 along with 
the two positive controls, combretastatin A-4 and thiocolchicine, on tubulin assembly 
were studied (Table 1). All these agents inhibited the assembly of tubulin. 
  
Examination of the initial docking model in detail illustrates (Figure 2), the pocket shape 
and size, as indicated by the green translucent surface. The occupancy of the JG-03-14 
compound in this pocket is shown by the dot surface (color coded by brown=lipophilic, 
green=polar), regions of the site that do not have optimum interactions and consequently, 
locations at which molecular modifications of the lead compound might be effective, can 
be seen.  For example, the left region of the pocket, which is quite hydrophobic, 
effectively accommodates the two methoxy group substituents to the aromatic ring of JG-
03-14, but may be able to tolerate more steric bulk.    
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Table 1: JG-03-14 inhibits tubulin assembly and [3H]colchicine binding to tubulin.  
The effects of JG-03-14, and the positive controls combretastatin A-4 and thiocolchicine, 
on tubulin assembly were studied.  All these agents inhibited the assembly of tubulin and 
the EC50 values for inhibition (at 10 µM tubulin) were calculated. The effects of these 
compounds on 5 µM [3H]colchicine binding to 1 µM tubulin were determined. ND =not 
determined.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Inhibition of binding by inhibitor at 
Inhibition of tubulin assembly (EC50 in μM) 1 μM 5 μM 
JG-03-14 1.5 ± 0.2 49 ± 3  84 ± 0.6 
Combretastatin A-4 1.3 ± 0.1 83 ± 2  97 ± 2 
Thiocolchicine 1.0 ± 0.1 ND  67 ± 0.07 
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Figure 2:   Difference between pocket (green surface) and JG-03-14 structure volumes 
indicates regions of interest for designing new active analogs. 
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This model also suggests that the pyrrole substituent α to the nitrogen [C(=O)OCH2CH3 
in JG-03-14] can be optimized to make better interactions with the residues at the 
entrance to the pocket. Highly selective novel analogs with minimal toxicity can be 
designed using the proposed HINT-based de novo design methodology. The primary aim 
of this research is to design a library of highly selective pyrrole-based analogues.  The 
fragment-based approach can, therefore, be considered as a good working hypothesis for 
rationally designing novel analogs since the individual building blocks have to be linked 
in order to be a meaningful inhibitor. If the individual building blocks can be chemically 
linked easily in a chemical fashion, the approach has the advantage that the building 
blocks can be synthesized separately and linked in the final stage of the synthesis.   
 
A very extensive library of compounds for the synthesis and evaluation of analogs of JG-
03-14 can be created using fragment-based methodology.   The rationale is to select the 
compounds which have demonstrated interesting bioactivity, and vary the A, B, X, Y and 
Z groups (Figure 1a) in a logical manner based on modeling studies and the use of 
standard QSAR considerations (lipophilic character, electronic effects and steric effects).  
Each of the target molecules can then be subsequently subjected to docking and QSAR 
evaluation prior to the synthesis.  Structure activity information from other known agents, 
which have similar binding properties, can also be incorporated into the selection of the 
indicated target molecules.  This study also appreciates the fact that the most active 
compound found may not be the ideal candidate due to toxicity effects on normal cells. It 
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serves little purpose for a drug to kill tumor cells if overall toxicity to host tissue is high 
(i.e., the drug has low selectivity and/or a narrow therapeutic index. One of the objectives 
of this research was to design novel analogues using structure-based/ligand based 
computational methods. This is only the starting point for one of several approaches to be 
explored as predictive tools for molecular design. Therefore, this methodology will allow 
generation of a large family of strong candidates, on which, further xenograft and clinical 
studies can be carried out.  
 
Another such attempt was carried out to design and develop novel stilbene analogs that 
also target the microtubules at the colchicine site and act as anti-leukemic agents. A 
series of novel stilbene derivatives have been synthesized and studied with the main goal 
to investigate SAR of the stilbene analogs, as well as to improve its water solubility, a 
potentially negative aspect of this molecule that could be a serious hindrance in the pre-
clinical development. We attempted to optimize stilbene 5C using computer-based drug 
design and synthesize derivatives with benzimidazole or indole group. Derivatives with 
good cytotoxic activity, in particular, the derivatives 5C and 6C (Figure 3) were obtained 
and the study gave rise to two novel leads for further investigation. Alternative approach 
was also adopted to make prodrugs of stilbene 5C. A morpholino-carbamate derivative, 
prodrug of 5C, has a very good solubility in water, and is active in suppressing growth of 
tumor cells at a concentration of 5000 nM, which is a concentration 100 times higher than 
the parent stilbene 5C.  
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 Figure 3: Stilbene 5C and 6C. 
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 These data suggest that stilbene analogs could be a good candidate for further pre-
clinical and clinical development as a new anti-tumor agent for cancer therapy. 
 
A second synergistic, goal of this research was to design and develop novel molecular 
modeling software tools that would de novo identify and characterize the binding site and 
design analogs within the binding site. The available crystal structure of tubulin protein 
has a low resolution of 3.58 Å, undermining the ability to design highly selective ligands.  
Target-based generation of lead compounds requires that the three-dimensional structure 
of the ligand binding site be known as accurately as possible. Identification and 
characterization of active sites is imperative in the study of protein structure, particularly 
for the design of molecules that interfere with its function and modulate activity. 
However, in a low resolution crystal structure model, knowledge about the correct 
orientation of side chains is limited by ambiguities in position and orientation because the 
experimental electron density envelopes are generally featureless. Through the 
computational modeling studies, it was intended to elucidate the binding process by 
better characterizing the binding site.  
 
This involved analyzing the hydropathic character of the binding site and generating 
synthetically viable functionalities on parent molecules to exactly complement the 
binding features in the active site. This feature effectively facilitated designing clinically 
viable drug candidate with minimal toxicity. The methodology can also be extended to 
other systems and may find extensive applications in de novo drug design projects. These 
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efforts are expected to give rise to a new class of selective and potent anti-tumor drugs 
for use in combination chemotherapy.   
 
1.5.2 Expectations, Interpretation and Impact 
A key success criterion for this research is to productively use the biological cytotoxicity 
data to design new and more potent analogs. Development and biological evaluation of 
diverse set of analogs will be accomplished by the collaborators. The synthetic 
methodology used by our collaborators is very flexible and rapid, making it possible to 
synthesize and test many compounds designed computationally and thus, allow 
significant diversity in pyrrole substituents. This research plans appropriate SAR 
(Structure Activity Relationship) guided structural alterations on the lead compounds to 
optimize the desired bioactivity and minimize toxicity. This will involve structural 
changes, which will probe steric, electronic and lipophilic character of the parent 
molecule. Once the targeted compounds are prepared, sensitivity will be compared in 
breast tumor cells and normal cells.  
 
Favorable findings in terms of new compounds based on this research design would 
guide the synthetic efforts to develop analogs with a higher degree of selectivity.  The 
success of this research project depends on the effectiveness of the multidisciplinary 
collaboration. For example, cytotoxicity studies will allow molecular models and QSAR 
approaches to be refined, which will then suggest the next round of pyrrole analogs to be 
synthesized and biologically evaluated with the ultimate goal of generating a significant 
clinical candidate.  
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The iterative cycles of modelingÆsynthesisÆtestingÆmodeling, etc. will be 
continuously monitored to improve the models and consequently, the predictions of the 
compound activities. 
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CHAPTER 2 
 
Docking and Hydropathic Scoring of Polysubstituted Pyrrole 
Compounds with Anti-Tubulin Activity 
 
 
2.0 Abstract  
Compounds that bind at the colchicine site of tubulin have drawn considerable attention 
with studies indicating that these agents suppress microtubule dynamics and inhibit 
tubulin polymerization. Data for eighteen polysubstituted pyrrole compounds are 
reported, including antiproliferative activity against human MDA-MB-435 cells and 
calculated free energies of binding following docking the compounds into models of αβ-
tubulin.  These docking calculations coupled with HINT interaction analyses are able to 
represent the complex structures and the binding modes of inhibitors such that calculated 
and measured free energies of binding correlate with an r2 of 0.76.  Structural analysis of 
the binding pocket identifies important intermolecular contacts that mediate binding. As 
seen experimentally, the complex with JG-03-14 (3,5-dibromo-4-(3,4-dimethoxyphenyl)-
1H-pyrrole-2-carboxylic acid ethyl ester) is the most stable.  These results illuminate the 
binding process and should be valuable in the design of new pyrrole-based colchicine site 
inhibitors as these compounds have very accessible syntheses. 
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2.1 Introduction 
A large number of targets are under exploration for chemotherapeutic treatments for 
cancer.  In the past several years, based on the efficacy and commercial successes of 
paclitaxel and the vinca alkaloids, there have been major efforts to design inhibitors that 
bind and interfere with the function of microtubules.  Microtubules are essential elements 
of the cytoskeleton and extremely important in mitosis and cell division.  Colchicine, the 
first drug known to bind to the tubulin protein110,111, inhibits microtubule formation and at 
high concentrations causes loss of cellular microtubules.  In contrast, paclitaxel and its 
analogues actually promote microtubule polymer formation112-114, albeit by acting at a 
different site on tubulin than colchicine.  A variety of small molecules with diverse 
molecular scaffolds have been shown to bind tubulin at the colchicine site115-118.  One 
class of these compounds receiving particular attention has been that based on the natural 
product combretastatin A-4 discovered by Pettit119,120.  Despite some successes, the 
discovery of new, more efficacious inhibitors is becoming increasingly important because 
of multi-drug resistance to tubulin-binding antimitotic agents121.   
 
Natural products containing pyrrole have diverse and interesting biological activities, and 
have proven to be particularly useful as lead compounds for drug development105,109,122. 
As part of long-term program to develop vinylogous iminum salt-based syntheses of 
natural products containing the pyrrole group, some early synthetic intermediates were 
evaluated against a panel of human and murine tumor cell lines123. Many of these 
synthetic compounds were highly active against cancer cell lines, and some inhibited 
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DNA synthesis without binding directly to DNA124. Earlier studies also provided clues to 
the design of pyrrole analogs that might have potent antiproliferative activities and the 
ability to bind to tubulin.  
 
The marine natural product lukianol A contains a highly oxygenated 3,4-diphenylpyrrole 
motif, and it potently inhibited the growth of the human KB cancer cell line125. Banwell 
and colleagues suggested that lukianol A represented a configurationally stable hybrid of 
combretastatin A-4 and colchicine126. John Gupton from University of Richmond has 
synthesized another class of biologically interesting pyrroles, which are somewhat related 
to the pyrrolomycin natural products by virtue of their halogenated pyrrole backbone127. 
Brominated analogs of previously synthesized pyrroles were prepared, and they retained 
the cytotoxic activity exhibited by the non-brominated pyrroles128. While mechanistic 
studies indicated that two of the brominated pyrrole compounds bound directly to DNA, 
causing DNA cross-linking, the mechanisms of action of other brominated pyrrole 
analogs remained unknown. Based on the structural similarity of the compounds to 
combretastatin A-4 and Banwell’s suggestion that several pyrrole containing natural 
products represent stable hybrids of combretastatin and colchicine, the effect of 
brominated pyrroles were examined on cellular microtubules. Several of the brominated 
pyrrole analogs had microtubule depolymerizing effects. The most potent was 3,5-
dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14; 
structure in Figure 4).  
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Figure 4: Substituted Pyrroles 
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It is significant to note that JG-03-14 is structurally unique among combretastatin-like 
compounds. It possesses a single phenyl group which is highly oxygenated; other 
combretastatin analogs always possess two highly oxygenated phenyl groups. The mode 
of action and the cellular effects of this compound were evaluated in detail, and it was 
found to be a potent antimitotic agent. Binding studies show that JG-03-14 binds to 
tubulin within the colchicine site. Our initial studies indicate that this compound has 
antitumor effects and it represents a promising lead for the generation of new analogs 
with important biological properties. While investigating the cytotoxic activity of 
compounds in a series of synthetic polysubstituted pyrroles (Figure 4), our interest in the 
colchicine binding site of tubulin as a putative target for computational drug design 
studies was piqued after a COMPARE129 analysis showed a correlation between one of 
the compounds (JG-03-14) and colchicine of 0.681 over the 45 cell lines that were 
assayed for both compounds. COMPARE evaluates similarities in activity profiles across 
the NCI cancer cell line panel, and has been used to elucidate modes of action for new 
anticancer agents129. COMPARE analysis and modeling studies suggest that JG-03-14 
represents a novel chemotype for the colchicine site. However, in any case, the true 
therapeutic potential of the colchicine site on tubulin has not been fully explored because 
of the lack of truly atomic level knowledge of the site.   
 
In 2000, Hamel and colleagues mapped the binding site of colchicinoids on β-tubulin130.  
Using molecular modeling and computational docking of colchicinoids into the electron 
crystallographic model of β-tubulin in protofilaments130, they found two potential binding 
sites. The first was entirely encompassed within β-tubulin with the colchicinoids forming 
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adducts with Cys 356.  The second potential site was located at the α/β interface and 
involved hydrogen bonding with Cys 241.  More recently, Nguyen and colleagues131 
developed a comprehensive pharmacophore model for structurally diverse colchicine-like 
tubulin inhibitors using a structure-based approach on the newly available α/β-
tubulin:DAMA-colchicine X-ray structure132.  This crystal structure definitively 
identified a cleft at the α/β interface as the colchicine binding site, but has a resolution of 
only 3.58 Å and thus requires considerable computational effort before models derived 
from it can be considered “all-atom”.  
 
In this chapter we report the results of docking this set of putative ligands into the 
colchicine site of tubulin to build stereochemically reasonable models.  We evaluated 
these docking models with the HINT free energy force field91 and found a good 
correlation between HINT scores and measured IC50s of cell proliferation by the 
compounds.  While the measured IC50s represent a downstream biological effect and we 
are making the pragmatic assumption that the modes of action for all compounds in this 
series are the same, these results do allow us to appropriately characterize the colchicine 
binding site and will also serve in design and validation of new compounds similar to JG-
03-14 in later stages of this research.  This is particularly relevant since these and other 
polysubstituted pyrrole compounds are synthetically accessible. 
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2.2 Materials and Methods 
2.2.1 Synthesis of Pyrrole Compounds   
The synthetic methods used to prepare the highly functionalized pyrroles and related 
derivatives depicted in Figure 4 can be found in previously reported work128,133-136. 
 
2.2.2 Antiproliferative Activity of Substituted Pyrroles against Human 
Tumor Cell Lines   
The antiproliferative effects of the compounds were evaluated in MDA-MB-435 cells 
using the SRB assay as previously described137. All the biological assays were carried out 
by Dr. Susan L. Mooberry and colleagues at SFBR. A 48 hr exposure time was used.  
The IC50 values, i.e., the concentration that causes 50% inhibition of proliferation, was 
calculated from the log dose-response curves and represents the mean of three 
independent experiments.  The effects of the compounds on cellular microtubules were 
evaluated using indirect immunofluorescence techniques.  Briefly, A-10 cells were 
exposed to the compounds for 18 hr and then the cells were fixed and microtubules 
visualized using a β-tubulin antibody and the DNA was visualized using DAPI.  The 
EC50s for microtubule depolymerization were determined using visual observation as 
previously described138. A range of concentrations was tested for each compound and the 
percent microtubule loss determined for each concentration.  The data from 3 
independent experiments were averaged and plotted as percent microtubule loss vs. 
concentration and EC50 values calculated.  
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2.2.3 Model Building   
The X-ray crystal structure (3.58 Å) of αβ-tubulin complexed with DAMA-colchicine132 
PDB code: 1SA0) was used in this study.  The stathmin-like domain and the C and D 
subunits were removed from the model.  After hydrogen atoms were added to the model, 
their positions were optimized to an energy gradient of 0.005 kcal-Å/mol with the Tripos 
force field (in Sybyl 7.1) while keeping heavy atom positions fixed.  The models for 
pyrrole analogues were constructed using the Sybyl 7.3 (www.tripos.com) suite and 
optimized similarly78.  
 
2.2.4 Docking   
Computational docking was carried out using the genetic algorithm-based ligand docking 
program GOLD 3.069.  GOLD explores ligand conformations fairly exhaustively and also 
provides limited flexibility to protein side chains with hydroxyl groups by reorienting the 
hydrogen bond donor and acceptor groups.  The GOLD scoring function is based on 
favorable conformations found in Cambridge Structural Database and on empirical 
results of weak chemical interactions139.  The active site was defined by a single solvent 
accessible point near the center of the protein active site, an approximate radius of 10 Å, 
and the GOLD cavity detection algorithm.  GOLD docking was carried out without 
constraints to get an unbiased result and to explore all possible binding modes of the 
ligands.  The tri-methoxy phenyl fragment of colchicine was used as the template for 
biasing the pose of all ligands. In this study we performed 100 GOLD genetic algorithm 
runs, as opposed to the default of 10 and early termination of ligand docking was 
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switched off.  All other parameters were the defaults.  To evaluate and validate GOLD 
performance the co-crystallized ligand DAMA-colchicine132 was extracted and docked.  
GOLD accurately reproduced the experimentally observed binding mode of DAMA-
colchicine in αβ-tubulin.  All remaining ligands were docked using the same parameters. 
 
Dockings with different/optional constraints such as enforced hydrogen bonds, 
hydrophobic regions and scaffold match were also explored.  For hydrogen bond 
constraints, docking was biased so that the ligands make hydrogen bonds with Asn258, 
Ser178, Asn101, and the backbone amides of Ala180 and Val181. For region 
hydrophobic constraints the ligand positions were constrained by defining a hydrophobic 
sphere where the tri-methoxy phenyl moiety of colchicine was positioned.  Then specific 
ligand atoms to be docked in the hydrophobic region of the active site were defined.  
Alternatively, scaffold match constraints were used to place the ligand at a specific 
position within the active site.   
 
2.2.5 Hydropathic Scoring   
The HINT (Hydropathic INTeractions) scoring function91 (version 3.11S β) was used to 
investigate the structural aspects of the interactions by analyzing and ranking the GOLD 
docking solutions.  For selection of the optimum docked conformation and to further 
differentiate the relative binding efficacy of the pyrrole ligands, interaction scores were 
calculated for each pose found by docking.  The protein and ligands were partitioned as 
distinct molecules. “Essential” hydrogen atoms, i.e., only those attached to polar atoms 
(N, O, S, P) were explicitly considered in the model and assigned HINT constants.  The 
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inferred solvent model, where each residue is partitioned based on its hydrogen count, 
was applied.  The solvent accessible surface area for the amide nitrogens of the protein 
backbone were corrected with the “+20” option. Finally, HINT scores were plotted 
against experimental binding free energies that were calculated using the standard Gibbs 
free energy equation: 
 
∆Gbinding =  - R T ln(Keq),     (7) 
 
where R is Boltzmann’s constant (1.9872 cal K-1 mol-1) and T is 298 K; Keq is an 
equilibrium binding constant, ideally KD.  In this work measured IC50 values are being 
used as approximations for equilibrium constants.   
 
2.3 Results and Discussion 
While the character of the colchicine binding site was investigated by Nguyen et al.131, 
their study was directed at deriving a generalized pharmacophore for the site and 
consequently the data set included only two polysubstituted pyrroles.  These compounds 
represent an emerging class of agents with potential activity against a variety of human 
tumors with activity expressed at nM or µM concentrations in human tumor cell 
lines108,135, but having advantages over natural products in terms of drug design and 
development.  In particular, we have been exploring a series of brominated pyrroles 
whose structure suggests that they might interfere with tubulin function.  One member of 
this series (JG-03-14, 3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic 
acid ethyl ester), for which NCI tumor panel activity had been obtained128, was suggested 
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by COMPARE129 to have an activity profile similar to colchicine.  Cellular studies with 
JG-03-14 further support the contention that these compounds function as microtubule 
poisons108.  In addition, JG-03-14 was found to promote autophagic cell death while 
retaining activity in tumor cells expressing the multidrug resistant pump108,133.  Because 
the development of additional synthetic or semi-synthetic pyrrole derivatives in this class 
is facilitated with their relatively facile syntheses, including modification of the molecule 
by adding and removing functional groups128, we have both a rather extensive collection 
of molecules in-hand (Figure 4) for building predictive molecular models and the 
potential for rational design and synthesis of many others.    
 
2.3.1 Antiproliferative Activity of Polysubstituted Pyrroles 
 Results from a number of assays have previously appeared regarding the cytotoxic 
activities of the lead compound JG-03-14108,128,140.  However, most of the compounds in 
this series have not been examined in detail.  An important component of structure-
activity relationships and/or computational activity predictions is having reproducible and 
comprehensive data for a relatively large series of compounds, even those with 
comparatively poor activity, because understanding why particular compounds are 
inactive is potentially just as valuable as data on active compounds.  Table 2 sets out the 
experimental antiproliferative assay results against human MDA-MB-435 cancer cells for 
the compounds in Figure 4.  While JG-03-14 remains the compound with the most potent 
(36 nM) activity, a few others (Table 2) have activities that are only about 7-10 fold less 
potent, thus suggesting that design of additional new compounds with desirable 
properties is possible.   
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Table 2: Experimental IC50, EC50 and docking results for polysubstituted pyrrole 
compounds. 
 
   
  
Compound Activity Set 
IC50 for anti-
proliferationa pIC50 
ΔGbinding 
(kcal mol-1) 
HINT 
score 
HINT 
LogP 
EC50 for loss of 
microtubulesb 
JG-03-14 36 nMc 7.74 -10.14 626 2.60 490nM 
JG-03-6 312 nM 6.51 -8.87 609 3.17 >50μM
f 
JG-05-1B 361 nM 6.44 -8.78 483 2.36 5.1 μM 
JG-05-3B 278 nM 6.55 -8.94 410 2.36 2.4 μM 
JG-05-5 
A 
919 nM 6.04 -8.23 559 3.02 >50 μM
f 
JG-05-8 2.2 μM 5.70 -7.71 433 2.97 >50 μM
f 
JG-03-12 2.6 μM 5.58 -7.61 221 4.88 >50 μM
f 
JG-05-4 1.1μM 5.95 -8.12 455 3.34 7.1 μM 
JG-05-6 1.4 μM 5.85 -7.98 351 3.59 7.5 μM 
JG-03-13 5 μM 5.30 -7.23 163 1.48 >50 μM
f 
JG-05-1A 1.9 μM 5.72 -7.80 508 5.62 >50 μM
f 
JG-05-2A 
B 
4.2 μM 5.37 -7.33 149 6.58 >50 μM 
JG-05-7 10 μM 5.00 -6.82 152 2.43 >50 μM 
JG-05-2B 13 μM 4.89 -6.66 136 2.90 >50 μM 
JG-03-9 10 μM 5.00 -6.82 54 4.63 >50 μM 
JG-03-4 10 μM 5.00 -6.82 27 6.66 >50 μM 
JG-03-8d >10 μM 4.00 -5.45 -241 3.69 >50 μM 
JG-05-3Ad 
C 
>20 μM 3.70 -5.04 296 9.02 >50 μM 
Colchicinee 2 μM 5.70 -7.77 563 3.24 N/D 
DAMA-colchicinee 
N/A 
2 μM 5.70 -7.77 455 3.70 N/D 
aAntiproliferative activity against human MDA-MB-435 cells using the SRB assay.  
bMicrotubule depolymerizing activity for microtubule loss. 
cFrom reference 110. 
dpIC50 and ΔGbinding calculated for 10×IC50. 
eReported colchicine IC50 data was an average of values reported previously in the literature, references 
110.  For calculation purposes DAMA-colchicine was assumed to have same binding as colchicine. 
fMechanism of cytotoxicity appears to be unrelated to microtubule disrupting activity.  
N/A – not applicable; N/D – not determined. 
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Results of a second assay, microtubule depolymerizing activity EC50s for microtubule 
loss that serves as a partial check on mechanism of action, are also reported in Table 2.    
 
2.3.2 The Colchicine Binding Site 
 Binding models for each pyrrole analogue were investigated to delineate steric, 
electrostatic and hydropathic features of the colchicine binding site.  Because we have 
focused on a series of eighteen compounds with IC50s ranging over more than three  
orders of magnitude (see Table 2), we performed detailed docking studies with 
GOLD69,139 followed by free energy scoring using the HINT protocol91,102 to assess the 
binding modes. Without added constraints GOLD was found to reliably re-dock the 
crystallographic DAMA-colchicine ligand (RMSD = 0.76 Å) that was then used as the 
reference for all other docking experiments.  The HINT score for co-crystallized DAMA-
colchicine was 139; in the re-docked pose this score was 455.  However, docking of the 
pyrrole analogues with GOLD produced a mixture of orientations that could not be 
rationalized with the GOLD docking score.  Thus, as we have described in an earlier 
report96, docked poses were re-scored with HINT and we chose the highest HINT-scored 
pose for further analysis (see Table 2).  Docking poses created using a variety of 
constraints (see Methods) did not yield higher scoring models and were less interpretable 
than the “freely” bound models we are using.  These docked models of substituted 
pyrroles fit within the pharmacophoric model proposed by Nguyen et al.131, and for the 
structural features in common between the substituted pyrroles and in the Nguyen et. al. 
study, the docking models are in generally good agreement. Key is that the hydrophobic 
methoxy substituted ring of the pyrrole analogues sits at the hydrophobic center where 
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the TMP moiety of colchicine is found.  Note that, although the pyrrole compounds have 
quite similar structures and are generally positioned in the binding pocket with essentially 
the same mode, the HINT scores are very sensitive and slight positional differences are 
detectable in the scores.  This sensitivity combined with the number of compounds in the 
data set allowed us to analyze the site in considerable detail.   
 
The focus of these computational investigations was on structural aspects of the 
interactions.  The colchicine binding site lies at the interface between the α and β subunits 
of tubulin, mostly in the β subunit lined by helices 7 and 8 (see Figure 5).  The funnel-
shaped binding cavity has a volume of about 600 Å3.  Residues Tyr202β, Val238β, 
Thr239β, Cys241β, Leu242β, Leu248β, Leu252β, Leu255β, Ile378β, and Val318β form 
the narrow funnel end-like part and confer a strong hydrophobic character to this part of 
the cavity.  At the wider portion, the cavity is surrounded by Ala250β, Asp251β, 
Lys254β, Asn258β, Met259β, Ala316β, Ala317β, Thr353β and Ala354β making it 
moderately polar/moderately hydrophobic.  The open mouth end is surrounded by 
Asn101α, Thr179α, Ala180α, Val181α and Thr314β, Asn349β, Asn350β, Lys352β.  The 
crystal structure for the complex indicates that DAMA-colchicine (and presumably 
colchicine) is positioned in the pocket such that its tri-methoxyphenyl (TMP) moiety sits 
snugly in the narrow hydrophobic pocket.  Colchicine also forms hydrogen bonds with 
the backbone amides of Ala180α and Val181α.  
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Figure 5: Colchicine binding site at the interface between the α and β subunits of tubulin.  
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2.3.3 Structure-Activity Binding Relationships  
 The pyrrole analogues were clustered into three activity sets in order to study them in 
detail (see Table 2).  The first set (A) was comprised of substituted pyrroles that showed 
antiproliferative activity with sub-µM IC50s.  The second set (B) consisted of ligands with 
IC50 values ranging from 1 μM to 5 μM.  The remaining ligands, with IC50 values above 5 
μM, comprised the third set (C).  The analogs from subset A have noticeable similarity in 
their structures and are relatively simpler molecules than those in sets B and C.  For all of 
these (set A) compounds the pyrrole ring is substituted by bromines at the 3 and 5 
positions and an ethyl ester group at position 2.  The differences among this group are 
substitutions to the phenyl ring at the 4 position of pyrrole.  In these, the more potent 
compounds, most substituents to the phenyl ring, i.e., Cl, Br and methoxy, serve to make 
this portion of the ligand hydrophobic.  Figure 6A illustrates the final docked orientations 
of the high-affinity pyrroles in the colchicine site of tubulin.  The hydrophobic substituted 
phenyl ring fits snugly in the hydrophobic (narrow funnel) region of the binding pocket.  
The docked model for JG-03-14 is qualitatively similar to one reported earlier108. 
 
HINT hydropathic analysis reveals more detail concerning the forces orienting these 
ligands in the binding site.  First, hydrophobic interactions are the dominating force 
contributing towards the stability of the complexes, with additional hydrogen-bonding 
interactions anchoring the ligands in the cavity.  As listed in Table 2, the most potent-
binding ligand has the highest HINT score (vide infra), i.e., JG-03-14 interacts with the 
binding site residues forming the most stable complex.  The methoxy-substituted phenyls 
are positioned deep in the hydrophobic cavity surrounded by Cys241β, Leu242β,  
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 Figure 6: Pyrrole analogues docked at colchicine binding site. (A) Substituted pyrroles 
with activity in sub-μM IC50. (B) Ligands with IC50 ranging from 1 μM to 5 μM. (C) 
Ligands with IC50 value above 5 μM.  
  
 
 
 
a 
b 
c 
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Leu248β, Ala250β, Leu255β, Ala354β and Ile378β, all of which contribute to favorable 
hydrophobic-hydrophobic binding. Figure 7 illustrates these interactions in a HINT map, 
where the relative sizes of the displayed contours represent the strength, and the colors 
represent the character, of the interactions between JG-03-14 and the tubulin colchicine 
binding site.  The phenyl ring of JG-03-14 fits in a hydrophobic glove formed by the 
Leu248 and Leu255. Favorable polar interaction with Asn101, Cys241 and Asn258 also 
contribute in binding.  The ethyl ester tail of the ligand faces towards the polar opening 
and is stabilized with a strong hydrogen-bond to the amide oxygen of Asp258β with a 
length of 2.41 Å.  Another set of strong hydrogen-bonds are formed between the amine of 
Asn101α and the carbonyl oxygen (1.48 Å) and alcoholic oxygen (2.72 Å) of the ligand’s 
ethyl ester substituent.  This latter feature, anchoring of the flexible ethyl ester tail, is 
somewhat different in our models as compared to those of Nguyen et al131, probably due 
to the lack of steric constraints at the open polar end of the cavity. 
 
On analyzing subset B, docked ligands in the low μM range, it can be seen that these 
ligands are somewhat similar to the subset A ligands, but with slightly bulkier groups 
overall as in JG-03-12, JG-05-6 and JG-05-1A, more highly substituted at the pyrrole 
ring as in JG-03-12, and/or with less hydrophobic substituents as in JG-03-13, JG-05-4, 
and JG-05-8.  For example, in JG-03-13 the single chlorine substitution is less 
hydrophobic than the two bromines of JG-03-14 and having only one methoxy also 
reduces this compound’s hydrophobicity.  In the case of JG-05-8 only a single methyl 
group substitutes the phenyl ring at the para position.   
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Figure 7: HINT interaction maps for JG-03-14 (ball and stick rendering) at colchicine 
binding site. Blue contours represent regions of favorable polar interactions, e.g., 
hydrogen bonds, red contours represent unfavorable polar interactions and green contours 
represent favorable hydrophobic interactions. 
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JG-03-12 and JG-05-1A have bulkier substitutions at the 5 position of the pyrrole, likely 
leading to their higher (less potent) IC50 values.  The docked models (Figure 6B) and 
detailed HINT analysis confirm this SAR by showing a relatively poor fit in the active 
site for the bulkier ligands, and poorer hydrophobic HINT scores for the less optimally-
substituted ligands.  A single exception, the napthyl-substituted JG-05-6 produces a high 
HINT score inconsistent with its relatively low potency, but this may be due to this 
compound being too hydrophobic (Table 2) for solubility or transport to the site (vide 
infra).  
 
Lastly, many of the subset C (inactive) ligands (Figure 6C) do not fit well in the site, 
while others are inappropriately decorated to make the required contacts with the site 
residues.  Many of them have one or more bulkier substituents on the pyrrole ring, and 
only fit in the binding pocket with their side chains protruding out of the pocket.   
 
2.3.4 Predictive Models for Ligand Binding 
 Figure 8 presents the correlation between the experimental binding (ΔGbinding as 
calculated from IC50, see Methods) in kcal mol-1 and HINT scores for the eighteen 
synthetic pyrroles in this study.  The IC50s, antiproliferative activities of the compounds, 
are being taken in this work as approximations of binding affinity, with the implicit 
assumption that the antiproliferative activity is wholly due to tubulin binding.  The 
consequences of this assumption will be discussed below.   
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Figure 8: Dependence of the experimental ∆G on HINT score units for Tubulin-pyrrole 
complexes. The solid black line represents the regression for ∆G vs. HINT score for all 
protein-ligand complexes. The red line represents the regression for ∆G vs. HINT score 
excluding the circled outlier (JG-05-3A). 
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The trend represented by the plot of Figure 8 indicates that higher scoring complexes are 
generally among those with more favorable free energies of binding, while lower scoring 
complexes are generally those with unfavorable binding.  The correlation equation: 
 
 ΔG = –0.0039 HTOTAL – 6.35,     (8) 
 
has an r2 = 0.5818 and a standard error of ± 0.52 kcal mol-1.  A better correlation is 
observed after omitting the outlier JG-05-3A from the correlation.  Although this 
compound shows a high HINT score suggesting optimal intermolecular interactions 
within the tubulin colchicine site, it has a very high logPo/w value of 9.02 (Table 2) 
suggesting that this compound would likely not be transported to the binding site and 
may even be insoluble.  The scoring function does not take into account cell permeability 
and completely ignores whether or not the compound could in vivo or in vitro be 
accessible to the binding site.  Thus, the unfavorable physiochemical properties of JG-05-
3A, and not statistical evaluation, warrant excluding it from the model and justify treating 
it as an outlier.  Ignoring this outlier gives an r2 = 0.76 and a standard error of ± 0.41 kcal 
mol-1, with a very similar correlation equation:  
 
         ΔG = –0.0039 HTOTAL – 6.51,     (9) 
 
We believe that this model is predictive such that we can identify the active (subset A) 
ligands from the inactive (subset C) ligands with reasonable confidence and that further 
refinement of the model with additional data will improve its usefulness.  However, it 
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must be noted that the EC50 for tubulin depolymerization data (Table 2) suggest that 
several of the compounds (two in set A) that dock in the colchicine binding site with high 
HINT scores do not appear to cause perturbations of cellular microtubules, i.e., their 
interactions within the colchicine binding site may not be the mechanism of cytotoxicity.  
Thus, while we cannot state that all antiproliferative activity is due to tubulin binding in 
the pyrrole compounds, there is enough experimental information for several of the more 
active compounds, and a compelling case for JG-03-14, to believe that designing ligands 
to bind with optimimum interactions in the tubulin colchicine binding site will produce 
compounds that will likely disrupt cellular microtubules and cause antimitotic actions.  
 
 2.4 Summary  
The present communication demonstrates that the state-of-the-art molecular modeling 
calculations along with HINT interaction calculations are able to complement 
experimental studies of binding in many aspects, including accurate representation of the 
structure of the complex and the binding mode of putative drugs.  The structural analysis 
of the binding pocket has identified important intermolecular contacts that mediate 
binding. The complex with JG-03-14 has the highest binding score corroborating the 
experimental data.  In conclusion, the present series of pyrrole analogues have yielded 
representative compounds that are potent tubulin polymerization inhibitors and others 
that bind with less efficacy, but that still provide useful information for designing 
compounds with improved performance and selectivity.   
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CHAPTER 3 
 
 
Hydropathic Analysis and Biological Evaluation of Stilbene 
Derivatives as Colchicine Site Microtubule Inhibitors with Anti-
Leukemic Activity. 
 
 
 
3.0 Abstract 
The crucial role of the microtubule in the cell division has identified tubulin as a target 
for the development of therapeutics for cancer; in particular tubulin is a target for 
antineoplastic agents that act by interfering with the dynamic stability of microtubules.  A 
molecular modeling study was carried out to accurately represent the complex structure 
and the binding mode of a new class of stilbene-based tubulin inhibitors that bind at the 
αβ-tubulin colchicine site.  Computational docking along with HINT score analysis fitted 
these inhibitors into the colchicine site and revealed detailed structure-activity 
information useful for inhibitor design.  Quantitative analysis of the results was in good 
agreement with the in vitro antiproliferative activity of these derivatives (ranging from 3 
nM to 100 μM) such that calculated and measured free energies of binding correlate with 
an r2 of 0.89 (standard error ± 0.85 kcal mol-1).  This correlation suggests that the activity 
of unknown compounds may be predicted.   
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 3.1 Introduction 
 
 
Stilbene-based compounds are largely present in nature and have become of particular 
interest to chemists and biologists because of their wide range of biological 
activities141,142. Stilbene itself does not occur in nature, but hydroxylated stilbenes have 
been found in many medicinal plants. The hydroxylated stilbene trans-resveratrol (trans-
3,40,5-trihydroxystilbene, Figure 9) is a phytoalexin present in grapes and plays a role in 
the prevention of coronary artery disease associated with red wine consumption141,143-145. 
Resveratrol has also antioxidant and anti-inflammatory properties and could be a 
potential chemopreventive and therapeutic agent in cancer146,147. In vitro inhibition of cell 
proliferation148 and in vivo anti-neovascularization by resveratrol have been 
demonstrated149. On the other hand, the cis-stilbene motif represents a key structural 
feature of a broad class of natural and synthetic compounds endowed with an 
exceptionally strong tubulin polymerization inhibitor activity interfering mainly with 
microtubule formation at the tubulin colchicine binding site. In this context, the natural 
cis-stilbene combretastatin A-4 (CA-4) (Figure 9), an antimitotic agent isolated from the 
bark of the South African tree Combretum caffrum, and its 30-amino derivative (AC-
7739) possess potent and interesting antitumor activity150,151.  
 
Combretastatins have been demonstrated to bind at the colchicine binding site and 
destabilize microtubule assembly and prevent spindle formation in mitotic cells152. The 
relatively simple structure and high affinity of combretastatins for the colchicine binding 
site has led to the synthesis and subsequent evaluation of a large number of
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RH3CO
OCH3 OCH3
A B
OR3
R4
R2O
R1
OR
trans-Resveratrol R=R1=R2=R3=R4=H
 Combretastatin A-4(CA-4) R=R2=R3=CH3, R1=OCH3, R4=OH
AC-7739 R=R2=R3=CH3, R1=OCH3, R4=NH2
a: Stilbene 5c R=NH3+Cl-
b: Stilbene 6c R=OH  
Figure 9. Natural and synthetic stilbenes 
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analogues; novel compounds derived from this core continue to hold interest as potential 
therapeutics152-154.  Stilbene and its analogues (Figure 9 a, b) are structurally similar to 
combretastatin and are also able to bind to microtubules, suppress microtubule dynamics, 
and arrest the cell cycle at a G2/M phase that is associated with induction of 
apoptosis155,156.  
 
Their mechanism of action is related to tubulin-binding properties that result in rapid 
tumor endothelial cell damage, neovascular shutdown and subsequent hemorrhagic 
necrosis157. Our collaborative group has recently synthesized a series of derivatives 
structurally related to both resveratrol and CA-4, in cis and trans orientations. 
Modifications were made by placing OH, NH2, or OCH3 groups at positions 30 and 40 
and OCH3 at positions 3,5. The IC50 for each of each stilbene was tested in HL60 cells. 
Several active stilbenes were identified and, among them, cis-3,40,5-trimethoxy-30-
aminostilbene (5C) and cis-3,40,5-trimethoxy-30-hydroxystilbene (6C) were found to 
induce HL60 apoptosis at nanomolar concentrations (IC50 = 30 nM)158. Examination of 
the structures of stilbenes 5C and 6C reveals similarity to colchicine, combretastatin 
CA4158, ZD6126, and AVE-8062.  
 
The new stilbenes interfere with microtubule formation at the tubulin colchicine binding 
site (Figure 10), in a similar manner as CA-4 and AC-7739, inducing apoptosis in HL60 
leukemia cells, but not in normal c-kit-positive hematopoietic progenitor cells at similar 
concentrations156. These two stilbenes have a similar cytotoxic effect in HL60 cells  
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 Figure 10. The Tubulin-colchicine:RB3-SLD complex, The complex includes  
alternating tubulin αβ heterodimers, with the colchicine binding site at the intradimer 
interface, the taxol binding site on the β subunit and the vinblastine binding site at the 
interdimer interface of the αβ subunit.  
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expressing multiple-drug resistant gene158, which is responsible for chemotherapeutic 
resistance to anthracycline in leukemia. In addition to the effect in leukemia cells, 
stilbene 5C is also highly potent against various solid tumor cells and blocks cell cycle 
progression in G2-M phase158. Stilbene 5C is tolerated in mice up to 100 mg/kg by 
intraperitoneal injection without major organ toxicity. In particular, there was no bone 
marrow toxicity, and the ability of bone marrow engraftment was not affected by stilbene 
5C treatment156. Similar to other colchicine site tubulin inhibitors, stilbene 5C selectively 
suppresses tumor vascular perfusion without damaging normal vascular perfusion based 
on a DCE-MRI study159. Most importantly, mice treated with five daily injections of 5C 
at 25 mg/kg/day did not show any compromise in heart function, indicating that it could 
be a colchicine site inhibitor with negligible cardiotoxicity159.  
 
As the synthesis of stilbene analogues is relatively facile, our goal for this study was to 
create a quantitative structure-activity model of these compounds that would guide the 
synthesis of new, potentially more efficacious stilbene derivatives. Thus, we report here 
on the structural requirements for interaction between stilbene analogs and tubulin with 
computational docking and hydropathic scoring of multiple stilbene analogs into the 
colchicine-binding site of tubulin. 
 
 3.2 Materials and Methods  
3.2.1 Synthesis 
Synthesis of stilbenes 5c, 6c and its analogs (Figure 11) was performed as described by 
Roberti et al.158 who provided all samples for bioactivity analysis. 
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Figure 11: Stilbene analogs 
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3.2.2 Antiproliferative Activity of Stilbenes against Human Tumor Cell 
Lines 
 The antiproliferative activity of stilbene derivatives was determined by Alamar BlueTM 
staining. The bioassays were carried out in the lab of Dr. Ray Lee at Massey Cancer 
Center, VCU. In brief, cells were grown in 96-well plates and treated with 0, 0.01, 0.03, 
0.1, 0.3, 1.0, and 3.0 μM of the stilbene for 48 hours before being harvested for Alamar 
blueTM staining. In this staining, 1/10 volume of Alamar Blue™ solution was added to 
each well and optical density (OD) at 570 and 600 nm was determined by a microplate 
reader.  The percentage of growth inhibition was calculated according to the 
manufacturer’s formula as follows:  [(117216 x A570) –(80586 x A600)]/[(117216 x Ao570)- 
(80586 x Ao600)] x 100. In this formula, A570 is the absorbance of the treated samples at 
570 nm; A600 is the absorbance of the treated samples at 600 nm; Ao570 is the absorbance 
of the untreated samples at 570 nm; and Ao600 is the absorbance of the untreated samples 
at 600 nm. The two constants, 117216 and 80586, are the extinction coefficients of 
Alamar Blue™ at 570 and 600 nm respectively. Each concentration was repeated in 
triplicates.   
 
3.2.3 Model Building 
The X-ray crystal structure (3.58 Å) of αβ-tubulin complexed with DAMA-colchicine132 
(PDB code: 1SA0) was used in this study. The stathmin-like domain and the C and D 
subunits were removed from the model.  After hydrogen atoms were added to the model, 
their positions were optimized to an energy gradient of 0.005 kcal-Å/mol with the Tripos 
force field (in Sybyl 7.3) while keeping heavy atom positions fixed. The models for stilbene 
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analogues were constructed using the Sybyl 7.3 (www.tripos.com) suite and optimized 
similarly78.  
 
3.2.4 Docking 
Computational docking was carried out using the genetic algorithm-based ligand docking 
program GOLD 3.069. GOLD explores ligand conformations fairly exhaustively and also 
provides limited flexibility to protein side chains with hydroxyl groups by reorienting the 
hydrogen bond donor and acceptor groups. The active site was defined by using 
colchicine as the reference molecule in the protein active site creating an approximate 
radius of 10 Å around the reference molecule using the GOLD cavity detection 
algorithm.  Because of the relatively poor resolution of the X-ray crystal structure and 
following the approach of Nguyen et al.131, GOLD docking was carried out with template 
similarity constraints. This constraint biases the conformation of docked ligands towards 
a given solution. The trimethoxyphenyl fragment of colchicine was used as the template 
for biasing the pose of all ligands. In this study we performed 100 GOLD genetic 
algorithm runs, as opposed to the default of 10 and early termination of ligand docking 
was switched off.  All other parameters were as the defaults.  To evaluate and validate 
GOLD performance the co-crystallized ligand DAMA-colchicine132 was extracted and 
docked.  GOLD accurately reproduced the experimentally observed binding mode of 
DAMA-colchicine in αβ-tubulin. Combretastatin was docked first and the resulting 
model was scored and optimized. The remaining stilbene analogs were docked and 
optimized using combretastatin as a reference within 0.5 Å RMSD by using the same 
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parameters. Docked ligands were scored using the HINT force field scoring function and 
iteratively optimized for maximal interaction.  
 
Dockings with different/optional constraints such as enforced hydrogen bonds, 
hydrophobic regions and scaffold match were also explored.  For hydrogen bond 
constraints, docking was biased so that the ligands make hydrogen bonds with Asn258, 
Ser178, Asn101, and the backbone amides of Ala180 and Val181. For region 
hydrophobic constraints the ligand positions were constrained by defining a hydrophobic 
sphere where the tri-methoxy phenyl moiety of colchicine was positioned.  Then specific 
ligand atoms to be docked in the hydrophobic region of the active site were defined.  
Alternatively, scaffold match constraints were used to place the ligand at a specific 
position within the active site.  Generally, however, because the binding site is rather 
featureless, constraint or template-free docking was not successful.   
 
3.2.5 Hydropathic Scoring 
The HINT (Hydropathic INTeractions) scoring function91 (version 3.11S β) was used to 
investigate the structural aspects of the interactions by analyzing and ranking the GOLD 
docking solutions.  For selection of the optimum docked conformation and to further 
differentiate the relative binding efficacy of the stilbene ligands, interaction scores were 
calculated for each pose found by docking. The protein and ligands were partitioned as 
distinct molecules. “Essential” hydrogen atoms, i.e., only those attached to polar atoms 
(N, O, S, P) were explicitly considered in the model and assigned HINT constants. The 
inferred solvent model, where each residue is partitioned based on its hydrogen count, 
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was applied.  The solvent accessible surface area for the amide nitrogens of the protein 
backbone were corrected with the “+20” option. Finally, HINT scores were plotted 
against experimental binding free energy. 
 
3.3 Results and Discussion  
3.3.1 Antiproliferative Activity of Stilbene Analogues 
The biological activity of all compounds was tested in UCI101 ovarian cancer cells and 
qualitatively similar trends were observed in MDA-MB231 breast cancer cells160. 
Compounds could be separated into three groups according to their potency. Group A 
contains the most potent compounds, including combretastatin, stilbene 5C, GG251, 
colchicine, DAMA-colchicine, VT23 and stilbene 6C with IC50 less than 100 nM. Group 
B contains GG240, GG247, GG245, GG249, which has IC50 in the intermediate range 
between 0.3 and 1.0 μM.  Group C is not active with IC50 above 5 μM (see Table 3). 
 
3.3.2 The Colchicine Binding Site 
A number of groups have performed modeling studies on the colchicine binding site 
because it is recognized as a potential target for anticancer drug development131. 
However, the low resolution of the available crystal structures for tubulin have made it 
difficult to fully delineate the essential structural and functional features involved in 
tubulin inhibition. In a low resolution crystal structure model our knowledge of the 
correct orientation of sidechains is limited by ambiguities in position and orientation 
because the experimental electron density envelopes are generally featureless. The crystal 
structure of tubulin protein used in this study has a fairly poor resolution of 3.58 Å, which  
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Table 3: Experimental IC50 and docking results for Stilbene and Campione derivatives. 
 
 
 
Compound Activity Set IC50
a pIC50 
ΔGbinding 
(kcal 
mol-1) 
HINT 
score 
HINT 
LogP 
Combretastatin 3.3 ± 0.4 nMb 8.53 -11.62 1015 4.43 
Stilbene 5C 32 ± 4 nM 7.53 -10.26 860 4.05 
GG251 28 ± 3 nM 7.53 -10.26 861 4.73 
Colchicine 30 ± 2 nM 7.53 -10.26 841 3.24 
DAMA-colchicine 29 ± 2 nM 7.53 -10.26 810 3.70 
Stilbene 6C 52 ± 7 nM 7.30 -9.96 673 3.94 
VT23 
A 
65 ± 8 nM 7.22 -9.85 446 3.17 
GG240 0.32 ± 0.02 μM 6.52 -8.89 579 2.85 
GG247 0.30 ± 0.04 μM 6.52 -8.89 563 3.99 
GG245 1.0 ± 0.08 μM 6.00 -8.18 285 3.44 
GG249 
B 
1.1 ± 0.07 μM 6.00 -8.18 278 3.10 
CTR104 5.2 ± 0.9 μM 5.30 -7.23 252 5.60 
CTR105 10 ± 0.9 μM 5.00 -6.82 -202 2.44 
CTR103 105 ± 6 μM 4.00 -5.45 49 5.44 
CTR106 110 ± 12μM 4.00 -5.45 -446 5.37 
VT54 
C 
107 ± 14μM 4.00 -5.45 -313 2.98 
  
 
 
 
 
 
 
aAntiproliferative activity against UCI-101 ovarian cancer cell line using the Alamar 
Blue assay.  
-pIC50 and ΔGbinding calculated for 10×IC50. 
-Colchicine IC50 data was recorded against UCI-101 ovarian cancer cell line.  For 
calculation purposes DAMA-colchicine was assumed to have same binding as 
Colchicine.  
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somewhat undermines our ability to structure-based design highly selective ligands132. In 
earlier studies with the colchicine binding site we carried out computational docking 
studies along with hydropathic interaction analysis on a family of substituted pyrroles and 
were able to represent the complex structure and the binding modes of the pyrrole class 
of inhibitors (see chapter 2)100.  
 
Binding modes for each stilbene analogue were investigated to understand the steric, 
electrostatic, and hydropathic features of the colchicine binding site. A molecular 
modeling study of docking these ligands into the colchicine site of αβ-tubulin was carried 
out in order to accurately represent the complex structure. The colchicine binding site is 
positioned at the interface between the α and β subunits of the tubulin protein, with the 
major part of it buried in the β subunit and lined by helices 7 and 8. The cavity, which is 
funnel shaped, has a volume of about 600 Å and opens up towards the α subunit of the 
interface surrounded by residues Asn101α, Thr179α, Ala180α, Val181α and Thr314β, 
Asn349β, Asn350β, Lys352β. The other, β subunit, end of the cavity is surrounded by 
residues Tyr202β, Val238β, Thr239β, Cys241β, Leu242β, Leu248β, Leu252β, Leu255β, 
Ile378β, and Val318β and forms the narrow funnel end-like part of the cavity. The 
predominance of hydrophobic residues confer a strong hydrophobic character to this part 
of the cavity. At the wider portion, the cavity is surrounded by Ala250β, Asp251β, 
Lys254β, Asn258β, Met259β, Ala316β, Ala317β, Thr353β and Ala354β making it 
moderately polar/moderately hydrophobic. DAMA-colchicine (and presumably 
colchicine) is snugly positioned in the crystal structure of the complex. The 
trimethoxyphenyl (TMP) moiety of colchicine is positioned in the pocket such that its sits 
snugly in the narrow hydrophobic region of the pocket with one of its methoxy oxygens 
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involved in hydrogen bonding with the thiol of Cys241β. Colchicine also forms hydrogen 
bonds with the backbone amides of Ala180α and Val181α. 
 
The structural complex as reported in the X-ray structure was refined through ligand 
functional group and protein sidechain optimization, as incorporated in the HINT 
program. Iteratively, colchicine was translated and rotated and optimized for interactions. 
Taking colchicine as the template, combretastatin was computationally docked and 
scored. Similar to above, the combretastatin-tubulin complex was optimized.  Next, the 
stilbene analogs were docked, this time taking combretastatin as the template, followed 
by HINT functional group and protein sidechain optimization. The docked models of the 
stilbene analogs fit within the pharmacophore model proposed by Nguyen et al.131 and 
are similar to the models we reported earlier in chapter 2 for the pyrrole derivatives 
bound to αβ-tubulin100.  These studies, coupled with HINT interaction analyses, are able 
to describe the complex structure and the binding modes of stilbene inhibitors. Note that 
HINT scores are very sensitive and slight positional differences are detectable in the 
scores. Qualitative analyses of the results showed general agreement with the 
experimental in vitro antiproliferative activity for these derivatives.  
 
3.3.3 Structure-Activity Binding Relationships  
Structural analysis of the binding pocket identified important intermolecular interactions 
that mediate binding. The stilbene analogues were clustered into three activity sets in 
order to study them in detail (see Table 3).  The first (A) was comprised of compounds 
that showed activity from 3 nM to 60 nM IC50.  The second (B) consisted of ligands with 
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IC50 values ranging from 0.3 μM to 1 μM.  The remaining ligands, with IC50 values of 5 
μM and above, comprised the third set (C).  HINT hydropathic analysis reveals 
significant detail concerning the forces orienting these ligands in the binding site.  First, 
hydrophobic interactions are the dominating force contributing towards the stability of 
the complexes, with additional hydrogen-bonding interactions anchoring the ligands in 
the cavity. The trimethoxyphenyl (TMP) moieties of colchicine and combretastatin are 
positioned within the narrow hydrophobic region of the cavity while the carbonyl oxygen 
on the unsaturated seven-member ring of colchicine and the hydroxyl group on 
combretastatin B ring are anchored through strong hydrogen bonding interactions with 
Asn258β and the Ala180α and Val181α backbone amides.  
 
First, in examining the docked models for activity subset A (see Figure 12A), it is 
interesting to note that, although the stilbene compounds and combretastatin are quite 
dissimilar structurally to colchicine (excepting the TMP moiety), they are generally 
positioned in the binding pocket with essentially the same mode. In the case of stilbene 
5C and GG251 the hydrophobic substituted phenyl ring fits snugly in the hydrophobic 
(narrow funnel) region of the binding pocket that superimposes on the TMP moiety of 
colchicine.  In fact, stilbene 5C and GG251 have a very similar binding mode to that of 
combretastatin, the major contribution towards binding coming from hydrophobic 
interactions. The methoxy substituted phenyls are positioned deep in the hydrophobic 
cavity surrounded by Cys241β, Leu242β, Leu248β, Ala250β, Leu255β, Ala354β and 
Ile378β, all of which contribute to favorable hydrophobic-hydrophobic binding. The 
phenyl ring of Stilbene5C and GG251 fits in a hydrophobic glove formed by the Leu248β 
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and Leu255β. Favorable polar interaction with Asn101α, Cys241β and Asn258β also 
contribute to the tight binding. The NH2 group on the B ring of Stilbene5C faces towards 
the polar opening and is stabilized with a strong hydrogen-bond to the amide oxygen of 
Asn258β with a length of 2.55 Å. Another set of strong hydrogen bonds is formed 
between the amide backbone of Val181α and the amine on the B ring of Stilbene5C with 
a hydrogen bond distance of 3.384 Å.  However, in the case of GG251 the hydrogen 
bonding interaction is not observed with the Asn258β and Val181α amide backbone, 
instead the complex is predominantly stabilized through hydrophobic interactions. 
Similar interactions are observed with stilbene 6C and VT23 with some subtle 
differences.   
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Figure 12. Stilbene analogs docked at the colchicine binding site on αβ-tubulin. (a) 
Substituted stilbenes with activity in sub-μM IC50. (b) Compounds with IC50 ranging 
from 0.3 μM to 1.0 μM. (c) Compounds with IC50 values above 5 μM.   
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In the case of stilbene 6C, although the hydroxyl group is retained on the B ring as in 
combretastatin, the removal of methoxy group from the position 4 of TMP moiety results 
in loss of activity. However, this loss is offset by introducing the NH2 group on ring B in 
stilbene 5C, thus accounting for the slight differences in their activity. In the case of 
VT23 the extension of methoxy chain on TMP moiety results in further loss of activity 
probably due to geometric constraints enforced by the narrow hydrophobic region of the 
cavity.  
 
On analyzing subset B (compounds GG240, GG247, GG245, and GG249), docked 
ligands in the low μM range, it can be seen that these ligands are relatively similar to the 
subset A ligands.  In this set of compounds substitution on ring B, in the cases of GG240, 
GG247 and GG249 the indole-carrying ring and in GG245 the amine and methoxy 
carrying ring, is varied. These substitutions result in a 10-fold decrease in the activity in 
compounds GG240 and GG247 where the N-methyl substitution is removed from the 
indole ring of GG251.  Flipping the ring, as in the 6- and 5- substituted indole ring of 
GG240 and GG247, does not have any significant affect on activity. Activity is further 
decreased if the indole ring is replaced by a benzimidazole ring as in compound GG249 
and a similar loss in activity is noted in GG245 where the methoxy groups of the stilbene 
5C methoxy phenyl moiety is replaced by a methyl group and a hydroxyl group, 
confirming the importance of the methoxy phenyl moiety on ring A in binding. The 
benzofuran and benzothiophene analogs in the CTR series of compounds (subset C) are 
similar to 2-aroylindoles, where the 2-aroylindole ring is replaced by benzofuran and 
benzothiophene. Our docked complexes with the CTR series of compounds agree with 
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the Nguyen et al. pharmacophore model131, but the rings are inappropriately substituted 
to make the required contacts with the binding site residues – leading to poor activity of 
these compounds.  Figure 13 represents the putative binding mode of Stilbene 5c, the 
most potent compound of the series. 
 
3.3.4 Predictive Models for Ligand Binding 
Figure 14 presents the correlation between the experimental binding (ΔGbinding as 
calculated from IC50) in kcal mol-1 and HINT scores for the synthetic stilbene analogs in 
this study.  The trend represented by this plot indicates that higher scoring complexes are 
generally among those with more favorable free energies of binding, while lower scoring 
complexes are generally those with unfavorable binding.  The correlation equation: 
 
 ΔG = –0.0041 HTOTAL – 6.877,     (10) 
 
has an r2 = 0.898 and a standard error of ± 0.85 kcal mol-1.   
 
The IC50s, antiproliferative activities of the compounds, are being taken in this work as 
approximations of binding affinity. The scoring function does not take into account cell 
permeability and completely ignores whether or not the compound could in vivo or in 
vitro be accessible to the binding site.   
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Figure 13: Representation of interactions of stilbene 5C in the colchicine active site of 
the tubulin protein.  
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Figure 14. Correlation plot between free energy of binding, ∆G vs. HINT score.  The line 
represents the regression for ∆G vs. HINT score for all protein-ligand complexes in this 
study.  
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However, the similar structures of these compounds and the fairly narrow range of LogPs 
suggest that these properties would be similar, if not the same, for all of these 
compounds, and thus can probably be ignored while comparing the compounds within 
the series.  We believe that the model of Figure 14 is predictive such that it can 
distinguish the active (subset A) ligands from the inactive (subset B) ligands with 
reasonable confidence. Refinement of the model with additional data will further improve 
the understanding of binding process and predictive ability of the model. 
  
3.4 Summary 
The aim of this study was to accurately represent the complex structures and the binding 
mode of a new class of stilbene-based tubulin inhibitors. Both qualitative and quantitative 
analysis of the results suggested that the model was in general agreement with the in vitro 
antiproliferative activity observed experimentally for these compounds. A good 
correlation between the modeled interaction energies and estimated free energies of 
binding calculated from IC50 suggest that our model is able to represent the complex 
structures and the binding modes of inhibitors and under some circumstances be 
predictive with respect to new members of the stilbene series. We believe that we can 
identify active ligands from inactive ligands with reasonable confidence; our analysis has 
provided a rationale for selecting substituents that will yield more tightly binding 
analogues. 
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CHAPTER 4 
 
 
A Novel and Efficient Tool for Identifying and Characterizing  
Protein Cavities and Binding Sites. 
 
 
 
4.0 Abstract 
 
Systematic investigation of a protein and its binding site characteristics are crucial for 
designing small molecules that modulate protein functions. However, fundamental 
uncertainties in binding site interactions and insufficient knowledge of the properties of 
even well-defined binding pockets have often made it difficult to design effective drugs 
with optimal activity. Herein, we report the development and implementation of a novel 
cavity detection algorithm that utilizes HINT toolkit functions that we are naming VICE 
(Vectorial Identification of Cavity Extents).  This algorithm, which is based on geometric 
criteria applied to simple integer grid maps to delineate binding sites, is very efficient.  In 
testing, we carried out a systematic investigation on a diverse set of proteins for locating 
and characterizing the indentations, cavities, pockets, grooves, channels and surface 
regions on proteins, protein-protein and protein-polynucleotide complexes.  An 
interactive front-end provides a quick and simple procedure for identifying, displaying 
and manipulating cavities in a known protein structure.  Information describing the cavity 
including its volume and surface area metrics, and lists of atoms, residues and/or chains 
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lining the binding pocket can be easily obtained and analyzed.  For example, the relative 
cross-sectional surface area (to total surface area) of cavity openings in well-enclosed 
cavities is 0.06 ± 0.04 and in surface clefts or crevices is 0.25 ± 0.09.   
 
4.1 Introduction 
Modulation of the dynamics of a target protein binding site to elicit a pharmacological 
response is the major therapeutic approach for the treatment of a plethora of diseases. 
This is usually accomplished by developing small molecules that occupy a ligand 
recognition site.  Drug development is a challenging process, owing to fundamental 
uncertainties in structural determination and associated issues such as structural and 
physicochemical characterization of the binding pockets, even under relatively static 
conditions such as in crystals subjected to x-ray analyses.  Reliable, rational and efficient 
approaches to identifying and characterizing the binding sites of protein and other 
bioactive molecules should be valuable in the design of new drugs161.  In recent years 
there has been a surge in the number of crystal structures deposited in Protein Data 
Bank162.  Concomitantly, NMR and X-ray crystallography have played an increasingly 
crucial role in drug discovery through structure-based methods and virtual screening of 
extensive libraries of compounds.  Facilitating this has been the design and development 
of many computational tools with a large range of functions.  In particular, a number of 
programs have been developed to de novo identify the binding pockets in proteins161,163.  
Such tools have provided valuable information for better understanding protein binding 
site architecture.  However, the accurate identification and quantitation of binding 
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pockets is not an entirely straightforward process, and the existing computational tools 
have numerous strengths and weaknesses. 
 
Proteins have “pockets” for molecules to bind; however, these pockets may not be 
observed from an initial inspection.  Protein surfaces are formed by numerous cavities 
and protrusions that are interlinked through small narrow channels and are often are 
interspersed with numerous holes or voids.  However, amidst all of this surface 
irregularity, the complex positioning of residues creates specific microenvironments for 
ligand recognition, binding and catalysis.  These ligand binding sites vary widely in 
shape and size and are often roughly classified according to their position on a protein 
and/or shape and described as deep pocket, grooves, indentations, surface concavities, 
branched pockets, voids, channels, etc.  The size and shape of these protein cavities 
dictates the three-dimensional geometry of ligands that will bind within, and guides the 
important intermolecular contacts that mediate this binding.  Binding sites that are 
formed by several neighboring pockets/cavities and auxiliary pockets near the active site 
are often suggested as providing additional ligand binding surface, which adds further to 
the complexity. Efficient analysis of the shape and size of protein pockets and cavities 
thus becomes important as structural changes due to side-chain rotations and backbone 
movements, loop motion and/or ligand-induced conformational changes may 
significantly alter the topography of the active site.  A thorough structural analysis of the 
target binding site is critical to propel a drug discovery project forward. There has been 
significant progress in this endeavor in recent years161,163,164.  
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4.1.1   Theoretical Approaches for Identifying Binding Sites on Proteins.  
Identification and characterization of active sites is key in studying protein structure, 
particularly when designing molecules that interfere with function and modulate activity.  
There are a number of ways in which binding sites or cavities in proteins can be located 
and characterized, e.g., with several existing programs such as VOIDOO 165, LIGSITE 
166, POCKET 167, POCKET-FINDER 168, CAST 169, PASS 170, APROPOS 171, SURFNET 
172, Q-SITEFINDER 173 and others.  These programs can be generally classified into 
categories according to the approach they take to identify and delineate the cavity: i) 
evolutionary methods (structure/sequence alignments); ii) probe/energy-based methods; 
and iii) geometric approaches.  
 
Evolutionary methods use a heuristic approach to predict cavities in unknown proteins 
from known protein structures based on family and/or functional criteria.  With the 
abundance of structural- and sequence-related data for many protein families, this 
approach has found increased application in identifying and characterizing protein target 
binding sites174,175.  Structural similarity and three-dimensional templates are used to 
compare and classify putative binding sites in uncharacterized protein structures with 
unknown functions, e.g., with similarity searches over functional site databases like 
LigBase 176 and INTERPRO 177 that detect functional similarity when homology is 
minimal.  The approach by Bickel et al. 178 uses statistical methods to identify active sites 
by residue identity within and outside functional subfamilies.  Programs like ConSurf 179 
identify functional regions of proteins by surface mapping of phylogenetic information, 
while Rate4Site 180 applies evolutionary determinants in mapping the functional regions 
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on a protein surface.  These methods are likely to continually evolve with the increasing 
availability of structural and sequence data from structural genomics projects. 
 
The idea of in silico mapping of protein surfaces was first conceptualized by Lee & 
Richards (1971) 181 based on the idea of an “accessible” surface area.  Connolly (1982, 
1983) 182 suggested the concept of “solvent excluded surface” and developed the 
eponymous algorithm for calculating molecular surfaces with a rolling spherical probe.   
Later, Kuntz et al. developed an algorithm that fills all pockets and grooves on the 
surface of receptor molecule with a set of balls 183.  While the probe sphere radius is 
generally 1.4 Å to approximate a water molecule surveying the solvent accessible surface 
of the protein, this sphere radius can be varied to map other representations such as the 
van der Waals surface.  Kuntz et al. used this approach to define the binding site in the 
first implementations of the DOCK automated docking program 33,184.  Another novel 
approach of using spherical probes on a regular Cartesian point grid was implemented by 
Peter Goodford in GRID 185 and by Martin Karplus in MCSS (multiple copy 
simultaneous searches) 186.  In GRID, a binding region on a protein is mapped by 
calculating interaction energies between a (functional) probe group placed at each grid 
point and the atoms of the protein.  In MCSS, about 1000 to 5000 small functional groups 
(probes) are interacted with the protein surface simultaneously and energy minima are 
calculated to define favorable interaction sites.  The generated functional maps of the 
binding site indicate the most favorable regions for placing ligand groups with properties 
similar to the probes.  A number of cavity detection algorithms based on this approach 
have been reported: Voorintholt et al. adopted an approach where grids are used to store 
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the distance to the nearest atom 187; a similar approach was taken by Del Carpio et al. 188 
in searching for pocket regions in a protein; the POCKET program by Levitt and 
Banaszak 167 uses a 3D Cartesian grid and spherical probes to map protein surfaces and 
pockets using a modification of the marching cubes algorithm; and the CHANNEL 
algorithm 189 uses a sphere of radius R to probe a node space that fills the unit cell of a 
crystal lattice.  
 
Some probe/energy-based approaches to detect cavities overlap with geometric 
approaches in a way that a probe of a specified volume is only used to exclude van der 
Waals overlap as the protein surface is surveyed.  The VOIDOO program reported by 
Kleywegt and Jones 165 uses atom fattening or a flood fill algorithm on a regular 3D grid 
to identify and delineate cavities.  Another such widely used algorithm for cavity 
detection is LIGSITE developed by Hendlich, Rippmann and Barnickel 166.  This 
algorithm is similar to POCKET, but circumvents many of its drawbacks: first, grid 
points within a protein atom’s van der Waals sphere are discarded; next, the remaining 
lattice points are scored according to their degree of burial by scanning grid points along 
the three Cartesian axes and the four cubic diagonals; and finally, the area delineating 
these grid points is clustered to describe contiguous cavities.  Another method totally 
relying on geometric criteria is the PASS algorithm developed by Brady and Stouten 170 
where the cavities in a protein are filled with a set of spheres.  
 
Cavity detection based on alpha shape theory 190 incorporates a different, purely 
algorithmic, approach.  The Automatic PROtein Pocket Search (APROPOS) method 
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developed by Peters, Fauck and Frömmel 171 is based on purely geometric criteria for 
identifying binding sites using atomic coordinates.  Atoms are represented as a set of 
points in 3D Euclidean space and the envelope or surface is derived by Delaunay 
triangulation 191 of these points.  The alpha shape algorithm describes these surfaces as 
lists of adjacent triangles and, depending on the value of alpha, delineates the cavity 
shape.  The program CAST developed by Liang and Woodward 169 also applies alpha 
shape principles along with discrete flow theory to determine the shape of the binding 
pocket as a negative image of cavity derived from Delaunay tetrahedrons 191.  Alpha 
shapes and Delaunay triangulations are rich in geometric information from which area 
and volumes of inaccessible cavities can also be calculated. Most of these algorithms can 
fairly easily identify binding pockets and can be used in combination with other drug 
design tools to provide valuable information for structure-based drug design projects.  
  
4.1.2   Vectorial Identification of Cavity Extents (VICE) 
 The present chapter describe our work in developing computational tools for drug design 
192,193. In this chapter we describe a new computer algorithm called VICE for identifying 
and delineating the active site in proteins or other biomacromolecules based on geometric 
criteria applied to simple integer grid maps using minimal floating point mathematics.  
Our objective in this chapter is to find pockets and shallow binding regions that have the 
characteristics of receptor sites, identify the amino acid residues surrounding them, and 
calculate descriptive metrics regarding the sites.  The algorithm was applied to a diverse 
set of over 60 proteins in order to locate, investigate and characterize their various 
indentations, cavities, pockets, grooves, channels and surface regions.  This is a starting 
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point towards comprehensive analysis of protein topography with respect to its function 
and an efficient and robust method for finding active sites that would be compatible with 
other tools and protocols we have developed based on our HINT empirical force field 
model 91,96,102.  
 
4.2 Materials and Methods 
The dataset of protein complexes in this study consisted of examples from the literature 
having binding pockets of diverse shapes, sizes and types.  Table 3 lists the proteins 
evaluated by their PDB code and the associated cavity type for which the binding sites 
were calculated.  All protein structure coordinates, in PDB format, were retrieved from 
the RCSB (Brookhaven) Protein Data Bank 162.  Molecular modeling was performed 
using the Sybyl 7.3 program suite (www.tripos.com) on Irix and Linux workstations 78.  
The protein structures were prepared for this study by removing all the water molecules, 
ions, and any cofactors associated with the structure.  Hydrogen atoms were added to the 
structures using the “Add Hydrogens” tool within the Sybyl Biopolymer module before 
further analysis.  
 
The cavity detection and analysis programs were constructed using subroutines from the 
HINT toolkit 103.  Several new subroutines were composed for 3D map manipulation and 
analysis.  Of particular value were an enhanced suite of functions for Boolean maps 
(where each grid value can only be zero or one) that forms the basis of the search 
algorithm as described in the Results and Discussion section.  The algorithm provides 
several user-adjustable options to optimize the cavity calculation.  With these parameters 
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it is possible to change the focus from the entire protein to a small region for a detailed 
investigation.  For the initial surveys in this study, the grid boxes were defined as the 
molecular extents of each biomacromolecule with a grid resolution of 1 Å and margin of 
3-5 Å.  Most importantly, the cavity definition was set at 0.5, which is the fraction of 
vectors reaching a protein “wall” instead of the box edge.  The maximum unrestrained 
path-length (vector length) was set to 20 Å by default but was increased to 40-60 Å to 
explore very large cavities or tunnels and channels.  The minimum closed contour 
volume was set to 100 Å2 to eliminate small clusters or irrelevant voids.  The shaping 
factor was usually set to be 0.50, but was varied from 0.35 to 0.6 to interactively smooth 
some pockets that presented small and inaccessible sub-pocket regions.  In the figures 
shown in this chapter, the surface of the pocket was displayed by contouring the cavity 
map at a value of 0.5, i.e., matching the cavity definition.    
 
4.3 Results and Discussion 
Protein binding regions provide a microenvironment for substrates, inhibitors, other 
proteins or biomacromolecules to interact and modulate the protein’s activity.  This 
chapter describes a computational tool for locating and investigating the binding regions 
of protein from a standard PDB file.  This section describes and illustrates the algorithm, 
outlines the quantitative cavity metrics that can be derived through this algorithm, and 
highlights in some detail several of the more than sixty cases we have used to validate the 
methodology for this work.  The rather remarkable variation that is observed in shapes 
and sizes of binding cavities is evident even from this small number of examples. 
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4.3.1 The VICE Algorithm  
The VICE (Vectorial Identification of Cavity Extents) algorithm is schematically 
illustrated through Figure 15 to 21.  After the region of interest, which can be the entire 
target protein or portions thereof, is defined, a grid cage with user selectable resolution is 
created.  While 1 Å resolution is typical, larger or smaller values may be appropriate 
depending on computational requirements.  The key advantage of this algorithm is that 
many of the calculations are performed on integers and on integer (Boolean) grid maps so 
that the method is very efficient.  In the first step grid points occupied by atoms in the 
target molecule are set to zero, while those unoccupied are set to one.  These latter points 
are potentially in the cavity; each will be examined by the algorithm.  The search tools 
are sets of vectors whose directions are determined by the grid nodes ( Figure 15).  In the 
first shell the set of 2D vectors are {(1,0);(1,1);(0,1);(-1,1);(-1,0);(-1,-1);(0,-1);(1,-1)}, 
while in the second shell set the unique 2D vectors are {(2,1);(1,2);(-1,2);(-2,1);(-2,-1);(-
1,-2);(1,-2);(2,-1)}.  Each vector is projected until it reaches an edge of the grid box 
(Figure 16) and the nodes that the vector passes through constitute a path list.   
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Figure 15: Vector representations of direction: red = shell 1, green = shell 2, blue = shell 3  
 
 
 
Figure 16: Vector (starting in green) continues until reaching grid box edge (red) and all 
nodes in path (orange shading) are tested. 
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Each vector is classified through analysis of its path list (Figure 17) as having: a clear 
path to edge, i.e., it does not pass through an occupied node; a blocked path; or is 
“stalled”, i.e., it has neither reached the box edge nor has it passed through an occupied 
node.  These latter vectors are treated as having clear path; their purpose is to ameliorate 
the possibility that a very long vector may inadvertently pass through occupied nodes 
belonging to another biomacromolecular subunit or because of a slightly curved pocket 
entrance.  The stalled vector length is a parameter that may be adjusted depending on the 
anticipated dimensions of the cavity.  The fraction of vectors classified as blocked is 
evaluated for each grid point.  Thus, each grid point is classified as “inside” or “outside” 
the putative cavity based on a parameter with nominal cutoff value of 0.5 (Figure 18).  A 
few grid points, mostly at the cavity mouth, are ambiguous (e.g., 0.5 ± 0.05); these are 
recalculated with additional shells of vectors and tightening criteria until a final 
disposition can be determined. 
 
Two steps are applied to refine the cavity definition.  First, narrow channels, i.e., one grid 
node in width, and tendrils are eliminated by forcing a requirement that each “inside” 
point have a minimum of “inside” neighbors (Figure 19).  This can be applied recursively 
to “shape” the cavity.  Lastly, to eliminate stray irrelevant pockets, each enclosed surface 
must have a minimum volume.  While these steps can be performed automatically 
without user input, the algorithm is designed to display the intermediate raw maps and 
allow interactive application of the refinement. 
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Figure 17: Each grid point is surveyed with set of vectors that: a) are blocked by 
molecule (black), b) have clear path to box edge (green), or c) are stalled  (pink) because 
with their finite length they do not reach box edge and thus are considered as having a 
clear path.  Node 1 is clearly outside the cavity (more clear than blocked paths), node 2 is 
clearly inside (more blocked than clear), while node 3 is ambiguous requiring further 
examination with shell 2 vectors. 
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Figure 18: The fraction of blocked vectors is represented as a contourable scalar quantity 
that most impacts the definition of “cavityness” at the mouth. 
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Figure 19: Tendrils, very narrow channels and other vague regions are tested with 
neighbor count that requires each node to have a minimum number of neighbors defined 
to be inside the cavity.  The nodes indicated in yellow are subject to this filter, which may 
be applied recursively.  Not shown: each closed solid contour must have a minimum 
volume or it will be deleted.  
 
 
 
   
 105
4.3.2 Overview of Protein Structure Studies  
We carried out a systematic investigation of VICE on a diverse set of proteins to locate 
and investigate the indentations, cavities, pockets, grooves, channels and surface regions 
on these proteins.  The dataset consisted of examples of proteins from the literature 
having binding pockets of diverse shapes and sizes.  All protein structure coordinates, 
retrieved from the RCSB (www.rcsb.org) 162, were prepared as described in the Methods 
section.  Our test set included: 16 cases where the binding pocket is a well-defined, well-
enclosed, deeply buried pocket; 9 cases where the cavity or groove is on the protein’s 
surface; 10 cases where the cavity is created by a protein–protein interface (more 
challenging since protein–protein dimers do not often show deep well-defined cavities 
that are putative binding sites for small molecules); 10 cases of cavities at DNA- or 
RNA-protein interfaces; 5 cases of protein structure pairs with very flexible binding 
pockets due to movements of flexible loops resulting in both open and closed cavities; 5 
cases of proteins with channels or tunnels, i.e., ion channels, porins, and ligand gated 
channels; and lastly, 4 cases of proteins with multiple and/or allosteric sites including 
some with adjacent auxillary sub-pocket sites that may have additional biochemical roles. 
 
A variety of metrics can be obtained or calculated for protein cavities.  Of the most 
potential interest is the cavity volume that can be reported in terms of both its ligand-
occupied and unoccupied fractions.  Figure 20 illustrates how these metrics are calculated 
through manipulation of integer grid maps.  We have also derived an automated 
algorithmic method (Figure 21) to estimate the cavity cross-sectional entrance areas.  
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Figure 20.  Cavity Volume Metrics.  The volume of the cavity (VC) is indicated by 
yellow shading, the volume of the ligand (VL) is indicated by vertical green bars, the 
volume of the ligand occupying the cavity (VO) is the intersection of VC and VL, i.e., 
yellow shading + green bars. The unoccupied cavity volume is VC – VO, and the volume 
of the ligand outside the cavity is VL – VO. 
   
 107
Figure 21: Cavity Entrance Calculation.  The cavity entrance is calculated from the 
derivative of the map illustrated in Figure 18.  Vectors are projected from each grid node 
toward the center-of-gravity of the cavity (dashed lines); the path (as in Figure 16) is 
determined and the absolute value of the difference between the starting grid point and 
the first node on that path is calculated as the derivative.  Paths completely inside or 
outside will have close to zero slope (white), paths clearly crossing from outside to inside 
will have slope values close to one (dark red), while the ambiguous cavity mouth grid 
points will have intermediate slope values. 
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These volume and area metrics for the 64 biomacromolecules, some with multiple 
pockets or symmetry-related sites, in this study are set out from Table 4 to 10.  Lastly, 
identification of protein residues and/or atoms lining the cavity may also be useful 
information for drug design and/or site-directed mutagenesis studies.  These data are 
indicated below for a few cases, but are readily available from the analysis module in the 
algorithm.  In the following paragraphs we focus on several examples, and present, 
somewhat qualitatively, the level of success the VICE algorithm has obtained in 
describing these cavities for a broad range of variations in the architecture of binding 
pocket viz. deeply buried binding pockets, cavities at protein-protein dimer, and with 
DNA/RNA interface.  The method is able to detect cavities, shallow grooves, cleft and 
channels within a protein. The program also addresses the problem of defining the limits 
of a cavity, especially its boundary with free space, i.e., at the entrance (vide infra).  
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4.3.3 Well-enclosed Cavities/Deeply Buried Pockets   
In the initial examples, we characterized deeply buried binding pockets that are, in other 
terms, well-enclosed cavities.  These cases also may be thought of as essentially closed 
continuous volumes in the interior of protein molecules.  While these binding pockets, 
which might bind small molecules, are sometimes not obvious from initial inspection, 
most available cavity detection software can effectively detect them.  Although there may 
be a number of these voids inside a protein, it has been observed that the active site is 
usually the largest cavity in a protein 168,173 because a large pocket provides increased 
surface area and hence increased opportunity for small molecule binding.  Thus, one of 
the problems faced by these algorithms is identifying the primary binding pocket amongst 
(often) numerous small clefts and voids.  In addition, the boundary of the active site is 
often not well demarcated and numerous snake-like tendrils can project from the binding 
envelope.  An important success factor of a cavity detection algorithm is in presenting a 
single, clean well-bounded cavity. 
 
Prostaglandin H2 synthase (PDB 1eqg) is an example of this class of cavity.  A detailed 
structural analysis of NSAID binding with prostaglandin H2 synthase is discussed by 
Selinsky et al. 194.  Figure 22 illustrates this protein and its detected cavity.  The inset at 
the upper left shows the relatively small opening (calculated as 22 Å2 by our algorithm) 
while the inset at the lower left extracts the cavity, ligand and surrounding residues 
(Pro86, Ile89, His90, Leu93, Met113, Val116, Arg120, Phe205, Val344, Ile345, Tyr348, 
Val349, Leu352, Ser353, Tyr355, Leu357, Leu359, Phe381, Leu384, Tyr385, Trp387, 
His513, Phe518, Glu520, Met522, Ile523, Glu524, Gly526, Ala527, Ser530, 
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Figure 22. Well-enclosed Cavity: Prostaglandin H2 synthase. Prostaglandin H2 
synthase (1eqg) examined with the VICE algorithm and displayed with MOLCAD and 
Sybyl.  a) The protein Connolly surface is displayed with opaque rendering.  The small 
opening to the cavity is indicated by the red arrow; b) the ligand, ibuprofen rendered in 
CPK (space-filled), and the residues lining the cavity are shown. The yellow translucent 
surface illustrates the extents of the cavity.  The protein is rendered with a translucent 
Connolly surface; c) shown as in b) but displaying the entire protein.  
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Leu531 and Leu 534).  The cavity volume is estimated at 814 Å3 of which only 214 Å3 
are occupied by ligand.  We have not included any volume contribution from water in 
calculated volume estimates as the number of water molecules detected by x-ray 
crystallography varies greatly with crystallographic resolution 195.  
 
Similarly, the anti-malarial compound fosmidomycin binds to IspC (PDB 1onp) 196 and 
the detected cavity is well-defined (Figure 23), surrounded by residues Ser151, Glu152, 
Gly185, Ser186, Gly187, Gly188, Trp212, Ser213, Ile218, Ser222, Asn227, Lys228, 
Glu231, Ser254, Met276 and a Mn ion.  Here, the binding site is deeply buried with a 
volume of 342 Å3, while the volume of fosmidomycin is 136 Å3 of which 127 Å3 
occupies the active site.  Most cavities in this class have opening surface areas that are 
about 10% or less of the total cavity surface area and have occupancy factors of around 
35-50% (See Table 4). 
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Figure 23. Well-enclosed Cavity: IspC.  IspC (1onp) examined with the VICE 
algorithm and displayed with MOLCAD and Sybyl.  a) The protein Connolly surface is 
displayed with opaque rendering.  The relatively small opening to the cavity can be seen; 
b) the ligand, the anti-malarial compound fosmidomycin rendered in CPK, and the 
residues lining the cavity are shown. The yellow translucent surface illustrates the extents 
of the cavity.  The protein is rendered with a translucent Connolly surface and the space-
filling magenta sphere is the manganese ion; c) shown as in b) but displaying the entire 
protein.   
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4.3.4 Groove/Cleft on the Surface of a Protein 
The more shallow cavities and surface grooves are also potential sites for binding of 
drugs, ligands, proteins and other biomacromolecules.  Identification and size 
characterization of surface pockets and occluded cavities are often the initial steps in 
protein structure-based drug design.  The most important of these binding pockets are 
generally found to be particularly large and deep clefts.  While internal cavities are fairly 
easy to define as they generally correspond to well-enclosed regions completely bounded 
by surrounding atoms, in many cases interactions between protein and small molecule 
tend to involve what can appear to be a nearly planar surface on the surface of the 
protein.  However, on the nano-scale protein surfaces are irregular with many clefts and 
grooves of varying shapes and sizes, and it is often difficult to define the boundaries of 
these shallow pockets.  In particular the “open” boundary at the mouth is ambiguously 
defined even in the best of circumstances with this class of protein cavity.  Our algorithm, 
as described in Figure 15-21, defines this boundary in terms of a user-adjustable 
parameter that represents the ratio of vectors finding the cavity wall over all vectors for 
each grid point.  For this work we used the default value of 0.5 for this parameter.  Most 
shallow cavities can be characterized one key metric: they generally have opening cross-
sectional areas (Table 5 ) of about 30% of the total cavity surface area.   
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One example of a shallow cavity on the surface of protein is illustrated with cytokine 
interleukin-2 (1m48) 197 in Figure 24.  Here, the binding site is mapped to a shallow 
groove on the surface of protein.  This particular protein is a symmetric homodimer so 
that there are two essentially identical binding sites.  Cytokine interleukin-2 has been 
implicated as one of the principal mediators in proliferation and differentiation of 
activated cells in an immune response.  It attaches through its surface to the trimeric IL-
2R receptor, thereby triggering an immune response.  Although the binding pocket is 
actually present as a surface cleft divided by a ridge, the cavity detection algorithm was 
able to capture both sides of the pocket.  Interestingly, while a large portion of the ligand 
hangs out of the pocket, the two terminal ends are buried within the pocket.  
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Figure 24. Shallow Cavity on Protein Surface: Cytokine interleukin-2.  The cytokine 
interleukin-2 dimer (1m48) has one essentially identical shallow cavity binding site on 
each of the two chains.  a) The inhibitor Ro26-4550 is bound in the cavity of chain A: the 
cavity extents are displayed as the orange contour volume.  Both ends are well-bound but 
much of the middle of the ligand is external to the cavity; b) both sites are displayed in 
this view of the entire protein.  
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In another example, as illustrated in Figure 25, a cavity was identified on the surface of 
the BCL-XL protein (1bxl, 2yxj) 198,199, a pro-survival protein whose function is regulated 
by the binding of anti- or pro-apoptotic factors.  Several anti-apoptotic proteins can bind 
to the BH3 domain of BCL-XL in tumor cells where it is overexpressed.  These 
interactions increase the survival rate of the cancer cell and may contribute to drug 
resistance.  In contrast, pro-apoptotic proteins such as BAK can induce apoptosis by their 
binding to the BH3 domain; thus, the BH3 domain on BCL-XL could be exploited as an 
attractive drug target in cancer chemotherapy.  The BH3 domain has a largely 
hydrophobic surface with an estimated volume of 1300 Å3.  The lower left inset of Figure 
25 shows BAK bound to the BH3 domain of BCL-XL (1bxl).  The associated cavity is 
indicated in yellow.  However, a smaller sub-pocket (indicated in orange) can also be 
identified on the BH3 domain that binds small molecule modulators such as ABT-737 
(2xyj) as shown in the upper right inset of Figure 25.  The overlap of these two sites is 
shown in the central portion of Figure 25, and suggests that the bound ABT-737 ligand 
would block the binding of BAK.   
 
Exploitation of such cavities and sub-pockets at the interface between proteins could have 
important implications in drug discovery as more is learned about the role of protein-
protein interactions in biological processes.  
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Figure 25. Shallow Cavity on Protein Surface: BCL-XL.   Two structures of the BCL-
XL protein with BAK protein and inhibitor ABT-737 bound within its binding cavity.  a) 
BCL-XL protein (1bxl) with sixteen residue BAK protein (red capped stick 
representation) bound within the surface cavity (yellow translucent envelope); b) BCL-
XL protein (2yxj) with ABT-737 inhibitor (blue capped sticks) bound in a relatively 
smaller sub-pocket (orange translucent surface); c) overlap superposition of 1bxl and 
2yxj structures showing the correspondence of the two pockets.  Cavity extents illustrated 
with yellow and orange translucent envelopes. 
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 4.3.5 Cavity Formed at a Protein-Protein Interface  
            Next, we consider examples of cavities at protein–protein interfaces. These interactions 
have an important role in many biological processes and cavities at the interface of 
protein-protein dimers offer particularly attractive, but as yet largely unrealized, 
opportunities for therapeutic intervention.  However, uncertainties owing to the structural 
changes due to domain movement upon binding and the often insufficient knowledge of 
well-defined binding pockets, coupled with the irregular shape and size of typical 
protein–protein interfaces, have made it difficult to design inhibitory ligands that can 
modulate protein-protein interactions.  Although a large surface area is usually buried on 
each side of the actual interface, there is often only a relatively small cavity or groove 
where a small molecule can fit and thus inhibit the protein-protein interaction.  Our cavity 
detection algorithm is able to identify and delineate these binding sub-pockets on large 
interfaces as described in the section above. Detailed information related to volume, 
surface area and chain, residues that line the pocket is also illustrated (see Table 6). 
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 However, in some cases, cavities at protein-protein interfaces can be observed, either at 
the joint between two subunits of the same protein or for a protein-protein complex.  In 
one example, for αβ-tubulin (1z2b) (Figure 26) 200, our cavity detection algorithm defined 
the binding envelope at the wide interface between protein-protein units.  Tubulin is the 
basic building block of microtubules, critical for mitosis and cell division, and an 
important target for anti-cancer drugs.  
 
Tubulin exists as a heterodimer and joins end-to-end to form a protofilament with 
alternating α and β subunits. The staggered assembly of 13 protofilaments forms hollow, 
cylindrical microtubule filaments.  Three distinct binding sites have been identified on 
tubulin heterodimers for the taxol, colchicinoids and vinca classes of drugs.  Although 
Taxol binds wholly on the β subunit, the colchicine binding site lies at the intradimeric 
interface of α and β subunits of tubulin and the vinblastine binding site is located at the 
interdimeric interface of αβ-subunits. The colchicine and vinblastine binding sites have 
been difficult to map as these binding pockets are poorly demarcated between the subunit 
interfaces and the crystallographic resolution is rather poor at 3.58 Å.  However, our 
algorithm was able to clearly identify and delineate binding envelopes at these subunit 
interfaces: the colchicine binding site (Figure 26, left inset) has a volume of 842 Å3 with 
an opening directly at the α-β interface with a estimated opening area of 28 Å2; and the 
vinblastine site cavity has an estimated volume of 1457 Å3 and an opening of 381 Å2.  
 
   
 123
 
Figure 26. Cavity at Protein-Protein Interface.  a) The tubulin protein (1z2b) with 
colchicine and vinblastine binding sites at interfaces between the α and β subunits.  The 
tubulin polymer is rendered in ribbon and tube with the α subunits shown in red and β 
subunits shown in blue; b) inset shows the colchicine binding pocket (yellow contour) at 
the intra-dimeric interface of the αβ-subunit; c) inset shows the vinblastine binding site 
(orange contour) at the inter-dimeric interface between αβ-subunits.  
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4.3.6 Cavity Formed at a Protein-Polynucleotide Interface 
Protein-DNA/RNA interactions primarily are related to regulation of gene expression and 
are thus associated with important functions.  Cavities or pockets formed by proteins at 
protein-nucleic acid interfaces are designed to mediate interactions and allow sequence-
specific recognition of a gene.  Each nucleic acid binding motif on a protein consists of a 
specific binding pocket that recognizes and stabilizes the DNA/RNA.  To bind in this 
fashion a protein must make contact with the nucleic acid in such a way that the 
nucleotide sequence can be recognized. Ligands that can interfere with this recognition, 
either by occupying the putative nucleic acid binding site and blocking DNA/RNA 
binding, or by exploiting cavities formed in the protein-polynucleotide complex, may be 
therapeutically significant.  As an example of the latter strategy, Figure 27 shows binding 
pockets detected on the 30S ribosomal subunit (1fjg) 201.  Three well-defined major 
cavities are detected indicating the binding sites for the antibiotics spectinomycin, 
paromomycin and streptomycin.  The binding pocket for spectinomycin, which inhibits 
elongation factor G catalyzed translocation of the peptidyl-tRNA from the A-site to the 
P-site, has a volume of 633 Å3 with spectinomycin completely enclosed within the cavity. 
The majority of interactions are with RNA bases C1063, G1064, C1066, G1068, C1069, 
A1191, C1192, G1193, U1194, G1386, G1387, with protein residues Ala121 & Gly 122 
lining the cavity envelope.  Paromomycin, an aminogycoside, binds in the major groove 
at the decoding center on H44 and induces errors in translation by increasing the affinity 
and stability of tRNA for the A-site.   
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Figure 27. Cavity at Protein/Polynucleotide Interface.   a) The 30S ribosomal subunit 
(1fjg) is rendered as ribbon and tube, except within 20 Å of binding region where a 
MOLCAD surface display is shown to highlight the binding pockets for the antibiotics 
spectinomycin, paromomycin and streptomycin; b) the binding site for paromomycin 
(orange envelope) and streptomycin (yellow envelope) are illustrated.  The antibiotic 
drugs are rendered in spacefill; c) the binding pocket for spectinomycin (yellow 
envelope) is illustrated. 
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 The volume of this cavity is 1605 Å3 and it is lined by bases C1404, G1405, U1406, 
C1407, A1408, C1409, G1410, G1488, G1489, C1490, G1491, A1492, A1493, G1494, 
U1495, C1496, G1497 and protein residue Lys47.  Adjacent to this binding pocket is a 
third cavity which binds streptomycin, a drug that inhibits protein synthesis by interfering 
with the initial selection and proofreading of tRNA.  The volume of the predicted binding 
pocket is 988 Å3 with numerous nucleotides from 16S RNA and residues from the S12 
protein lining the binding envelope. While a limited numbers of base pairs are involved 
in recognition and stabilization, designing an inhibitor that binds at an interface must 
involve sufficient nucleic acid and protein contact so that the ligand fits snugly.  
 
Detailed analysis of cavities formed at the protein-polynucleotide was carried out and 
information retrived is tabulated in table 7. 
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4.3.7 Flexible Cavities with Loop or Domain Movements 
All proteins have an intrinsic flexibility that is required for a wide range of biochemical 
processes in catalysis, regulation, and protein assembly. However, in some cases 
experimental evidence has indicated that the shape and size of the ligand binding 
envelope may change due to domain movements; e.g., molecular recognition and ligand 
binding is induced by large loop movements where flexibility in the protein main chain 
influences the ligand binding202.  Ligand binding may involve a wide range of structural 
changes in the receptor protein, from hinge movement of entire domains to small side-
chain rearrangements in the binding pocket residues.  Many protein functions in fact 
involve conformational transitions that involve opening and closing of relatively rigid 
parts of that protein about flexible joints.  The analysis of side chain flexibility gives 
insight valuable for improving docking algorithms and for ligand design when domain 
movement and/or loop flexibility opens and closes the binding pocket.  Instead of well-
defined binding pockets, most proteins that have ‘induced’ domain movement lack deep 
clefts or clearly shaped binding pockets.  Thus, this is an interesting case study for cavity 
detection – where the change in the size and shape of binding pocket due to domain 
movement is calculated by comparison between pairs of holo and apo proteins (See Table 
8).   
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 Figure 28 shows the example of citrate synthase, 5cts 203 and 5csc 204, which are the apo 
(unliganded) and holo (ligand-bound) forms with cavity volumes of 439 Å3 and 967 Å3, 
respectively. The bound ligand, oxaloacetate, which has a volume of 704 Å3, appears to 
induce this large domain movement in the enzyme and causes binding pocket residues to 
undergo side-chain conformational changes as well as changes in overall shape.   
 
Residues His238, Asn242, Leu273, His274, Val314, Val315, Gly317, Tyr318, Gly319, 
His320, Ala321, Arg329, Gln364, Ala367, Ala368, Asn373, Asp375, Phe397 surround 
the binding pocket in the closed structure, while only residues His238, His274, His320, 
Arg329, Asp375, and Phe397 line the unliganded pocket.  
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Figure 28. Flexible Cavity with Loop or Domain Movement. The citrate synthase 
protein, 5cts (red) and 5csc (blue), the apo (unliganded) and holo (ligand-bound) forms, 
respectively, is illustrated.  A relatively smaller binding pocket is detected in 5cts (orange 
envelope); however, the native ligand oxaloacetate (green capped sticks) induces a 
domain movement that significantly alters the shape and size of the binding pocket 
(yellow envelope) in 5csc.   
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4.3.8 Multi-Domain Proteins with Channels or Tunnels 
Understanding the structure and function of channels and pores within biomolecules is 
important, e.g., to a large number of critical disease states and in compensating for drug 
resistance due to efflux.  Channels and pores and other passages across cell membranes 
facilitate the movement of small molecules and ions.  These transmembrane proteins, 
such as ion channels, transporters and G-protein coupled receptors, are exceptionally 
significant drug targets.  Apart from this, channels and tunnels also facilitate the access 
and exit for substrates/products in some catalytic processes.  Channels/pores are often 
dynamic in nature and can be relatively flexible in size and shape and access through 
them is often regulated by small molecules binding to an active site.  Thus, while many of 
the available algorithms and associated programs developed to detect and characterize 
binding pockets are successful with well-enclosed pockets and surface grooves, for the 
most part these procedures fail to detect long, twisted tunnels connecting the interior of a 
binding pocket to the exterior environment.  In fact, it is surprisingly difficult 
mathematically to differentiate between true channels and tunnels and random voids if 
the tunnel has a narrow diameter or constriction point(s). 
 
With the recent availability of crystal structures for large membrane-bound proteins, 
detection and mapping of the interior of these channels can give insight into the binding 
process for design and development of more selective drugs.  Our cavity detection 
algorithm provides sufficient flexibility and interactivity to map binding sites as well as 
the channels and tunnels through a protein (See Table 9).   
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In the example illustrated in Figure 29, the KcsA potassium channel (1j95) 205, we 
applied our cavity detection algorithm to first identify the binding pocket inside the 
channel, which is occupied by tetrabutylammonium in this structure.  This was easily 
detected with the program’s default parameters, e.g., a grid resolution of 1.0 Å.  Next, by 
decreasing the grid spacing to 0.3 Å, the program successfully identified and delineated a 
long, narrow porous channel traversing the entire length of the protein’s transmembrane 
axis.  It should be noted that this latter calculation was resource intensive due to the very 
large number of surveyed grid points, but this level of computation was necessary in 
order to adequately sample the protein structure.   The total volume of channel was 
calculated to be 1342 Å3 with the binding cavity of 615 Å3, while the 
tetrabutylammonium occupies 168 Å3 inside the binding cavity of the channel and is 
well-enclosed by hydrophobic residues.  
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Figure 29. Channels and Tunnels.   a) The KscA K+ ion channel (1j95) plotted with 
translucent MOLCAD surface.  The binding pocket at the center of the channel is 
illustrated with an orange contour map; its tetrabutylammonium inhibitor is rendered in 
CPK (space-fill).  The channel, traversing the entire length of the protein, is highlighted 
with the yellow contour map.  Detection of the channel required calculations with a very 
large number of grid map points and high resolution.  The potassium ions are rendered as 
the red spheres; b) expanded view of the inhibitor binding cavity. 
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4.3.9 Multiple Cavities and Allosteric Binding Pockets  
The detection of auxiliary binding sites is becoming increasingly crucial as many proteins 
have more than one biochemical role and are likely to employ separate binding sites in 
performing these distinct biochemical tasks.  Allosteric binding pockets may offer 
additional recognition sites that modulate the catalytic function of a protein.  These 
auxiliary binding pockets may be located far away from the catalytic site, as in case of 
glycogen phosphorylase, or may overlap with the active site.  Traditionally, allosteric 
sites were considered to be distal binding sites for molecules that modulate the function 
of a protein by a feedback mechanism.   
 
While the mechanisms of allosteric modulation of proteins have been extensively studied, 
discovery efforts to efficiently identify and characterize these binding sites continue as 
exploiting them may lead to development of entirely new classes of drugs.  However, it 
can be a non-trivial matter to find and characterize allosteric binding sites when these 
sites are present as auxiliary pockets overlapping with the main active site.  Figure 30 
illustrates an example of an allosteric site on glycogen phosphorylase b (1c50) 206.  The 
crystal structure shows an allosteric binding site for the co-crystallized molecule 
CP320626.  Our program identified this binding site with a volume of 431 Å3 close to the 
AMP binding site with a volume of 728 Å3. The main PLP catalytic site, with a volume 
of 849 Å3, is about 30 Å distant from the allosteric site. 
 
Table 10 shows detailed analysis of other proteins with auxillary and allosteric pockets. 
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Figure 30. Auxiliary and allosteric sites.  The glycogen phosphorylase b (1c50) with 
multiple binding pockets. a) A close-up view of the allosteric/auxiliary site.  The AMP 
cofactor (red sticks, green cavity contour) and allosteric site (yellow contour) with 
inhibitor CP320626 (blue sticks) are in separate subsites of the overall surface groove 
(orange contour); b) the main catalytic site (cyan contour) is bound with PLP and is quite 
deeply buried in the protein.  
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 4.4 Summary and Outlook 
 The identification, delineation and visualization of protein active sites is a critical facet 
of drug design.  These site topographies play crucial roles in molecular recognition. 
Proteins may have many pockets and cavities of various sizes, some of which whose 
function, e.g., protein-protein interaction, is unknown; it is possible that some may be 
usefully exploited with selective molecules that bind and modulate that protein’s 
function.  Thus it is important to be able to characterize these binding pockets, 
quantitatively and qualitatively. This algorithm and program provides a simple and 
interactive tool for locating and delineating all the cavities, pockets, grooves, clefts and 
tunnels of a protein whose structure is known.  In most cases the default parameters 
produce good results very rapidly because the majority of the calculations are performed 
with integer arithmetic.  Thus, we believe that this tool could be a useful starting point for 
virtual screening by automatically identifying potential binding sites in a first pass.  Of 
course, more reliable and biologically meaningful results will be obtained if the user can 
focus on particular regions or features by selecting one or more of the pockets and 
investigating them in detail by adjusting a relatively small number of calculational 
parameters.   
 
A second major advantage of this program is that it calculates a fairly extensive set of 
metrics describing a binding pocket and its occupants.  Cavity volumes, cavity surface 
areas, and lists of atoms, residues and/or chains lining the binding pocket can be 
retrieved.  The estimated cross-section surface area of cavity openings is particularly 
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interesting as it may suggest methods to describe the maximum size of ligands to enter a 
site. 
 
With this rapid and robust cavity algorithm in place, we are exploring virtual screening 
and docking algorithms that use property-encoded cavities, e.g., the HINT complement 
map, as first stage targets.  Such cavity maps would be inherently suited for grid-based 
pose generation and scoring. 
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CHAPTER 5 
 
Complexity in Modeling and Understanding Protonation States: 
Computational Titration of HIV-1 Protease Inhibitor Complexes 
 
5.0 Abstract 
The computational titration algorithm based on the “natural” HINT (Hydropathic 
INTeractions) force field is described.  The HINT software model is an empirical, non-
Newtonian force field derived from experimentally measured partition coefficients for 
solvent transfer between 1-octanol and water (LogPo/w). The titration algorithm allows the 
identification, modeling and optimization of the multiple protonation states of residues 
and ligand functional groups at the protein-ligand active site.  The importance of taking 
into account pH and ionization states of residues, which strongly affect the process of 
ligand binding, for correctly predicting the binding free energy is discussed.  The 
application of the computational titration protocol to a set of six HIV-1-cyclic inhibitor 
complexes is presented and the advance of HINT as a virtual screening tool is outlined.  
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5.1 Introduction  
A typical problem in modeling biomolecular systems or molecular recognition systems is 
accurately modeling the energetics of binding. Thermodynamic analyses of protein-
ligand interactions not only give vital insight into the free energy changes of the system, 
but also elaborate whether an interaction is enthalpy or entropy driven207-209.  Calculation 
of binding free energy involves evaluation of both enthalpic and entropic contributions 
and forms an integral part of structure-based drug design protocols210,211.  To this end, 
computer simulations have strived to predict binding free energy and concomitantly 
interpret experimental data.  The fundamental idea behind development of robust 
computational models was to incorporate as much of the physiochemical parameters 
defining protein-ligand interactions as possible212.  These models can contribute 
significantly to the understanding of the structural and energetic basis of biomolecular 
interactions, with the goal of de novo predicting the binding free energy of protein-ligand 
complexes.  
 
Generally, enthalpic contributions are estimated by theoretical methods, knowledge-
based potential functions, or parameters derived from experimental data213.  The force-
fields used for calculations of free energy and intermolecular interactions assume that 
steric and electrostatic forces are sufficient to account for the observed biological 
interactions213.  However, these terms alone are never sufficient for accurate prediction of 
biomolecular interactions as they do not always include solvation/desolvation effects.  
The entropic contributions to binding are much less well-defined and often poorly 
quantitated or even ignored in most cases.  Most approaches sum up these interactions 
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separately as distinct enthalpic and entropic contributions, whereas, in reality, the ligand-
protein recognition is a concerted event and thermodynamic quantities cannot be just 
simply added up214.  The phenomenon of solvation/desolvation within the protein active 
site, resulting in hydrophobic interactions and other phenomena, has been particularly 
difficult to model computationally.  However, developments in free energy calculation 
over the past several years have made significant progress towards this goal215,216.  
Among the methods currently available to calculate free energy, those based on complex 
and time-consuming molecular dynamics simulations, with explicit consideration of 
water molecules, have been shown to correlate fairly well with free energy.  Free energy 
perturbation (FEP) calculations, based on statistical mechanics, can predict the free 
energy of a system by analyzing ensemble averages (calculated by molecular dynamics 
(MD) or Monte Carlo (MC) simulations) and treating solvent molecules and ions 
explicitly217.  Unfortunately, besides being computationally expensive, calculation of free 
energy using MD or MC is plagued by errors and problems from a variety of sources218.  
Thus, computational time and uncertainty is compounded for complex biomolecular 
systems with solvents and counterions218,219.  
 
∆Gbinding values computed via sophisticated simulations often do not correlate well with 
experimental binding measurements.  This could be due to several reasons.  First, it is 
becoming common practice in the drug discovery community to use assays generating 
IC50s rather than equilibrium constants, and computational scientists often 
interchangeably use IC50 instead of Ki or Kd to calculate free energies.  Furthermore, the 
experimental binding data itself present uncertainties, i.e., there are often differences of 
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one order of magnitude (corresponding to about 1 kcal mol-1) between inhibition data 
collected in different laboratories, and thus they are not always of a quality to enable 
accurate quantitative correlations with computational data.  On the other hand, structural 
data available from x-ray crystallography and NMR has undeniably fostered an 
understanding of the biological complexity of molecular recognition.  However, often 
only partial agreement between experimental and theoretical binding energy data based 
on crystal structures has been observed.   
 
It is difficult to correlate solution binding data and crystallographic structural data 
because of a number of inherent experimental limitations.  Biomolecular interactions are 
sensitive to subtle changes in experimental conditions such as pH, buffer, ionic strength, 
and temperature under which data are collected220.  While the pH used for making the 
binding measurements is generally perceived as the pH at which binding takes place, that 
pH may not actually be the optimum pH for binding.  This discrepancy is magnified 
when crystals for x-ray analysis are grown under a still different pH condition.  Unless at 
very high resolution, an x-ray structure by itself reveals little direct information regarding 
the protonation states of the active site residues in a protein.  As protein-ligand specificity 
and stability are known to be sensitive to structural details, presumably because 
protonation states of ionizable residues and the details of the hydrogen-bonding network 
are very important for optimum interaction, it is imperative to identify, characterize and 
understand the protonation states of residues.   Even a change in the ionization state of a 
single residue or ligand functional group may have a profound effect on the results for 
structure-based energy calculations.   
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In general, molecular association depends on the ionic strength and pH of the solution220.  
Protein crystals may contain between 30% and 70% solvent221, which includes the buffer 
solution as well.  These solvent molecules and ions are distributed among the protein 
molecules of the crystal lattice.  However, due to their inherent electrostatic properties, 
they may distribute themselves in different solvent channels depending on the nature of 
the residues lining these solvent pockets.  Thus, pH influences ligand binding both 
directly, by changing the hydrogen-bonding character of ionizable site residues, and 
indirectly, by altering the shape and properties of the site with specifically bound solvent 
molecules222,223.  Another significant factor in quantitative estimation of interaction 
strength is the microscopic dielectric constant, which is almost never known224.  While 
many approximations can be made for the dielectric constant of the protein interior225,226, 
the most accurate modeling of dielectric effects within proteins requires consideration of 
the atomic polarizabilities of the heterogeneous protein and the solvent (both water and 
counter ions)227,228.  However, the size of a typical protein-ligand system renders 
approaches of this nature very computationally expensive; thus, simplified models that 
use macroscopic dielectric models – uniform or distance dependent – are generally 
applied229. 
 
In order to accurately predict binding free energies, it is fundamental to take into account 
pH, ionization and entropic contributions for virtual screening experiments.  However, in 
many biomolecular systems the lack of extensive binding and inhibition data as a 
function of pH limits the likelihood of good correlation between calculated and measured 
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binding data.  In this chapter we have examined x-ray structures of HIV-1 protease in 
complex with several cyclourea and cyclic sulfamide inhibitor analogs.  The binding of 
ligands to a biological macromolecule is made even more complicated with the presence 
of multiple ionizable groups, and the HIV-1 protease/ligand system has several230.  
Existing modeling techniques are insufficient to characterize atomic level details of 
binding and do not often consider the multiple protonation states and ensemble of 
protonation states that can exist in these systems, many of which are quite similar in 
energy. We have applied our computational titration protocol, based on HINT 
(Hydropathic INTeraction), to analyze and identify the best protonation models for these 
complexes.  Our main interest in developing the computational titration algorithm is its 
ability to identify and optimize all possible protonation states so that rational models with 
atomic details can be constructed and applied to modeling ligand binding energetics. 
 
5.2 Materials and Methods 
Optimized molecular models of the HIV-1 protease-ligand complexes in this work were 
taken from our previous study on the contribution of water molecules to the energetics of 
HIV-1/ligand binding101.  In that study, the GRID program was used 185 for identifying 
and placing water in favorable locations that were unoccupied due to crystallographic 
uncertainty.  In the cyclic urea complexes, only complex 1AJX had crystallographically 
detected waters 313 and 313’, while these waters were not experimentally reported for 
complexes 1DMP and 1QBT and were positioned with GRID.  However, in case of 
cyclic sulfamide complexes, crystallographic water 313 and 313’ were experimentally 
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confirmed for the three complexes 1AJV, 1G35 and 1G2K except for water 313’ on 
1G2K, where it was positioned using GRID.  
 
The modeling programs Sybyl 7.2 (www.tripos.com)78 suite and HINT 3.11S were used 
in this study.  In the HINT computational titration protocol, the protein, ligand and water 
were partitioned as distinct molecules: only hydrogen atoms deemed “semi-essential”, 
i.e., only those attached to polar atoms (N, O, S, P) and those attached to unsaturated 
carbons were explicitly considered in the model and assigned HINT constants.  The 
inferred solvent model, where each residue is partitioned based on its hydrogen count, 
was applied.  The solvent accessible surface area for the amide nitrogens of the protein 
backbone were corrected with the “+20” option.  All Asp, Glu and His residues within an 
8 Å radius of the ligand and the ionizable functional groups on the ligand (amine, 
phosphine, carboxylate groups) were selected for titration.  In this study only aspartates 
were present at the HIV-1 active site and only one ligand had a titratable amine.  
 
Optimization of each protonation state model focuses on exhaustive optimization of the 
R–XHn bond dihedral angles that are exhaustively optimized by forcing rotation through 
the entire 360°.  This rotation positions the polar hydrogens for optimum hydrogen 
bonding and intermolecular HINT energy score.  The procedure targets primary amine, 
hydroxyl and thiol groups on both protein and ligand.  Note that the –OH on protonated 
carboxylate groups are also optimized in this way.  In His the imidazole ring is flipped to 
optimize hydrogen bonding, as are the terminal amides of Asn and Gln.  All the possible 
models were composed and scored using equation 1.  Finally, HINT scores were plotted 
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as a function of pH for all the models.  Normal and Boltzmann-weighted averages were 
then obtained for each protonation level.   
 
5.3 Results and Discussion  
5.3.1 The Computational Titration Algorithm 
The Computational Titration (CT) algorithm is based on the empirical HINT 
(Hydropathic INTeractions) free energy non-covalent forcefield92, and involves modeling 
of optimum ionization conditions at the binding site99,192.  The Computational Titration 
methodology allows exploration of the ionization states of active site residues and ligand 
functional groups as a function of protonation.  This novel method, implemented in the 
HINT software, involves building and scoring of distinct protonation models, i.e., a 
defined ionization state for each relevant residue or ligand functional group.  First, all the 
possible ionization states of residues and ligand functional groups are enumerated with 
user choices of residue types192,231,232.  The illustration of Figure 31 indicates how this is 
accomplished.  Each box represents a potential position for a proton.  With no added 
protons there is only 1 model, but with one added proton there are 14 unique models, and 
so on.  In the example of Figure 31, one of the ligand’s amines is protonated and one of 
the two carboxylate oxygens of Asp125 is protonated.  The acidic residues Asp and Glu 
are usually subjected to titration; the basic residues Lys and Arg are usually kept in their 
protonated states, while His is normally selected for titration.  The CT algorithm further 
allows selection of Tyr and Cys for titration in cases where exploring the ionization of 
these residues is desired.   
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Figure 31. Protonation model. Schematic representation of active site ionizable residues 
and ligand functional groups subjected to computational titration; in this case for complex 
1DMP.  Boxes indicate potential protonation sites, i.e., potential positions for protons.  
The sole protonation site on amines is indicated by a solid box, whereas the two potential 
protonation sites on aspartates are indicated by dotted boxes.  (Protons can be placed on 
either carboxylate oxygen, but not both).  The illustrated model has two added protons: 
one of the two amine groups on the ligand and one of the two carboxylate oxygens on 
Asp125 are protonated (“occupied” solid boxes); the other carboxylate oxygen is 
unavailable for protonation. 
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The analogous functional groups on the ligands, i.e., carboxylic acids, amines, aromatic 
alcohols and thiols, are user-selectable for titration.  Cofactors or water molecules are 
also taken into account. The HINT Titration algorithm identifies and exhaustively 
optimizes the water molecules that are in potentially bridging positions, i.e., within a 4Å 
radius from both protein and ligand, and thus able to interact with both98.  During the 
computation, each model corresponding to a particular protonation state is built and then 
optimized.  Here, all rotatable bonds involving polar hydrogens (R-XHn) – including 
those newly created via protonations such as the -OHs of carboxylic acids – at both the 
protein active site and on the ligand will be examined and exhaustively optimized192 to 
maximize hydrogen bonds formation, i.e., by rotation of these bonds through the entire 
360°.  In addition, Asn and Gln side chain amides are rotated ± 180° and oriented for 
optimal interaction.  Simply, this algorithm creates rotameric models that are 
isocrystallographic in that all of the models should fit within the experimental electron 
density envelopes and be indistinguishable.  Next, the algorithm calculates the HINT 
score of each rotameric model and creates a table of HINT score as a function of site 
charges.  From that a “titration curve” can be calculated.  To translate the HINT scores to 
free energy, we used the equation102: 
 
ΔG = -0.00195 HTOT – 5.543     (11)  
 
Finally, the statistical thermodynamics Boltzmann energy partition function is applied to 
each site charge to calculate population-weighted averages of binding free energy for 
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each site charge.  The Maxwell–Boltzmann distribution from statistical mechanics forms 
the basis of understanding classical molecular phenomena in terms of how energy is 
distributed in an average sample of states.  Mathematically, the Boltzmann distribution 
can be expressed in the form: 
 
f (E) = Ae-E/kT                (12) 
 
It gives the probability of any molecule existing in an energy state E as a function of its 
free energy.  In our case, it elucidates the possibility of an ionization state existing in a 
particular energy state as a function of that state’s free energy.  The probability decreases 
exponentially as the free energy of the state increases.  The Boltzmann average energy 
weights the energies of each state by these probabilities and is more representative of the 
overall ensemble energy than a normal average. 
 
5.3.2  Ionization State Ensemble of HIV-1 Protease.  
HIV-1 protease, which has been widely studied because of its crucial role in propagation 
of the AIDS virus, but also as a prototypical target enzyme vital for proteolytic cleavage 
of viral proteins, is a homodimeric aspartyl protease with 99 amino acid residues in each 
subunit230.  The active site of the enzyme is situated at the interface between the two 
monomers.  A conserved water molecule, water 301, located at the HIV-1 protease 
symmetry axis and bridging the two subunits, has been observed in all HIV protease-
ligand complexes hydrogen bonded to residues Ile50 and Ile150 and to specific 
inhibitors.  Two other water molecules, water 313233 and its pseudo-symmetrical 313’, 
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are largely conserved and crystallographically detected in several HIV-1 protease-ligand 
complexes.  Initially, protease inhibitors, mostly linear peptide analogues, were designed 
such that they coordinated with water 301, linking them to the amide hydrogens of Ile50 
and Ile150 on the flaps of the protease dimer.  It was observed from several studies that 
this water molecule was crucial for the binding of these inhibitors234.  Thus, it was 
hypothesized that incorporation of the binding features of this structural water molecule 
into an inhibitor would energetically favor the binding interactions, increasing both 
binding affinity as well as specificity, since this structural water is unique to the aspartyl 
proteases and its substitution would be thermodynamically favorable at least partly due to 
increased entropy.   
 
Meticulous design of cyclic ureas as HIV-1 protease inhibitors specifically designed to 
displace water 301 was reported by Lam et al. in 1994235.  An essential feature of this 
class of analogues was the carbonyl oxygen that mimicked the hydrogen bonding features 
of the key water molecule.  Furthermore, the conversion of the flexible linear peptidic 
inhibitors into rigid, cyclic structures with restricted conformations provided additional 
favorable entropic benefits.  The preferred conformations and stereochemistry of these 
inhibitors were confirmed by x-ray crystallography235,236 (see Figure 32).  The crystal 
structures also revealed the hydrogen bonds between the ligand diol groups and the 
carboxylates of the catalytic aspartates (Asp25 and Asp125) that serve to anchor the 
scaffold in the active site.  However, since protons are normally not detected by x-ray 
crystallography, there is experimental uncertainty in the correct assignment of the 
protonation state of the catalytic dyad.   
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Figure 32 . Cyclic inhibitors of HIV-1 protease. 
   
 154
 
Careful analysis of all the possible protonation states can reveal more about the hydrogen 
bonding, including the possible existence of alternative networks of hydrogen bonds.  
This understanding could lead to the design of better inhibitors with greater binding 
affinity.  
 
In the current study we examined six HIV-1 protease-inhibitor complexes (see Figure 32) 
representing cyclic urea derivatives, SD146 (pdb code 1QBT237), DMP450 (pdb code 
1DMP238) and Aha001 (pdb code 1AJX239), and cyclic sulfamide derivatives, Aha024 
(pdb code 1G35240), Aha047 (pdb code 1G2K240) and Aha006 (pdb code 1AJV239).  For 
the cyclic urea analogs the carbonyl oxygen substitutes the position occupied by the 
oxygen of water 301 and thus forms hydrogen bonds with Ile50 and Ile150.  For the 
sulfamide analogs both oxygens of the sulfamide group are engaged in hydrogen 
bonding, with one oxygen hydrogen-bonded to the amide nitrogen of Ile50, and the other 
to the amide nitrogen of Ile150.  The diols are engaged in hydrogen bond networks with 
the catalytic aspartates.   
 
The HIV-1 protease active site presents a number of ionizable residues ideally suited for 
the computational titration protocol.  In the six HIV-1-ligand complexes ionizable 
residues located within 8 Å of the ligand were chosen for titration. The contributions of 
waters 313 and 313’ were also included in the calculations.  Note that, in a sense, water, 
being both a potential hydrogen bond donor and acceptor, may act as a pH buffer by re-
orientating after a protonation change on a neighboring functional group.  Thus, allowing 
it to freely rotate is an important component of the CT algorithm.  For all complexes, the 
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active site residues Asp25, Asp29, and Asp30 on chain A, and Asp125, Asp129 and 
Asp130 on chain B were selected for titration, while only the aminic groups on the 1DMP 
ligand were subjected to titration.  Thus, complex 1DMP has a total of eight ionizable 
functional groups – six on the protein and two on the ligand – yielding 2916 protonation 
models for building and scoring.  All the remaining complexes have six ionizable 
residues at the protein active site – yielding 729 protonation models. 
 
The results of the titration are shown in Figure 33 for each of the six HIV-1-ligand 
complexes investigated, where the HINT scores for each protonation model are plotted as 
a function of site charge.  The normal (arithmetic) average and the Boltzmann average 
(statistically weighted average based on site populations) are calculated for each site 
charge and the corresponding “titration curves” are obtained. Details of the CT 
calculations, i.e., number of models, normal average and Boltzmann average free 
energies, for each site charge are listed in Table 11 and 12.  With the exception of 
complex 1QBT, the titration curves for all the complexes show a bell-like shape, 
particularly evident in complex 1DMP (Figure 33b).  The 1QBT titration curve (Figure 
33a) has a different trend and while the free energy diminishes with protonation, the 
curve does not reach a minimum.  The ligands considered in this study have mostly 
similar chemical structure and size, but the ligand in 1QBT is bulkier with two 
substituted benzoimidazole groups.  This complex has the highest experimental binding 
free energy, but its calculated energy is underestimated by the HINT scoring function.  
This could be due to the structure of the ligand itself: possibly the protonation state of the 
benzomidazole groups that are not  
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Table 11.  Computational Titration results for the HIV-1 protease-cyclic inhibitor 
complexes: cyclic urea ligands.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) HINT scores are converted into free energies using eq. (11). 
 
 
 
Cyclic Urea Ligands 
PDB Site Charge 
Model 
Count 
Normal 
Average a) 
[kcal mol-1] 
Boltzmann 
Average a) 
[kcal mol-1] 
-6 1 -4.67 -4.67 
-5 12 -5.02 -5.11 
-4 60 -5.39 -5.55 
-3 160 -5.72 -5.95 
-2 240 -6.01 -6.32 
-1 192 -6.29 -6.65 
1QBT 
0 64 -6.53 -6.91 
-6 1 -8.28 -8.28 
-5 14 -8.56 -10.09 
-4 85 -8.83 -11.50 
-3 292 -9.05 -11.79 
-2 620 -9.23 -11.82 
-1 832 -9.37 -11.61 
0 688 -9.49 -11.23 
1 320 -9.59 -10.69 
1DMP 
2 64 -9.71 -10.02 
-6 1 -7.40 -7.41 
-5 12 -7.68 -7.79 
-4 60 -7.81 -7.98 
-3 160 -7.93 -8.13 
-2 240 -7.99 -8.21 
-1 192 -8.00 -8.22 
1AJX 
0 64 -7.95 -8.10 
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Table 12.  Computational Titration results for the HIV-1 protease-cyclic inhibitor 
complexes: cyclic sulfamide ligands.  
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) HINT scores are converted into free energies using eq. (11). 
  
 
Cyclic Sulfamide Ligands 
PDB Site Charge 
Model 
Count 
Normal 
Average a) 
[kcal mol-1] 
Boltzmann 
Average a) 
[kcal mol-1] 
-6 1 -6.65 -6.65 
-5 12 -6.69 -6.82 
-4 60 -6.89 -7.04 
-3 160 -6.95 -7.19 
-2 240 -6.98 -7.30 
-1 192 -6.97 -7.34 
1G35 
0 64 -6.93 -7.31 
-6 1 -6.36 -6.36 
-5 12 -6.57 -6.71 
-4 60 -6.78 -7.04 
-3 160 -6.92 -7.34 
-2 240 -7.03 -7.59 
-1 192 -7.10 -7.74 
1G2K 
0 64 -7.11 -7.67 
-6 1 -6.94 -6.94 
-5 12 -7.17 -7.35 
-4 60 -7.32 -7.66 
-3 160 -7.36 -7.89 
-2 240 -7.31 -8.05 
-1 192 -7.17 -8.15 
1AJV 
0 64 -6.93 -8.11 
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subjected to titration with our current algorithm.  The lowest free energy point determined 
by Boltzmann statistics – the minimum of the Boltzmann average titration curve – is what 
we define to be the “optimal” calculated free energy of binding representing the most 
favorable site charge, and by inference pH, for the specific ligand binding.  Figure 34 
illustrates the best model for HIV-1 protease in complex with the cyclic urea inhibitor 
1DMP, for which the titration curve is shown in Figure 33b.  While the “best” model is the 
one with the highest HINT score and presumably represents the protonation model 
corresponding to the best binding, it must be highlighted that there are many models with 
similar energy, and that it is likely that many of them coexist, especially at room 
temperature or above where binding assays are performed.  For 1DMP the best model 
corresponds to a -3 site charge, where the two amine groups on the ligand and only Asp 
125 on the protein are protonated.  As expected, Asp25 and Asp125 are engaged in a 
complex network of hydrogen bonds with the ligand’s diols.  The two ammonium groups 
on the ligand make hydrogen bonds with Asp29/Asp30/water313, and 
Asp129/Asp130/water313’, respectively.  The deprotonated Asp29 and Asp129 residues 
are also involved in hydrogen bonds with waters 313 and 313’, respectively. 
 
Experimental and calculated binding free energies for the examined HIV-1 ligand 
complexes are reported in Table 13.  The “optimal” site charges, i.e., the optimal 
protonation states that correspond to the optimal binding energies calculated by the 
Boltzmann statistical analysis, are also reported.  The results are encouraging, giving an 
average error of ± 2.5 kcal mol-1 in the prediction of binding energy, excluding the outlier  
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Figure 34. Complex 1DMP. Best model for HIV-1 protease in complex with a cyclic urea 
inhibitor (complex 1DMP). Ligand (ball and stick representation, colored by atom type), 
key active site residues (titratable aspartates in stick representation, colored by atom type; 
Ile50/150 stick representation, orange) and waters 313/313’ (stick representation, magenta) 
are highlighted.  Asp125 and the two amine groups on the ligand are protonated in this 
model.  The network of hydrogen bonds at the active site is illustrated with yellow dashed 
lines.   
 
 
 
 
 
  
Asp25 Asp125 
Asp129 
Asp130 
Ile150 Ile50 
Asp29 
Asp30 
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Table 13: Experimental and calculated optimal (Boltzmann-weighted average) binding 
free energies for HIV-1 ligand complexes.  
 
 
 
 
 
 
 
 
 
 
 
a) Data from.185 
b) HINT scores are converted into free energies using eq. (11). 
c) 1QBT has not reached a true titration curve minimum.  This is the value at the curve’s lowest 
point, thus the “optimal” site charge may be at a more positive value (see Figure 33a).  
PDB 
Experimental 
∆Gbindinga) 
[kcal mol-1] 
Optimal Calculated 
∆Gbindingb) 
 [kcal mol-1] 
Optimal 
site 
charge 
1QBT -14.44 -6.91    0c) 
1DMP -12.99 -11.82 -2 
1AJX -10.79 -8.22 -1 
1G35 -11.06 -7.34 -1 
1G2K -10.82 -7.74 -1 
1AJV -10.52 -8.15 -1 
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complex 1QBT where the calculated energy is underestimated by the computational 
titration and which displayed an atypical titration profile (Figure 33a).  It is important to 
recognize that using an equation correlating HINT scores with binding energies that is 
calibrated for the specific analyzed system, instead of a general equation, would likely 
improve free energy prediction.   
  
5.4 Summary 
The computational protocol described here allows modeling of the multiplicity of 
protonation states, an often overlooked aspect of structure that has implications for drug 
discovery.  This approach allows generating hypotheses on the best model for binding, i.e., 
the model with protonation corresponding to the optimal binding energy.  The binding 
energy is evaluated with the HINT scoring function, which has previously been shown to 
fairly accurately predict binding free energies 101. In considering all the ionizable residues 
at the active site and modeling all the possible protonation states of residues and functional 
groups at this site, the computational titration algorithm represents fairly realistically the 
fluxional behavior of hydrogens in solvated biological systems. Hydrogens, in fact, are not 
static elements of a real biomolecular system. However, the computational titration 
procedure remains computationally expensive.  The number of models increases rapidly as 
the number of ionizable residues/functional groups in the binding pocket increases.  The 
inclusion of water molecules in the calculations makes these procedures even more time 
consuming. Nevertheless, we are committed to making this tool available and are currently 
developing a web-enabled version that will be publicly accessible. 
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CHAPTER 6 
 
 
 
Conclusions 
 
 
Computational tools have been extensively used in drug design and development from 
exploration of targets to corroborate experimental data. Computer aided drug design has 
been used to design new bioactive compounds with the aim of optimizing the overall 
pharmacodynamic and pharmacokinetic profile of a drug candidate and expediting the 
process of drug discovery. These techniques have substantially reduced the time and 
economic resources needed to discover novel drug candidates. This dissertation discussed 
the computational modeling aspects of drug design for anti-cancer agents with a focus on 
their interactions with potential targets and an emphasis on explaining and suggesting each 
drug candidate’s mechanism of action at the molecular level. Molecular modeling studies 
and development of computational tools that aid in drug design were also discussed. A 
novel de novo program for cavity detection and its application were described. The 
software tool identifies and delineates the active site within the protein. Another 
computational tool that allows identification, modeling and optimization of the multiple 
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protonation states of residues and ligand functional groups at the protein-ligand active site 
was also described and discussed.   
 
The compounds which bind to the colchicine site of tubulin have drawn considerable 
attention and studies indicated that these agents may influence microtubule dynamics by 
inhibiting polymerization. However, fundamental uncertainties in many aspects of 
microtubule biology and insufficient knowledge of the binding site interactions have 
undermined the possibility of identifying effective drugs with minimal toxicity. 
Nevertheless, the compounds which bind to the colchicine site of tubulin have recently 
emerged as attractive targets for cancer therapy. Pyrrole-containing molecules derived 
from nature have proven to be particularly useful as lead compounds for drug 
development. We designed and developed a series of substituted pyrroles that inhibit 
growth and promote death of breast tumor cells at nM and μM concentrations in human 
breast tumor cell lines. Subsequent experimental studies demonstrated that the highest 
degree of antiproliferative activity was expressed by JG-03-14 (3,5-dibromo-4-(3,4-
dimethoxyphenyl)-1Hpyrrole-2-carboxylic acid ethyl ester). COMPARE analysis across 
the NCI panel of cancer cell lines, along with molecular modeling studies, showed that JG-
03-14 had a similar mechanism of action to colchicine and combretastatin.  
 
The current work demonstrated that molecular modeling docking calculations along with 
HINT interaction analysis were able to complement experimental studies of binding in 
many aspects, including accurate representation of the complex structure and the binding 
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mode of inhibitors. HINT scoring function was used to investigate the structural aspects of 
the interactions. On the basis of calculations, the complexes were ranked according to their 
decreasing HINT scores. These results, calculated for 22 pyrrole compounds, provide insights 
into the structural requirements for the growth inhibitory activity/cytotoxicity of this class of 
agents and offer significant opportunity for structural alterations, which could lead to an 
improved drug candidate. Complex with JG-03-14 is the most stable corroborating the 
experimental data. These results are important for the understanding the binding process 
and valuable in the design of new Pyrrole-based colchicine site inhibitors. Compounds of 
this type have potential for further development. Hydropathic interaction analysis has 
provided a rationale for selecting the substituent on a parent ligand which will yield more 
tightly binding analogues.  
 
Stilbenes are a group of natural compounds with many biological activities. The 
mechanism of action of stilbenes is by interfering with microtubule polymerization through 
the colchicine-binding site. Two highly potent stilbenes, cis-3,40,5-trimethoxy-30-
aminostilbene (stilbene 5c) and cis-3,40,5-trimethoxy-30-hydroxystilbene (stilbene 6c) 
induce G2/M cell-cycle arrest and leukemic cell death in nanomolar range without 
affecting normal bone marrow progenitor cells. Animal studies showed that stilbenes are 
well tolerated and suppresses tumor growth in mice. Further experimental results indicated 
that stilbene 5c is a microtubule- interfering agent and can be potentially useful in 
leukemic therapy. A molecular modeling study was carried out to accurately represent the 
complex structure and the binding mode of a new class of stilbene-based tubulin inhibitors 
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that bind at the αβ-tubulin colchicine site.  Computational docking along with HINT score 
analysis fitted these inhibitors into the colchicine site and revealed detailed structure-
activity information useful for inhibitor design.  Quantitative analysis of the results was in 
good agreement with the in vitro antiproliferative activity of these derivatives (ranging 
from 3 nM to 100 μM) such that calculated and measured free energies of binding correlate 
with an r2 of 0.89 (standard error ± 0.85 kcal mol-1).  This correlation suggests that the 
activity of unknown compounds may be predicted. The results are important for 
understanding the binding process and valuable in the design of new stilbene-based 
colchicine site inhibitors.  
 
Apart from the application of computational methodologies, design and development of 
new computational tools has also been discussed in the manuscript. The development and 
implementation of a novel cavity detection algorithm is also reported and discussed. The 
algorithm named VICE (Vectorial Identification of Cavity Extents) utilizes HINT toolkit 
functions to identify and delineate binding pocket in a protein. This algorithm, which is 
based on geometric criteria applied to simple integer grid maps to delineate binding sites, 
is very efficient. The program was applied to a representative set of proteins from different 
classes having binding pockets of different shapes and sizes. It was demonstrated that the 
application is capable of detecting and delineating indentations, cavities, pockets, voids, 
grooves, channels, tunnels, pores and surface regions on protein. The interactive front-end 
provides a quick and simple procedure for identifying, displaying and manipulating 
cavities in a known protein structure. In addition to computing volumes, our method also 
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provides information on atoms, residues and chains which contribute to the cavities. These 
observations have been most thoroughly characterized and correlate well with the 
experimental data.  
 
The study also implemented the computational titration algorithm to understand the 
complexity of ligand binding and protonation state in the active site of HIV-1 protease.  
The importance of taking into account pH and ionization states of residues, which strongly 
affect the process of ligand binding, for correctly predicting the binding free energy is 
discussed. The application of the computational titration protocol to a set of six HIV-1-
cyclic inhibitor complexes was carried out. The binding energy was evaluated with the 
HINT scoring function. The results were encouraging, giving an average error of ± 2.5 kcal 
mol-1 in the prediction of binding energy. The titration algorithm allowed the 
identification, modeling and optimization of the multiple protonation states of residues and 
ligand functional groups at the protein-ligand active site.  This approach allows generating 
hypotheses on the best model for binding, i.e., the model with protonation corresponding to 
the optimal binding energy.  In considering all the ionizable residues at the active site and 
modeling all the possible protonation states of residues and functional groups at this site, 
the computational titration algorithm represents fairly realistically the fluxional behavior of 
hydrogens in solvated biological systems.   
  
To conclude, the overall purpose of this multidisciplinary endeavour was to design and 
develop novel therapeutics for cancer and understand the molecular mechanism involved 
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in drug action using computational tools. A second synergistic goal was to develop new 
computational tools that will aid in design bioactive molecules and understanding the 
molecular mechanism of protein-ligand binding process. To this end, application of 
molecular modeling has facilitated the design and development of the new anti-cancer 
compounds and has served to improve the understanding of the underlying mechanisms of 
microtubule depolymerizing agents. In its most general terms, the overall design and 
refinement of the novel antitumor compounds proposed herein is a fundamental step 
towards establishing a knowledge base that will enable the synthesis and testing of 
effective chemotherapeutic agents. The HINT force field can provide atomic level details 
of interactions and may help in the design of more selective drug molecules. The HINT 
program finds extensive application in drug design project and the knowledge acquired 
will prove to be productive and of scientific significance. This research will further provide 
the scientific community with additional knowledge that will help them in the de novo 
identification and characterization of binding site and to understand the relevant molecular-
level interactions.   
   
 169
 
 
 
 
 
Literature Cited 
 
 
 
 
 
 
 
 
   
 170
 
 
(1) Garcia, M.; Jemal, A.; Ward, E. M.; Center, M.; Hao, Y. et al. Global Cancer Facts 
& Figures 2007. American Cancer Society, 2007 2007. 
(2) American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American 
Cancer Society; 2008. 2008. 
(3) World Health Organization Fact Sheet N0 297. 2009. 
(4) The World Health Organization’s Fight Against Cancer: Strategies That Prevent, 
Cure and Care. 2007. 
(5) Ltadani, H.; Mizuarai, S.; Kotani, H. Can systems biology understand pathway 
activation? Gene expression signatures as surrogate markers for understanding the 
complexity of pathway activation. Current Genomics 2008, 9, 349-360. 
(6) Xiao, G. G.; Recker, R. R.; Deng, H.-W. Recent advances in proteomics and cancer 
biomarker discovery. Clinical Medicine: Oncology 2008, 2, 63-72. 
(7) Croce, C. M. Oncogenes and cancer. New England Journal of Medicine 2008, 358, 
502-511. 
(8) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70. 
(9) Oliff, A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. 
Biochim Biophys Acta 1999, 1423, C19-30. 
(10) Cerutti, P. A. Prooxidant states and tumor promotion. Science 1985, 227, 375-381. 
(11) Griswold, D. P., Jr.; Harrison, S. D., Jr. Tumor models in drug development. 
Cancer Metastasis Rev 1991, 10, 255-261. 
(12) Zarbl, H. Cellular oncogenes and carcinogenesis. Molecular Carcinogenesis and 
the Molecular Biology of Human Cancer 2006, 103, 103-129. 
(13) Weiss, G. R.; Burris, H. A., 3rd; Eckhardt, S. G.; Rodriguez, G. I.; Sharma, S. et al. 
New anticancer agents. Cancer Chemother Biol Response Modif 1997, 17, 178-
194. 
(14) Weiss, G. R. Drugs in the treatment of cancer chemotherapy. Appleton and Lange: 
East Norwalk 1997. 
(15) Isoldi, M. C.; Visconti, M. A.; Castrucci, A. M. Anti-cancer drugs: molecular 
mechanisms of action. Mini Rev Med Chem 2005, 5, 685-695. 
(16) Pervaiz, S. Anti-cancer drugs of today and tomorrow: are we close to making the 
turn from treating to curing cancer? Curr Pharm Des 2002, 8, 1723-1734. 
(17) Wilson, L.; Jordan, M. A. New microtubule/tubulin-targeted anticancer drugs and 
novel chemotherapeutic strategies. J Chemother 2004, 16 Suppl 4, 83-85. 
(18) Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat Rev 
Cancer 2004, 4, 253-265. 
(19) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for 
anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998, 
18, 259-296. 
   
 171
(20) Houston, J. G.; Banks, M. The chemical-biological interface: developments in 
automated and miniaturised screening technology. Curr Opin Biotechnol 1997, 8, 
734-740. 
(21) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gordon, E. M. 
Applications of combinatorial technologies to drug discovery. 1. Background and 
peptide combinatorial libraries. J Med Chem 1994, 37, 1233-1251. 
(22) Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gallop, M. A. 
Applications of combinatorial technologies to drug discovery. 2. Combinatorial 
organic synthesis, library screening strategies, and future directions. J Med Chem 
1994, 37, 1385-1401. 
(23) Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening- an overview. Drug 
Discovery Today 1998, 3, 160-178. 
(24) Verlinde, C. L. M. J.; Hol, W. G. J. Structure-based drug design: progress, results 
and challenges. Structure 1994, 2, 577-587. 
(25) Kapetanovic, I. M. Computer-aided drug discovery and development (CADDD): In 
silico-chemico-biological approach. Chemico-Biological Interactions 2008, 171, 
165-176. 
(26) Tajkhorshid, E.; Suhai, S. The dielectric effect of the environment on the pKa of 
the retinal Schiff base and on the stabilization of the ion pair in bacteriorhodopsin. 
Journal of Molecular Structure (Theochem) 2000, 501-502, 297-313. 
(27) Murphy, K. P. Predicting binding energetics from structures: Looking beyond δG°. 
Medicinal research reviews 1999, 19, 333-339. 
(28) Lee, C. Calculating binding energies. Curr. Opin. Struct. Biol. 1992, 2, 217-222. 
(29) Anderson, A. C. The Process of Structure-Based Drug Design. Chemistry & 
Biology 2003, 10, 787-797. 
(30) Campbell, S. J.; Gold, N. D.; Jackson, R. M.; Westhead, D. R. Ligand binding: 
functional site location, similarity and docking. Curr Opin Struct Biol 2003, 13, 
389-395. 
(31) Kleywegt, G. J. Detection, delineation, measurement and display of cavities in 
macromolecular structures. Acta Crystallogr D 1994, 50, 178-185. 
(32) Selway, C. N.; Terrett, N. K. Parallel-compound synthesis: methodology for 
accelerating drug discovery. Bioorg Med Chem 1996, 4, 645-654. 
(33) DesJarlais, R. L.; Sheridan, R. P.; Seibel, G. L.; Dixon, J. S.; Kuntz, I. D. et al. 
Using shape complementarity as an initial screen in designing ligands for a receptor 
binding site of known three-dimensional structure. J Med Chem 1988, 31, 722-729. 
(34) Murcko, M. A. Recent advances in ligand design methods. Reviews in 
Computational Chemistry 2007, 11, 1-66. 
(35) Dean, P.; Harris, B.; Willems, H. De novo design of focused libraries of drug-like 
compounds. DrugPlus international 2005. 
(36) Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. 
Nat Rev Drug Discov 2005, 4, 649-663. 
(37) Beavers, M. P.; Chen, X. Structure-based combinatorial library design: 
methodologies and applications. J Mol Graph Model 2002, 20, 463-468. 
   
 172
(38) Hindle, S. A.; Rarey, M.; Buning, C.; Lengaue, T. Flexible docking under 
pharmacophore type constraints. J Comput Aided Mol Des 2002, 16, 129-149. 
(39) Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in 
virtual screening for drug discovery: methods and applications. Nat Rev Drug 
Discov 2004, 3, 935-949. 
(40) Honma, T. Recent advances in de novo design strategy for practical lead 
identification. Med Res Rev 2003, 23, 606-632. 
(41) Lengauer, T.; Rarey, M. Computational methods for biomolecular docking. 
Current Opinion in Structural Biology 1996, 6, 402-406. 
(42) Matthews, B. W. Solvent content of protein crystals. J. Mol. Biol., 1968, 33, 491-
497. 
(43) Gilson, M. K. Theory of electrostatic interactions in macromolecules. Curr. Opin. 
Struct. Biol. 1995, 5, 216-223. 
(44) Vajda, S.; Guarnieri, F. Characterization of protein-ligand interaction sites using 
experimental and computational methods. Curr Opin Drug Discov Devel 2006, 9, 
354-362. 
(45) Burgoyne, N. J.; Jackson, R. M. Predicting protein interaction sites: binding hot-
spots in protein-protein and protein-ligand interfaces. Bioinformatics 2006, 22, 
1335-1342. 
(46) RosenfieId, R. E.; Swanson, J. S. M.; Meyer, E. F.; CarrelI, J. H. L.; Murray-Rust, 
P. Mapping the atomic environment of functional groups: turning 3D scatter plots 
into pseudo-density contours. Journal of Molecular Graphics 1984, 2, 43-46. 
(47) Patel, Y.; Gillet, V. J.; Bravi, G.; Leach, A. R. A comparison of the pharmacophore 
identification programs: Catalyst, DISCO and GASP. Journal of Computer-Aided 
Molecular Design 2002, 16, 653-681. 
(48) Barillari, C.; Marcou, G.; Rognan, D. Hot-spots-guided receptor-based 
pharmacophores (HS-Pharm): a knowledge-based approach to identify ligand-
anchoring atoms in protein cavities and prioritize structure-based pharmacophores. 
J Chem Inf Model 2008, 48, 1396-1410. 
(49) Ebalunode, J. O.; Ouyang, Z.; Liang, J.; Zheng, W. Novel approach to structure-
based pharmacophore search using computational geometry and shape matching 
techniques. J Chem Inf Model 2008, 48, 889-901. 
(50) Ghose, A. K.; Wendoloski, J. J. Pharmacophore Modelling: Methods, Experimental 
Verification and Applications. Perspectives in Drug Discovery and Design 1998, 
253–271. 
(51) Landon, M. R.; Lancia, D. R., Jr.; Yu, J.; Thiel, S. C.; Vajda, S. Identification of 
hot spots within druggable binding regions by computational solvent mapping of 
proteins. J Med Chem 2007, 50, 1231-1240. 
(52) Chen, J.; Lai, L. Pocket v.2: Further Developments on Receptor-Based 
Pharmacophore Modeling. J. Chem. Inf. Model. 2006, 46, 2684-2691. 
(53) Bohm, H. J. The computer program LUDI: A new method for the de novo design 
of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78. 
   
 173
(54) Gohlke, H.; Klebe, G. Approaches to the Description and Prediction of the Binding 
Affinity of Small-Molecule Ligands to Macromolecular Receptors. Angew. Chem. 
Int. Ed 2002, 41, 2644-2676. 
(55) Spyrakis, F.; Cozzini, P.; Kellogg, G. E. Docking and scoring in drug discovery. 
Burger's Medicinal Chemistry and Drug Discovery Seventh Edition 2009, 1, 
Chapter 7. 
(56) Leach, A. A Survey of Methods for searching the Conformational Space of Small 
and Medium-Sized Molecules. Reviews in Computational Chemistry. 1991 VCH, 
New York. 1991, 1-55. 
(57) Brooijmans, N., Kuntz, ID. Molecular recognition and docking algorithms. Annu 
Rev Biophys Biomol Struct 2003, 32, 335-373. 
(58) Perola, E., Xu, K, Kollmeyer, TM, Kaufmann, SH, Prendergast, FG, Pang, YP, 
Successful virtual screening of a chemical database for farnesyltransferase inhibitor 
leads. J Med Chem 2000, 43, 401-408. 
(59) Jiang, F.; Kim, S. Soft docking": matching of molecular surface cubes. J Mol Biol 
1991, 219, 79-102. 
(60) Kuntz, I., Blaney, JM, Oatley, SJ, Langridge, R, Ferrin, TE. A geometric approach 
to macromolecule-ligand interactions. J Mol Biol 1982, 161, 269-288. 
(61) Sandak, B., Nussinov, R, Wolfson, HJ. An automated computer vision and 
robotics-based technique for 3-D flexible biomolecular docking and matching. 
Comput Appl Biosci 1995, 11, 87-99. 
(62) DesJarlais, R., Sheridan, RP, Dixon, JS, Kuntz, ID, Venkataraghavan, R. Docking 
flexible ligands to macromolecular receptors by molecular shape. J Med Chem 
1986, 29, 2149-2153. 
(63) Sandak, B., Nussinov, R, Wolfson, HJ. A method for biomolecular structural 
recognition and docking allowing conformational flexibility. J Comput Biol 1998, 
5, 631-654. 
(64) Metropolis, N., Rosenbluth, A, Rosenbluth, M, Teller, A, Teller, E. Equation of 
State Calculations by Fast Computing Machines. J Chem Phys 1953, 21, 1087. 
(65) Hart, T., Read, RJ. A multiple-start Monte Carlo docking method. Proteins 1992, 
13, 206-222. 
(66) Clark, D., Westhead, DR. Evolutionary algorithms in computer-aided molecular 
design. Comput Aided Mol Des 1996, 10, 337-358. 
(67) Judson, R. Genetic Algorithms and their use in Chemistry. Reviews in 
Computational Chemistry. 1997 VCH Publishers, New York. 1997, 1-73. 
(68) Morris, G., Goodsell, DS, Halliday, RS, Huey, R, Hart, WE, Belew, RK, Olson, 
AJ. Automated docking using a Lamarckian genetic algorithm and an empirical 
binding free energy function. Comput Chem 1998, 19, 1639-1662. 
(69) Jones, G., Willett, P, Glen, RC, Leach, AR, Taylor, R, Development and validation 
of a genetic algorithm for flexible docking. J Mol Biol 1997, 267, 727-748. 
(70) Vieth, M., Hirst, J, Dominy, B, Daigler, H, Brooks, C. Assessing search strategies 
for flexible docking. J Comput Chem 1998, 19, 1623-1631. 
   
 174
(71) Wu, G., Robertson, DH, Brooks, CL, 3rd, Vieth, M. Detailed analysis of grid-based 
molecular docking: A case study of CDOCKER-A CHARMmbased MD docking 
algorithm. J Comput Chem 2003, 24, 1549-1562. 
(72) Baxter, C., Murray, CW, Clark, DE, Westhead, DR, Eldridge, MD. Flexible 
docking using Tabu search and an empirical estimate of binding affinity. Proteins 
1998, 33, 367-382. 
(73) Price, M., Jorgensen, W. Analysis of Binding Affinities for Celecoxib Analogues 
with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations 
and Insight into the COX-2/COX-1 Selectivity. J Am Chem Soc 2000, 122, 9455-
9466. 
(74) Hoffmann, D., Kramer, B, Washio, T, Steinmetzer, T, Rarey, M, Lengauer, T. 
Two-stage method for protein-ligand docking. J Med Chem 1999, 42, 4422-4433. 
(75) Bohm, H., Stahl, M. The use of scoring functions in drug discovery applications. 
Reviews Comput Chem. 2002 Wiley-VCH, John Wiley and Sons, Inc., New York. 
2002, 41-87. 
(76) Kaminski, G., Jorgensen, WL. Performance of the AMBER94, MMFF94, and 
OPLS-AA Force Fields for Modeling Organic Liquids. J Phys Chem 1996, 100, 
18010-18013. 
(77) Weiner, S., Kollman, PA, Nguyen, DT, Case, DA. An all atom force field for 
simulations of proteins and nucleic acids. J Comput Chem 1986, 252, 230-252. 
(78) The SYBYL software, TI, http://www.tripos.com/. 1995; Tripos Inc.: St. Louis, 
MO. 
(79) Halgren, T. Merck molecular force field. I. Basis, form, scope, parameterization, 
and performance of MMFF94. J Comput Chem 1996, 17, 490-519. 
(80) Dinur, U., Hagler, A. New Approaches to Empirical Force Fields. Reviews in 
Computational Chemistry. 1991 VCH, New York. 1991, 99-164. 
(81) Nemethy, G., Gibson, KD, Palmer, KA, Yoon, CN, Paterlini, G, Zagari, A, 
Rumsey, S, Scheraga, HA. Energy parameters in polypeptides. 10. Improved 
geometrical parameters and nonbonded interactions for use in the ECEPP/3 
algorithm, with application to proline-containing peptides. J Phys Chem 1992, 96, 
6472-6484. 
(82) Naim, M., Bhat, S, Rankin, KN, Dennis, S, Chowdhury, SF, Siddiqi, I, Drabik, P, 
Sulea, T, Bayly, CI, Jakalian, A, et al. Solvated interaction energy (SIE) for scoring 
protein-ligand binding affinities. 1. Exploring the parameter space. J Chem Inf 
Model 2007, 47, 122-133. 
(83) Zou, X., Yaxiong, S, Kuntz, ID. Inclusion of Solvation in Ligand Binding Free 
Energy Calculations Using the Generalized-Born Model. J. Am. Chem. Soc. 1999, 
121, 8033-8043. 
(84) Verdonk, M., Chessari, G, Cole, JC, Hartshorn, MJ, Murray, CW, Nissink, JW, 
Taylor, RD, Taylor, R. Modeling water molecules in protein-ligand docking using 
GOLD. J Med Chem 2005, 48, 6504-6515. 
(85) Koppensteiner, W., Sippl, MJ. Knowledge based potentials-back to the roots. 
Biochemistry (Mosc) 1998, 63, 247-252. 
   
 175
(86) Muegge, I. PMF scoring revisited. J Med Chem 2006, 49, 5895-5902. 
(87) Clark, R., Strizhev, A, Leonard, JM, Blake, JF, Matthew, JB. Consensus scoring for 
ligand/protein interactions. J Mol Graph Model 2002, 20, 281-295. 
(88) McCammon, J. A. Free energy from simulations. Current Opinion in Structural 
Biology 1991, 1, 196-200. 
(89) Ajay; Murcko, M. A. Computational Methods to Predict Binding Free Energy in 
Ligand-Receptor Complexes. Journal of Medicinal Chemistry 1995, 38, 4953-
4967. 
(90) Kollman, P. Free energy calculations-applications to chemical and biochemical 
phenomena. Chem. Rev. 1993, 93, 2395-2417. 
(91) Kellogg, G. E. Hydrophobicity: is LogPo/w more than the sum of its parts? Eur J 
Med Chem 2000, 35, 651-661. 
(92) Kellogg, G. E.; Burnett, J. C.; Abraham, D. J. Very empirical treatment of solvation 
and entropy: a force field derived from log Po/w. J Comput Aided Mol Des 2001, 
15, 381-393. 
(93) Kellogg, G. E.; Abraham, D. J. Development of Empirical Biomolecular 
Interaction Models that Incorporate Hydrophobicity and Hydropathy. The HINT 
Paradigm. Analysis 1999, 27, 19-22. 
(94) Kellogg, G. E.; Joshi, G. S.; Abraham, D. J. New Tools for Modeling and 
Understanding Hydrophobicity and Hydrophobic Interactions. Med. Chem. Res. 
1992, 1, 444-453. 
(95) Kellogg, G. E.; Semus, S. F.; Abraham, D. J. HINT: a new method of empirical 
hydrophobic field calculation for CoMFA. J Comput Aided Mol Des 1991, 5, 545-
552. 
(96) Spyrakis, F.; Amadasi, A.; Fornabaio, M.; Abraham, D. J.; Mozzarelli, A. et al. The 
consequences of scoring docked ligand conformations using free energy 
correlations. Eur J Med Chem 2007, 42, 921-933. 
(97) Hansch, C.; Leo, A. J. Substituent Constants for Correlation Analysis in Chemistry 
and Biology. John Wiley and Sons, Inc. New York, NY, 1979. 1979. 
(98) Kellogg, G. E.; Chen, D. L. The importance of being exhaustive. Optimization of 
bridging structural water molecules and water networks in models of biological 
systems. Chem Biodivers 2004, 1, 98-105. 
(99) Kellogg, G. E.; Fornabaio, M.; Spyrakis, F.; Lodola, A.; Cozzini, P. et al. Getting it 
right: modeling of pH, solvent and "nearly" everything else in virtual screening of 
biological targets. J Mol Graph Model 2004, 22, 479-486. 
(100) Tripathi, A.; Fornabaio, M.; Kellogg, G. E.; Gupton, J. T.; Gewirtz, D. A. et al. 
Docking and hydropathic scoring of polysubstituted pyrrole compounds with 
antitubulin activity. Bioorg Med Chem 2008, 16, 2235-2242. 
(101) Fornabaio, M.; Spyrakis, F.; Mozzarelli, A.; Cozzini, P.; Abraham, D. J. et al. 
Simple, intuitive calculations of free energy of binding for protein-ligand 
complexes. 3. The free energy contribution of structural water molecules in HIV-1 
protease complexes. J Med Chem 2004, 47, 4507-4516. 
   
 176
(102) Cozzini, P.; Fornabaio, M.; Marabotti, A.; Abraham, D. J.; Kellogg, G. E. et al. 
Simple, intuitive calculations of free energy of binding for protein-ligand 
complexes. 1. Models without explicit constrained water. J Med Chem 2002, 45, 
2469-2483. 
(103) Kellogg, G. E.; Fornabaio, M.; Chen, D. L.; Abraham, D. J. New Application 
Design for a 3D Hydropathic Map–Based Search for Potential Water Molecules 
Bridging between Protein and Ligand. Internet Electron. J. Mol. Des. 2005, 4, 194-
209. 
(104) Wilson, E. K. Plumbing the Ocean Depths for Drugs. Chem. and Eng. News 2003, 
37-38. 
(105) Bailly, C. Lamellarins from A to Z: A Family of Anticancer Marine Pyrrole 
Alkaloids. Curr.  Med. Chem.-Anti-Cancer Agents 2004, 4, 363-378. 
(106) Evans M. A. , S. D. C., Holub J. M., Argenti A., Hoff M , Dalglish G. A., Wilson 
D. L., Taylor B. M., Berkowitz J. D., Burnham B. S., Krumpe K., Gupton J. T., 
Scarlett T. S., Durham, Jr. R. W., Hall I. H. Synthesis and Cytotoxicity of 
Substituted Ethyl 2-Phenacyl-3-phenylpyrrole-4 carboxylate. Arch. Pharm. Pharm. 
Med. Chem. 2003, 336, 181-190. 
(107) Lee, M. Pyrrole Natural Products with Antitumor Properties. Heterocyclic 
Antitumor Antibiotics: Topics in Heterocyclic Chemistry, Vol.2, Ed. by , Springer 
Verlag, Berlin/Heidelberg 2006, 53-92. 
(108) Mooberry, S. W., K.; Dakshanamurthy, S.; Hamel, E.; Banner, E.; Kharlamova, A.; 
Hempel, J.; Gupton, J.; Brown, Identification and characterization of a new tubulin-
binding tetrasubstituted brominated pyrrole. M. Mol. Pharmacol. 2007, 72, 132-
140. 
(109) Handy, S. T.; Zhang, Y. Approaches to the synthesis of the Lamellarins and related 
natural products. Org. Prep. Proc. Int. 2005, 37, 411-445. 
(110) Owellen, R. J.; Owens, A. H., Jr.; Donigian, D. W. The binding of vincristine, 
vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 1972, 47, 
685-691. 
(111) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for 
anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998, 
18, 259-296. 
(112) Kumar, N. Taxol-induced polymerization of purified tubulin. Mechanism of action. 
J Biol Chem 1981, 256, 10435-10441. 
(113) Sengupta, S.; Boge, T. C.; Liu, Y.; Hepperle, M.; Georg, G. I. et al. Probing the 
environment of tubulin-bound paclitaxel using fluorescent paclitaxel analogues. 
Biochemistry 1997, 36, 5179-5184. 
(114) Altmann, K. H.; Gertsch, J. Anticancer drugs from nature--natural products as a 
unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007, 24, 327-
357. 
(115) Sackett, D. L. Podophyllotoxin, steganacin and combretastatin: natural products 
that bind at the colchicine site of tubulin. Pharmacol Ther 1993, 59, 163-228. 
   
 177
(116) Verdier-Pinard, P.; Lai, J. Y.; Yoo, H. D.; Yu, J.; Marquez, B. et al. Structure-
activity analysis of the interaction of curacin A, the potent colchicine site 
antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 
breast cancer cells. Mol Pharmacol 1998, 53, 62-76. 
(117) Kruse, L. I.; Ladd, D. L.; Harrsch, P. B.; McCabe, F. L.; Mong, S. M. et al. 
Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity 
relationship of oncodazole analogues. J Med Chem 1989, 32, 409-417. 
(118) Mejillano, M. R.; Shivanna, B. D.; Himes, R. H. Studies on the nocodazole-induced 
GTPase activity of tubulin. Arch Biochem Biophys 1996, 336, 130-138. 
(119) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S. et al. Isolation and 
structure of the strong cell growth and tubulin inhibitor combretastatin A-4. 
Experientia 1989, 45, 209-211. 
(120) Simoni, D.; Romagnoli, R.; Baruchello, R.; Rondanin, R.; Rizzi, M. et al. Novel 
combretastatin analogues endowed with antitumor activity. J Med Chem 2006, 49, 
3143-3152. 
(121) Ferguson, R. E.; Jackson, S. M.; Stanley, A. J.; Joyce, A. D.; Harnden, P. et al. 
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal 
cell carcinoma. Int J Cancer 2005, 115, 155-163. 
(122) Gupton, J. T. Pyrrole natural products with antitumor properties. Heterocyclic 
Antitumor Antibiotics: Topics in Heterocyclic Chemistry, Vol.2, Ed. by , Springer 
Verlag, Berlin/Heidelberg 2006, 53-92. 
(123) Burnham, B. S., Gupton, J. T., Krumpe, K., Webb, T., Shuford, J., Bowers, B., 
Warren, A. E., Barnes, C., Hall, I. H. Cytotoxicity of substituted alkyl-3,4-bis(4-
methoxyphenyl)pyrrole-2-carboxylates in L1210 lymphoid leukemia cells. Arch. 
Pharm. 1998, 331, 337-341. 
(124) Gupton, J. T., Burham, B. S., Byrd, B. D., Krumpe, K. E., Stokes, C., Shuford, J., 
Winkle, S., Webb, T., Warren, A. E., Barnes, C. R., Henry, J., Hall, I. H. The 
cytotoxicity and mode of action of 2,3,4-trisubstituted pyrroles and related 
derivatives in human Tmolt4 leukemia cells. Pharmazie 1999, 54, 691–697. 
(125) Yoshida, W. Y., Lee, K. K., Carroll, A. R.,Scheuer, P. J. A complex 
pyrrolooxazinone and its iodo derravative isolated from a tunicate. Helv. Chim. 
Acta 1992, 75, 1271-1275. 
(126) Banwell, M. G., Flynn, B. L., Hamel, E., Hockless, D. C. R. Convergent synthesis 
of the pyrrolic marine natural products lamellarin-O, lamellarin-Q, lukianol-A and 
some more highly oxygenated congeners. Chem. Commun. 1997, 2, 207-208. 
(127) Charan, R. D., Schlingmann, G., Bernan, V. S., Feng, X., Carter, G. T. 
Dioxapyrrolomycin biosynthesis in Streptomyces fumanus. J. Nat. Prod. 2006, 69, 
29-33. 
(128) Gupton, J. T.; Burham, B. S.; Krumpe, K.; Du, K.; Sikorski, J. A. et al. Synthesis 
and cytotoxicity of 2,4-disubstituted and 2,3,4-trisubstituted brominated pyrroles in 
murine and human cultured tumor cells. Arch Pharm (Weinheim) 2000, 333, 3-9. 
   
 178
(129) Cleaveland, E. S.; Monks, A.; Vaigro-Wolff, A.; Zaharevitz, D. W.; Paull, K. et al. 
Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted 
by the compare program. Biochem Pharmacol 1995, 49, 947-954. 
(130) Bai, R.; Covell, D. G.; Pei, X. F.; Ewell, J. B.; Nguyen, N. Y. et al. Mapping the 
binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-
demethylthiocolchicine covalently reacts predominantly with cysteine 239 and 
secondarily with cysteine 354. J Biol Chem 2000, 275, 40443-40452. 
(131) Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W. et 
al. A common pharmacophore for a diverse set of colchicine site inhibitors using a 
structure-based approach. J Med Chem 2005, 48, 6107-6116. 
(132) Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S. et al. Insight into 
tubulin regulation from a complex with colchicine and a stathmin-like domain. 
Nature 2004, 428, 198-202. 
(133) Gupton, J. T. K., Keith E.; Burnham, Bruce S.; Webb, Tammy M.; Shuford, Jordan 
S.; Sikorski, James A. The application of vinylogous iminium salt derivatives to a 
regiocontrolled and efficient relay synthesis of lukianol A and related marine 
natural products. Tetrahedron 1999, 55, 14515-14522. 
(134) Gupton, J. T. C., Stuart C.; Miller, Robert B.; Lukens, John R.; Henry, Charlotte 
A.; Kanters, Rene P. F.; Sikorski, James A. The application of vinylogous iminium 
salt derivatives to the synthesis of Ningalin B hexamethyl ether. Tetrahedron 2003, 
59, 207-215. 
(135) Gupton, J. T. M., Robert B.; Krumpe, Keith E.; Clough, Stuart C.; Banner, Edith J.; 
Kanters, Rene P. F.; Du, Karen X.; Keertikar, Kartik M.; Lauerman, Nicholas E.; 
Solano, John M.; Adams, Bret R.; Callahan, Daniel W.; Little, Barrett A.; Scharf, 
Austin B.; Sikorski, James A. The application of vinylogous iminium salt 
derivatives to an efficient relay synthesis of the pyrrole containing alkaloids 
polycitone A and B. Tetrahedron 2005, 61, 1845-1854. 
(136) Gupton, J. T. B., Edith J.; Scharf, Austin B.; Norwood, Bradley K.; Kanters, Rene 
P. F.; Dominey, Raymond N.; Hempel, Jonathan E.; Kharlamova, Anastasia; 
Bluhn-Chertudi, Itta; Hickenboth, Charles R.; Little, Barrett A.; Sartin, Melissa D.; 
Coppock, Matthew B.; Krumpe, Keith E.; Burnham, Bruce S.; Holt, Herman; Du, 
Karen X.; Keertikar, Kartik M.; Diebes, Anthony; Ghassemi, Shahnaz; Sikorski, 
James A. The application of vinylogous iminium salt derivatives to an efficient 
synthesis of the pyrrole containing alkaloids Rigidin and Rigidin E. Tetrahedron 
2006, 62, 8243-8255. 
(137) Clark, E. A.; Hills, P. M.; Davidson, B. S.; Wender, P. A.; Mooberry, S. L. 
Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 
2-methoxyestradiol. Mol Pharm 2006, 3, 457-467. 
(138) Rao, P. N.; Cessac, J. W.; Tinley, T. L.; Mooberry, S. L. Synthesis and antimitotic 
activity of novel 2-methoxyestradiol analogs. Steroids 2002, 67, 1079-1089. 
(139) Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical 
databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 
2000, 43, 4759-4767. 
   
 179
(140) Arthur, C. R. G., John T.; Kellogg, Glen E.; Yeudall, W. Andrew; Cabot, Myles C.; 
Newsham, Irene F.; Gewirtz, David A. Autophagic cell death, polyploidy and 
senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a 
novel microtubule poison. Biochemical Pharmacology 2007, 74, 981-991. 
(141) Burns, J.; Yokota, T.; Ashihara, H.; Lean, M. E.; Crozier, A. Plant foods and herbal 
sources of resveratrol. J Agric Food Chem 2002, 50, 3337-3340. 
(142) Simoni, D.; Invidiata, F. P.; Eleopra, M.; Marchetti, P.; Rondanin, R. et al. Design, 
synthesis and biological evaluation of novel stilbene-based antitumor agents. 
Bioorg Med Chem 2009, 17, 512-522. 
(143) Soleas, G. J.; Diamandis, E. P.; Goldberg, D. M. Resveratrol: a molecule whose 
time has come? And gone? Clin Biochem 1997, 30, 91-113. 
(144) Zhou, H. B.; Chen, J. J.; Wang, W. X.; Cai, J. T.; Du, Q. Anticancer activity of 
resveratrol on implanted human primary gastric carcinoma cells in nude mice. 
World J Gastroenterol 2005, 11, 280-284. 
(145) Pace-Asciak, C. R.; Hahn, S.; Diamandis, E. P.; Soleas, G.; Goldberg, D. M. The 
red wine phenolics trans-resveratrol and quercetin block human platelet 
aggregation and eicosanoid synthesis: implications for protection against coronary 
heart disease. Clin Chim Acta 1995, 235, 207-219. 
(146) Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F. et al. Cancer 
chemopreventive activity of resveratrol, a natural product derived from grapes. 
Science 1997, 275, 218-220. 
(147) Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y. J.; Bernard-Gallon, D. J. 
Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr 
Food Res 2005, 49, 462-471. 
(148) Larrosa, M.; Tomas-Barberan, F. A.; Espin, J. C. The grape and wine polyphenol 
piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. 
Eur J Nutr 2004, 43, 275-284. 
(149) Kimura, Y. New anticancer agents: in vitro and in vivo evaluation of the antitumor 
and antimetastatic actions of various compounds isolated from medicinal plants. In 
Vivo 2005, 19, 37-60. 
(150) Chaudhary, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S. et al. 
Combretastatin a-4 analogs as anticancer agents. Mini Rev Med Chem 2007, 7, 
1186-1205. 
(151) Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr 
Med Chem 2003, 10, 1697-1722. 
(152) Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S. et al. Medicinal chemistry 
of combretastatin A4: present and future directions. J Med Chem 2006, 49, 3033-
3044. 
(153) Bellina, F.; Cauteruccio, S.; Monti, S.; Rossi, R. Novel imidazole-based 
combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and 
molecular modeling study of their binding to the colchicine site of tubulin. Bioorg 
Med Chem Lett 2006, 16, 5757-5762. 
   
 180
(154) Ji, Y.; Tian, R.; Lin, W. QSAR and molecular docking study of a series of 
combretastatin analogues tubulin inhibitors. LNCS 2007, 4689, 436. 
(155) Belleri, M.; Ribatti, D.; Nicoli, S.; Cotelli, F.; Forti, L. et al. Antiangiogenic and 
vascular-targeting activity of the microtubule-destabilizing trans-resveratrol 
derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol 2005, 67, 1451-1459. 
(156) Cao, T. M.; Durrant, D.; Tripathi, A.; Liu, J.; Tsai, S. et al. Stilbene derivatives that 
are colchicine-site microtubule inhibitors have antileukemic activity and minimal 
systemic toxicity. Am J Hematol 2008, 83, 390-397. 
(157) Lippert, J. W., 3rd Vascular disrupting agents. Bioorg Med Chem 2007, 15, 605-
615. 
(158) Roberti, M.; Pizzirani, D.; Simoni, D.; Rondanin, R.; Baruchello, R. et al. Synthesis 
and biological evaluation of resveratrol and analogues as apoptosis-inducing 
agents. J Med Chem 2003, 46, 3546-3554. 
(159) Durrant, D.; Corwin, F.; Simoni, D.; Zhao, M.; Rudek, M. A. et al. cis-3, 4', 5-
Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging 
normal organ perfusion. Cancer Chemother Pharmacol 2009, 63, 191-200. 
(160) Durrant, D. E.; Richards, J.; Tripathi, A.; Kellogg, G. E.; Marchetti, P. et al. 
Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-
aminostilbene for optimization and use in cancer therapy. Invest New Drugs 2009, 
27, 41-52. 
(161) Sotriffer, C.; Klebe, G. Identification and mapping of small-molecule binding sites 
in proteins: computational tools for structure-based drug design. Farmaco 2002, 57, 
243-251. 
(162) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N. et al. The 
Protein Data Bank. Nucleic Acids Res 2000, 28, 235-242. 
(163) Campbell, S. J.; Gold, N. D.; Jackson, R. M.; Westhead, D. R. Ligand binding: 
functional site location, similarity and docking. Curr Opin Struct Biol 2003, 13, 
389-395. 
(164) Pazos, F.; Sternberg, M. J. Automated prediction of protein function and detection 
of functional sites from structure. Proc Natl Acad Sci U S A 2004, 101, 14754-
14759. 
(165) Kleywegt, G. J.; Jones, T. A. Detection, delineation, measurement and display of 
cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr 1994, 
50, 178-185. 
(166) Hendlich, M.; Rippmann, F.; Barnickel, G. LIGSITE: automatic and efficient 
detection of potential small molecule-binding sites in proteins. J Mol Graph Model 
1997, 15, 359-363, 389. 
(167) Levitt, D. G.; Banaszak, L. J. POCKET: a computer graphics method for 
identifying and displaying protein cavities and their surrounding amino acids. J 
Mol Graph 1992, 10, 229-234. 
(168) An, J.; Totrov, M.; Abagyan, R. Pocketome via comprehensive identification and 
classification of ligand binding envelopes. Mol Cell Proteomics 2005, 4, 752-761. 
   
 181
(169) Liang, J.; Edelsbrunner, H.; Woodward, C. Anatomy of protein pockets and 
cavities: measurement of binding site geometry and implications for ligand design. 
Protein Sci 1998, 7, 1884-1897. 
(170) Brady, G. P., Jr.; Stouten, P. F. Fast prediction and visualization of protein binding 
pockets with PASS. J Comput Aided Mol Des 2000, 14, 383-401. 
(171) Peters, K. P.; Fauck, J.; Frommel, C. The automatic search for ligand binding sites 
in proteins of known three-dimensional structure using only geometric criteria. J 
Mol Biol 1996, 256, 201-213. 
(172) Laskowski, R. A. SURFNET: a program for visualizing molecular surfaces, 
cavities, and intermolecular interactions. J Mol Graph 1995, 13, 323-330, 307-328. 
(173) Laurie, A. T.; Jackson, R. M. Q-SiteFinder: an energy-based method for the 
prediction of protein-ligand binding sites. Bioinformatics 2005, 21, 1908-1916. 
(174) Lichtarge, O.; Bourne, H. R.; Cohen, F. E. An evolutionary trace method defines 
binding surfaces common to protein families. J Mol Biol 1996, 257, 342-358. 
(175) Aloy, P.; Querol, E.; Aviles, F. X.; Sternberg, M. J. Automated structure-based 
prediction of functional sites in proteins: applications to assessing the validity of 
inheriting protein function from homology in genome annotation and to protein 
docking. J Mol Biol 2001, 311, 395-408. 
(176) Stuart, A. C.; Ilyin, V. A.; Sali, A. LigBase: a database of families of aligned ligand 
binding sites in known protein sequences and structures. Bioinformatics 2002, 18, 
200-201. 
(177) Apweiler, R.; Attwood, T. K.; Bairoch, A.; Bateman, A.; Birney, E. et al. The 
InterPro database, an integrated documentation resource for protein families, 
domains and functional sites. Nucleic Acids Res 2001, 29, 37-40. 
(178) Bickel, P. J.; Kechris, K. J.; Spector, P. C.; Wedemayer, G. J.; Glazer, A. N. 
Inaugural Article: finding important sites in protein sequences. Proc Natl Acad Sci 
U S A 2002, 99, 14764-14771. 
(179) Armon, A.; Graur, D.; Ben-Tal, N. ConSurf: an algorithmic tool for the 
identification of functional regions in proteins by surface mapping of phylogenetic 
information. J Mol Biol 2001, 307, 447-463. 
(180) Pupko, T.; Bell, R. E.; Mayrose, I.; Glaser, F.; Ben-Tal, N. Rate4Site: an 
algorithmic tool for the identification of functional regions in proteins by surface 
mapping of evolutionary determinants within their homologues. Bioinformatics 
2002, 18 Suppl 1, S71-77. 
(181) Lee, B.; Richards, F. M. The interpretation of protein structures: estimation of static 
accessibility. J Mol Biol 1971, 55, 379-400. 
(182) Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 
1983, 221, 709-713. 
(183) Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric 
approach to macromolecule-ligand interactions. J Mol Biol 1982, 161, 269-288. 
(184) Meng, E.; Shoichet, B.; Kuntz, I. D. Automated docking with grid based energy 
evaluation. J. Comput Chem 1992, 13, 505-524. 
   
 182
(185) Goodford, P. J. A computational procedure for determining energetically favorable 
binding sites on biologically important macromolecules. J Med Chem 1985, 28, 
849-857. 
(186) Miranker, A.; Karplus, M. Functionality maps of binding sites: a multiple copy 
simultaneous search method. Proteins 1991, 11, 29-34. 
(187) Voorintholt, R.; Kosters, M. T.; Vegter, G.; Vriend, G.; Hol, W. G. A very fast 
program for visualizing protein surfaces, channels and cavities. J Mol Graph 1989, 
7, 243-245. 
(188) Del Carpio, C. A.; Takahashi, Y.; Sasaki, S. A new approach to the automatic 
identification of candidates for ligand receptor sites in proteins: (I). Search for 
pocket regions. J Mol Graph 1993, 11, 23-29, 42. 
(189) Kisljuk, O. S.; Kachalova, G. S.; Lanina, N. P. An algorithm to find channels and 
cavities within protein crystals. J Mol Graph 1994, 12, 305-307, 296. 
(190) Edelsbrunner, H.; Mucke, E. Three-dimensional alpha-shapes. ACM Trans Graph 
1994, 13, 43-72. 
(191) Lee, D. T.; J., S. B. Two Algorithms for constructing a Delaunay triangulation. Int 
J Comput Inf Sci 1980, 9, 219-242. 
(192) Kellogg, G. E.; Fornabaio, M.; Chen, D. L.; Abraham, D. J.; Spyrakis, F. et al. 
Tools for building a comprehensive modeling system for virtual screening under 
real biological conditions: The Computational Titration algorithm. J Mol Graph 
Model 2006, 24, 434-439. 
(193) Chen, D. L.; Kellogg, G. E. A computational tool to optimize ligand selectivity 
between two similar biomacromolecular targets. J Comput Aided Mol Des 2005, 
19, 69-82. 
(194) Selinsky, B. S.; Gupta, K.; Sharkey, C. T.; Loll, P. J. Structural analysis of NSAID 
binding by prostaglandin H2 synthase: time-dependent and time-independent 
inhibitors elicit identical enzyme conformations. Biochemistry 2001, 40, 5172-
5180. 
(195) Carugo, O.; Bordo, D. How many water molecules can be detected by protein 
crystallography? Acta Crystallogr D Biol Crystallogr 1999, 55, 479-483. 
(196) Steinbacher, S.; Kaiser, J.; Eisenreich, W.; Huber, R.; Bacher, A. et al. Structural 
basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-
erythritol 4-phosphate synthase (IspC). Implications for the catalytic mechanism 
and anti-malaria drug development. J Biol Chem 2003, 278, 18401-18407. 
(197) Arkin, M. A.; Randal, M.; DeLano, W. L.; Hyde, J.; Luong, T. N. et al. Binding of 
small molecules to an adaptive protein-protein interface. Proc.Natl.Acad.Sci.USA 
2003, 100, 1603-1608. 
(198) Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E. et al. 
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of 
apoptosis. Science 1997, 275, 983-986. 
(199) Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K. et al. Crystal 
structure of ABT-737 complexed with Bcl-xL: implications for selectivity of 
antagonists of the Bcl-2 family. Cell Death Differ 2007, 14, 1711-1713. 
   
 183
(200) Gigant, B.; Wang, C.; Ravelli, R. B.; Roussi, F.; Steinmetz, M. O. et al. Structural 
basis for the regulation of tubulin by vinblastine. Nature 2005, 435, 519-522. 
(201) Carter, A. P.; Clemons, W. M.; Brodersen, D. E.; Morgan-Warren, R. J.; Wimberly, 
B. T. et al. Functional insights from the structure of the 30S ribosomal subunit and 
its interactions with antibiotics. Nature 2000, 407, 340-348. 
(202) Hayward, S. Identification of specific interactions that drive ligand-induced closure 
in five enzymes with classic domain movements. J Mol Biol 2004, 339, 1001-1021. 
(203) Karpusas, M.; Branchaud, B.; Remington, S. J. Proposed mechanism for the 
condensation reaction of citrate synthase: 1.9-A structure of the ternary complex 
with oxaloacetate and carboxymethyl coenzyme A. Biochemistry 1990, 29, 2213-
2219. 
(204) Liao, D. I.; Karpusas, M.; Remington, S. J. Crystal structure of an open 
conformation of citrate synthase from chicken heart at 2.8-A resolution. 
Biochemistry 1991, 30, 6031-6036. 
(205) Zhou, M.; Morais-Cabral, J. H.; Mann, S.; MacKinnon, R. Potassium channel 
receptor site for the inactivation gate and quaternary amine inhibitors. Nature 2001, 
411, 657-661. 
(206) Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; Gavalas, N. G.; Johnson, 
L. N. A new allosteric site in glycogen phosphorylase b as a target for drug 
interactions. Structure 2000, 8, 575-584. 
(207) Ajay; Murcko, M. A. Computational methods to predict binding free energy in 
ligand-receptor complexes. J Med Chem 1995, 38, 4953-4967. 
(208) Bohm, H. J.; Klebe, G. What can we learn from molecular recognition in protein-
ligand complexes for the design of new drugs? Angew Cbem Int Ed 1996, 35, 2588-
2614. 
(209) Burt S. K., H. C. W., Greer J. Predicting receptor-ligand interactions. Curr. Opin. 
Struct. Biol. 1991, 1, 213-218. 
(210) Lee C. Calculating binding energies. Curr. Opin. Struct. Biol. 1992, 2, 217-222. 
(211) Murphy, K. P. Predicting binding energetics from structure: looking beyond DeltaG 
degrees. Med Res Rev 1999, 19, 333-339. 
(212) Kollman, P. Advances and continuing challenges in achieving realistic and 
predictive simulations of the properties of organic and biological molecules. Acc 
Chem Res 1996, 29, 461-469. 
(213) Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding 
affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int 
Ed Engl 2002, 41, 2644-2676. 
(214) Dill, K. A. Additivity principles in biochemistry. J Biol Chem 1997, 272, 701-704. 
(215) Reddy, M. R.; Krzysztof, A. Free Energy Calculations in Rational Drug Design. 
Springer, Kluwer Academic/Plenum Publishers, New York. 2001, 317. 
(216) Luque, F. J.; Curutchet, C.; Muriedas, J. M.; Bidon-Chanal, A.; Soteras, I. et al. 
Continuum  solvation  models: Dissecting the  free   energy  of  solvation. Physical 
Chemistry Chemical Physics 2003, 5, 3827-3836. 
   
 184
(217) Thomas, S. Free energy calculations. Computational Biochemistry and Biophysics 
2001, 169-197. 
(218) Reddy, M. R., Erion M. D., Agarwal A. Free energy calculations: Use and 
limitations in predicting ligand binding affinities. Rev. Comput. Chem. 2000, 16, 
217-307. 
(219) Wang W., D. O., Reyes C. M., Kollman, P. A. Biomolecular simulations: recent 
developments in force fields, simulations of enzyme catalysis, protein-ligand, 
protein-protein, and protein-nucleic acid noncovalent interactions. Annual Review 
of Biophysics and Biomolecular Structure 2001, 30, 211-243. 
(220) Antosiewicz, J.; McCammon, J. A.; Gilson, M. K. Prediction of pH-dependent 
properties of proteins. J Mol Biol 1994, 238, 415-436. 
(221) Matthews, B. W. Solvent content of protein crystals. J Mol Biol 1968, 33, 491-497. 
(222) Tajkhorshid E., S. S. The dielectric effect of the environment on the pKa of the 
retinal Schiff base and on the stabilization of the ion pair in bacteriorhodopsin. 
Journal of Molecular Structure (Theochem) 2000, 501-502, 297-213. 
(223) Williams, R. J. P. The symbiosis of metal ion and protein chemistry. Pure and 
Appl. Chem. 1983, 55, 35-46. 
(224) Honig, B.; Nicholls, A. Classical electrostatics in biology and chemistry. Science 
1995, 268, 1144-1149. 
(225) Åqvist, J. Calculation of absolute binding free energies for charged ligands and 
effects of long range electrostatic interactions. J. Comp. Chem. 1996, 17, 1587-
1597. 
(226) Mazur, J.; L., J. R. Distance-dependent dielectric constants and their application to 
double-helical DNA. Biopolymers 2005, 31, 1615-1629. 
(227) Sternberg, M. J.; Hayes, F. R.; Russell, A. J.; Thomas, P. G.; Fersht, A. R. 
Prediction of electrostatic effects of engineering of protein charges. Nature 1987, 
330, 86-88. 
(228) Feig, M.; Brooks, C. L., 3rd Recent advances in the development and application of 
implicit solvent models in biomolecule simulations. Curr Opin Struct Biol 2004, 
14, 217-224. 
(229) Mehler, E. L.; Solmajer, T. Electrostatic effects in proteins: comparison of 
dielectric and charge models. Protein Eng 1991, 4, 903-910. 
(230) Navia, M. A.; Fitzgerald, P. M.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C. et 
al. Three-dimensional structure of aspartyl protease from human immunodeficiency 
virus HIV-1. Nature 1989, 337, 615-620. 
(231) Fornabaio, M.; Cozzini, P.; Mozzarelli, A.; Abraham, D. J.; Kellogg, G. E. Simple, 
intuitive calculations of free energy of binding for protein-ligand complexes. 2. 
Computational titration and pH effects in molecular models of neuraminidase-
inhibitor complexes. J Med Chem 2003, 46, 4487-4500. 
(232) Spyrakis, F.; Fornabaio, M.; Cozzini, P.; Mozzarelli, A.; Abraham, D. J. et al. 
Computational titration analysis of a multiprotic HIV-1 protease-ligand complex. J 
Am Chem Soc 2004, 126, 11764-11765. 
   
 185
(233) Jhoti, H.; Singh, O. M.; Weir, M. P.; Cooke, R.; Murray-Rust, P. et al. X-ray 
crystallographic studies of a series of penicillin-derived asymmetric inhibitors of 
HIV-1 protease. Biochemistry 1994, 33, 8417-8427. 
(234) Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: a major success of 
structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998, 27, 249-284. 
(235) Lam, P. Y.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y. et al. Rational 
design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. 
Science 1994, 263, 380-384. 
(236) Ala, P. J.; DeLoskey, R. J.; Huston, E. E.; Jadhav, P. K.; Lam, P. Y. et al. 
Molecular recognition of cyclic urea HIV-1 protease inhibitors. J Biol Chem 1998, 
273, 12325-12331. 
(237) Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C. H.; Garber, S. S. et al. Cyclic urea 
amides: HIV-1 protease inhibitors with low nanomolar potency against both wild 
type and protease inhibitor resistant mutants of HIV. J Med Chem 1997, 40, 181-
191. 
(238) Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C. H.; Eyermann, C. J. et al. 
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, 
resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 
450. Chem Biol 1996, 3, 301-314. 
(239) Backbro, K.; Lowgren, S.; Osterlund, K.; Atepo, J.; Unge, T. et al. Unexpected 
binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J Med Chem 1997, 
40, 898-902. 
(240) Schaal, W.; Karlsson, A.; Ahlsen, G.; Lindberg, J.; Andersson, H. O. et al. 
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and 
nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J Med Chem 2001, 44, 
155-169. 
 
  
  
 
  
   
 186
 
 
VITA 
 
 
 
Ashutosh Tripathi was born on 23rd February, 1977 in Lucknow, Uttar Pradesh, India. He 
received his Bachelor of Pharmacy degree from Institute of Engineering and Technology, 
M.J.P. Rohilkhand University, Bareilly in 2002. He received his Master of Science degree 
in Cheminformatics from University of Manchester, United Kingdom in 2004. He joined 
Dr. Glen E. Kellogg’s research group in the Department of Medicinal Chemistry & 
Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University 
in January 2005. Ashutosh Tripathi was recipient of 2005-06 Graduate and First 
Professional Student Technology Research Grant, Virginia Commonwealth University, in 
2005. He received J. Doyle Smith Award for achieving the greatest distinction in the areas 
of research, teaching, scholarship and service in the Department of Medicinal Chemistry at 
Virginia Commonwealth University, in 2008. Ashutosh also received American 
Association of Pharmaceutical Scientists (AAPS) Graduate Student Symposium Award 
from the Drug Design and Discovery section sponsored by Bristol-Myers and Squibb, in 
2008. 
 
